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3.1 12 % SDS-PAGE showing protein purification summary. a) Summary
gel for the purification of AlaRS. Lane 1 - AmershamTM protein
marker, Lane 2 - 10 50,000 xg supernatant, Lane 3 - 10 pooled
IMAC fractions, Lane 4 - 10 pooled anion exchange fractions. b)
Summary gel for the purification of SerRS. Lane 1 - AmershamTM
protein Marker, Lane 2 - 10 50,000 xg supernatant, Lane 3 - 10 pooled
IMAC fractions, Lane 4 - 10 pooled SEC fractions. c) Summary gel
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Lane 2 - 10 50,000 xg supernatant, Lane 3 - 10 pooled IMAC fractions,
Lane 4 - 10 pooled SEC fractions, Lane 5 - 10 pooled anion exchange
fractions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
3.2 Michaelis-Menten kinetics of AlaRS. A plot of the reaction velocity
(V0) as a function of a) cognate amino acid (L-Ala) concentration and
b) non-cognate amino acid (L-Ser) concentration. Apparent kcat, km,
and kcat/km are presented. R2 = 0.96 and 0.94 for a) and b) respectively.
Mean and standard deviation were plotted from triplicate data sets.
GraphPad Prism (Version 7.0c) was used for data analysis and figure
preparation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
xiv
3.3 Michaelis-Menten kinetics of ThrRS. A plot of the reaction velocity
(V0) as a function of cognate amino acid (L-Thr) concentration. a)
Assay using ADPNP as the ATP analogue. Data collected in triplicate
with average and standard deviation plotted. R2 = 0.96. b) Assay
using ADPCP as the ATP analogue. Data collected in singlicate.
R2 = 0.94. Apparent Kcat, Km, and catalytic efficiency Kcat/Km are
presented. GraphPad Prism (Version 7.0c) was used for data analysis
and figure preparation. . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
3.4 Effect of H2O2 on aminoacylation activity of AlaRS and ThrRS. a)
Initial velocity of AlaRS amino acid activation with L-Ala or L-Ser in
the presence and absence of 50 mM H2O2. b) Initial velocity of ThrRS
amino acid activation with L-Thr in the presence and absence of 50
mM H2O2. Mean and standard deviation were plotted from triplicate
data sets. NS = not statistically significant as determined by a paired
t-test or one-way ANOVA. GraphPad Prism (Version 7.0c) was used
for data analysis and figure preparation. . . . . . . . . . . . . . . . . . 88
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3.5 Effect of H2O2 on pre-transfer and post-transfer editing rates of
AlaRS. 0.5 µM AlaRS with 200 mM L-Ala or 200 mM L-Ser were
used in these spectrophotometric assays to obtain suitable rates of
reaction. a) The rate of pre-transfer editing of L-Ser (or L-Ala as a
negative control) by AlaRS at varying concentrations of H2O2. b) Bar
chart showing pre-transfer editing rates of AlaRS at 0 and 75 mM
H2O2 with both L-Ser and L-Ala (negative control). c) The rate of
post-transfer editing of L-Ser (or L-Ala as a negative control) by AlaRS
at varying concentrations of H2O2. d) Bar chart showing post-transfer
editing rates of AlaRS at 0 and 75 mM H2O2 with both L-Ser and L-Ala
(negative control). Mean and standard deviation were plotted from
triplicate data sets. NS = not statistically significant, S = statistically
significant, as determined by a paired t-test or one-way ANOVA.
GraphPad Prism (Version 7.0c) was used for data analysis and figure
preparation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
3.6 Effect of H2O2 on pre-transfer and post-transfer editing rates of
ThrRS. 10 µM ThrRS with 50 mM L-Thr or 50 mM L-Ser was used in
these spectrophotometric assays to obtain suitable rates of reaction. a)
The rate of pre-transfer editing of L-Ser (or L-Thr as a negative control)
by ThrRS at varying concentrations of H2O2. b) Bar chart showing
pre-transfer editing rates of ThrRS at 0 and 50 mM H2O2 with both
L-Ser and L-Thr (negative control). c) The rate of post-transfer editing
of L-Ser (or L-Thr as a negative control) by ThrRS at varying concentrations
of H2O2. d) Bar chart showing post-transfer editing rates of ThrRS at 0
and 50 mM H2O2 with both L-Ser and L-Thr (negative control). Mean
and standard deviation were plotted from triplicate data sets. NS =
not statistically significant, S = statistically significant, as determined
by a paired t-test or one-way ANOVA. GraphPad Prism (Version 7.0c)
was used for data analysis and figure preparation. . . . . . . . . . . . 92
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3.7 Effect of pre-incubation time for AlaRS and H2O2 on pre- and
post-transfer editing activity of L-Ser. a) 30 minute time-course
showing pre-transfer editing of AlaRS following incubation with
H2O2. b) 30 minute time-course showing post-transfer editing of
ThrRS following incubation with H2O2. The final concentration of
AlaRS and H2O2 in the assay was 0.5 µM and 5 mM respectively.
Incubation of AlaRS with 0 mM H2O2 was used as a negative control.
Mean and standard deviation were plotted from triplicate data sets.
GraphPad Prism (Version 7.0c) was used for data analysis and figure
preparation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
3.8 Effect of pre-incubation time for ThrRS and H2O2 on pre- and
post-transfer editing activity of L-Ser. a) 40 minute time-course
showing pre-transfer editing of ThrRS following incubation with
H2O2. b) 40 minute time-course showing post-transfer editing of
ThrRS following incubation with H2O2. The final concentrations of
ThrRS and H2O2 in the assay were 10 µM and 2 mM respectively.
Incubation of ThrRS with 0 mM H2O2 was used as a negative control.
Mean and standard deviation were plotted from triplicate data sets.
GraphPad Prism (Version 7.0c) was used for data analysis and figure
preparation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
3.9 Effect of H2O2 controls. Effect of presence of DTT in master mix on
Post-transfer editing of a) AlaRS and b) ThrRS, following 0 min and
10 min incubation with 50 mM H2O2. Spectrophotometric data of the
coupled reactions occurring in real-time as detected by changes in
absorbance at 340 nm c) in the absence of H2O2 d) in the presence
of 50 mM H2O2. NS = not statistically significant, as determined by
a paired t-test or one-way ANOVA. GraphPad Prism (Version 7.0c)
was used for data analysis and figure preparation. . . . . . . . . . . . 99
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3.10 12 % SDS-PAGE showing ThrRS protein purification summary. a)
Summary gel for the purification of N-terminally tagged ThrRS. Lane
1 - Amersham Protein Marker, Lane 2 - 10 50,000 x g supernatant,
Lane 3 - 10 pooled IMAC fractions, Lane 4 - 10 pooled SEC fractions. 101
3.11 Electrospray mass spectrometric analysis of AlaRS. Electrospray
mass spectrometry in positive ion mode. a) Electrospray mass spectrum
b) Electrospray mass spectrum (black) overlaid with mock spectrum
(red) c) Maximum Entropy interpretations of this spectra in the mass
range 60,000 Da to 130,000 Da d) Deconvoluted Maximum Entropy
interpretations of this spectra in the mass range 60,000 Da to 130,000
Da expanded between 97,000 and 99,000 Da. . . . . . . . . . . . . . . 103
3.12 Electrospray mass spectrometric analysis of AlaRS following incubation
with H2O2 at a molar ratio of 1:10,000. Electrospray mass spectrometry
in positive ion mode. a) Electrospray mass spectrum b) Electrospray
mass spectrum (black) overlaid with mock spectrum (red) c) Maximum
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to 130,000 Da d) Deconvoluted Maximum Entropy interpretations
of this spectra in the mass range 60,000 Da to 130,000 Da expanded
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3.13 Electrospray mass spectrometric analysis of ThrRS. Electrospray
mass spectrometry in positive ion mode. a) Electrospray mass spectrum
b) Electrospray mass spectrum (black) overlaid with mock spectrum
(red) c) Maximum Entropy interpretations of this spectra in the mass
range 60,000 Da to 100,000 Da d) Deconvoluted Maximum Entropy
interpretations of this spectra in the mass range 60,000 Da to 100,000
Da expanded between 97,500 and 78,500 Da. . . . . . . . . . . . . . . 105
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3.14 Electrospray mass spectrometric analysis of ThrRS following incubation
with H2O2 at a molar ratio of 1:200. Electrospray mass spectrometry
in positive ion mode. a) Electrospray mass spectrum b) Electrospray
mass spectrum (black) overlaid with mock spectrum (red) c) Maximum
Entropy interpretations of this spectra in the mass range 60,000 Da
to 100,000 Da d) Deconvoluted Maximum Entropy interpretations
of this spectra in the mass range 60,000 Da to 100,000 Da expanded
between 97,500 and 78,500 Da. . . . . . . . . . . . . . . . . . . . . . . . 106
3.15 Intact protein mass spectrometry of AlaRS with and without hydrogen
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3.16 Intact protein mass spectrometry of ThrRS with and without hydrogen
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3.17 12 % SDS-PAGE of AlaRS and ThrRS samples for peptide based
mass spectrometry. Lane 1 - Amersham Protein Marker, Lane 2 - 15
AlaRS, Lane 3 - 15 AlaRS (H2O2 treated), Lane 4 - 15 ThrRS, Lane
5 - 15 ThrRS (H2O2 treated). Red boxes indicate bands which were
excised for tryptic digest and mass spec analysis. . . . . . . . . . . . . 110
3.18 Sequence coverage and modified residues of AlaRS. a) AlaRS control
sample, b) AlaRS H2O2 treated sample. Sequence coverage (yellow)
and modified residues (green) are displayed. Results analysed in
Scaffold (Version 4.8.1). . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
3.19 Sequence coverage and modified residues of ThrRS. a) ThrRS control
sample, b) ThrRS H2O2 treated sample. Sequence coverage (yellow)
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Scaffold (Version 4.8.1). . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
4.1 12 % SDS-PAGE showing 4 hour expression of MurM a) MurMPn16(1)
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4.2 12 % SDS-PAGE showing IMAC purification of MurM159(1). Lane
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supernatant, Lane 3 - 10 protein from column load, Lane 4 - 10
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4.19 Negative ion ES-MS of UDP-MurNAc-5P a) Full spectra, b) Enlarged
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4.27 Purified tRNA summary gel. Lane 1 - NEB Low Molecular Weight
DNA ladder, Lane 2 - 10 E. coli crude tRNA, Lane 3 - 10 S. pneumoniae
(159) crude tRNA, Lane 4 - 5 pure tRNAAla, Lane 5 - 5 pure tRNASer1,
Lane 6 - 5 pure tRNASer2, Lane 7 - 5 pure tRNASer3, Lane 8 - 5 pure
tRNAThr1, Lane 9 - 5 pure tRNAThr2. 7 M urea 12 polyacrylamide gel.155
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presence of gMurM159 or b) in the absence of gMurM159. Arrows
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4.31 Aminoacylation of in vitro transcribed pure tRNA isoacceptors by
AlaRS, SerRS and ThrRS in the presence of cognate amino acids
a) aminoacylation of tRNAAla by AlaRS in the presence of L-Ala,
b) aminoacylation of tRNASer1 by SerRS in the presence of L-Ser,
c) aminoacylation of tRNASer2 by SerRS in the presence of L-Ser,
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5.1 Application ranges for molecular modeling at different resolutions:
quantum, all-atom, coarse-grained, and mesoscale. The plot shows
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5.2 Cartoon representation of gMurM159 predicted structure. 14 α-helices
(red), 12 β-sheet (yellow) and unstructured regions (blue). Best model
obtained based on SOAP and DOPE scores following homology
modelling using MODELLER with S. aureus FemX as a template. . . 177
5.3 Cartoon and Surface comparisons of previous and current MurM
models. Panel a) previous MurM model (Fiser et al., 2003), b) current
MurM model. Models are displayed in the orientation shown in (Fiser
et al., 2003) for direct comparison. Key differences are highlighted in
the cartoon representation and putative binding sites indicated on
the electrostatic surface representation. Figure prepared in PyMOL
(Version 2.2.0) using the APBS Electrostatics Pluggin. . . . . . . . . . 178
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5.4 Ramachandran Plot of MurM159 model. Shows 91.3 of all residues
are within favoured regions (light blue lines) and 97.0 of all residues
are in allowed regions (dark blue lines). There are 12 residues that are
outliers (pink circles). Plot generated in MolProbity (Lovell et al., 2003).181
5.5 Comparison of UDP-MurNAc-5P substrates in the W. viridescens
FemX binding site. a) stick structure of UDP-MurNAc-5P as found in
FemX (Biarrotte-Sorin et al., 2004), b) stick structure of UDP-MurNAc-
peptidyl-RNA conjugate as found in FemX (Fonvielle et al., 2013),
c) overlay of UDP-MurNAc-5P and UDP-MurNAc-peptidyl-RNA
conjugate. Box 1 = UDP, Box 2 = MurNAc, Box 3 = 5P and Box 4 =
peptidyl-RNA conjugate. Figure made in PyMOL (Version 2.2.0). . . 182
5.6 Current MurM model with UDP-MurNAc-5P overlaid. a) Cartoon
representation of MurM with UDP-MurNAc-5P overlaid (cyan) b)
surface representation of MurM with UDP-MurNAc-5P overlaid.
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is the proposed binding site for the Lipid II(Lys) substrate of MurM.
Figure prepared in PyMOL (Version 2.2.0). . . . . . . . . . . . . . . . 184
5.7 Pairwise sequence alignment of MurM sequences. Black arrows
indicate residues proposed to be involved in substrate binding. Residues
coloured according to identity using Jalview (Version 2.10.5). . . . . 185
5.8 Potential MurM159 binding site residues. MurM with UDP-MurNac-5P
overlaid, inset close up of proposed binding site with residues F103,
K35, W38, R215 and Y316 in green shown to be pointing towards the
substrate. Note: single letter code for amino acids used in this diagram.187
5.9 Electrostatic surface representation of MurM159. a) MurM159 b)
proposed MurM159 Lipid II(Lys) binding site c) MurM159 negatively
charged surface patch. Figure prepared in PyMOL (Version 2.2.0)
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5.10 Cartoon representation of MurM159 with regions required for activity.
N-terminal residues (red), C-terminal residues (blue) and residues
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5.11 Molecular docking prediction of current MurM model with modified
Lipid II(Lys). a) Cartoon representation of MurM with docked modified
Lipid II(Lys) (cyan) b) Surface representation of MurM with docked
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MurM model with docked Lipid II(Lys). Inset: close up of residues
predicted to form hydrogen bonds. Lys35, Ser36, Asp37, Arg144 and
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a) Surface representation of MurM overlaid with UDP-MurNAc-5P, b)
Surface representation of MurM with molecular docking of truncated
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Abstract
Streptococcus pneumoniae is responsible for a large amount of morbidity and mortality
worldwide, and in addition high-level penicillin resistant strains are emerging
rapidly. However, MurM is a protein involved in peptidoglycan branching, which
may provide hope for the reversal of β-lactam resistance in pneumococcal infection
because it is essential for high-level penicillin resistance. Streptococcus pneumoniae
produces large amounts of H2O2 during aerobic metabolism, but lacks the major
oxidative stress response mechanisms. Therefore it is proposed that MurM plays
an additional role in maintaining translational fidelity during oxidative stress. This
work firstly demonstrates that H2O2 causes a reduction in post-transfer editing of
two aminoacyl-tRNA synthetases (AlaRS and ThrRS) in vitro, which may result in a
decrease in protein synthesis fidelity in vivo. Preliminary experiments indicate for
the first time, that iGln Lipid II(Lys) can serve as a substrate for MurM in addition
to Lipid II(Lys). A range of tRNA substrates have been prepared for investigating
the substrate preference of MurM towards mis-charged tRNA. In silico modelling
of MurM has provided an improved structure, allowing identification of the lipid
substrate binding site. Additionally, interactions of MurM with the membrane,
Lipid II(Lys) substrate, and membrane phsopholipids have similarly been simulated
in silico. It is hoped that a better understanding of MurM’s structure, mechanism of
action, and interplay with other areas of Streptococcus pneumoniae metabolism will
be important advances, which may assist development of new clinical approaches
towards treatment of pneumococcal infection.
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1.1 Pathogenesis of Streptococcus pneumoniae
Streptococcus pneumoniae or pneumococcus is a Gram-positive, non-motile, non spore
forming, coccoid bacterium. It most commonly appears as a diplococcus but can
also be found individually and in short chains (Toit et al., 2014). The pneumococcus
is encapsulated by complex capsular polysaccharides (CPS), which are critical for
evasion of the immune system of the host and is an important virulence factor
(Geno et al., 2015). The composition of the capsule gives rise to 91 antigenically
different serotypes (which belong to 46 serogroups) (Henrichsen, 1995; Park et al.,
2007). Streptococci, like other Lactobacillales, are catalase-negative organisms which
produce L-(+)-lactic acid as the main product of carbohydrate metabolism (Toit
et al., 2014). S. pneumoniae is a facultative anaerobe which produces hydrogen
peroxide (H2O2) as a metabolic bi-product during aerobic growth. Haemophilus
influenzae resides in the same environmental niche, and as such it is possible that the
inhibitory and bactericidal effects of H2O2 may provide a competitive advantage
for S. pneumoniae (Pericone et al., 2000). The genome of S. pneumoniae is relatively
small ∼2.2 Mbp; whilst a genome of this size would typically reduce the cost of
maintaining and replicating a larger genome, its metabolic capacity and ability
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to adapt to environmental changes would be limited. However, streptococci are
naturally transformable, and so can actively take-up extracellular deoxyribonucleic
acid (DNA) and integrate it into their genomes. This provides a mechanism for
adjusting to environmental pressures through the acquisition of genes or alleles
from a larger shared pool known as the supragenome (Ola et al., 2007). This type
of horizontal gene transfer results in huge genetic variation and S. pneumoniae is
often referred to as having a mosaic genome. Between serotypes, ∼10 % of genes
are divergent with 160 kb accounting for half of the variable genes, many of which
are associated with transposases or are involved in antibiotic resistance (Brückner
et al., 2004; Hakenbeck et al., 2001).
S. pneumoniae resides asymptomatically in the nasopharynx of many healthy children
and adults worldwide. However in susceptible individuals, such as the very young,
elderly or immunocomprimised, S. pneumoniae is the causative agent of otitis media,
community-acquired pneumonia (CAP) and invasive pneumococcal diseases (IPD)
such as bacterial meningitis and bacteraemia (Musher et al., 2002). According to the
Centers for Disease Control and Prevention (CDC), whilst the incidence of invasive
pneumococcal disease (meningitis and bacteraemia) in the United States of America
is decreasing, there has been a marginal increase in mortality between 1997 and
2016 (Figure 1.1). Most recent global estimates indicate that 8-12 % of all deaths
in children <5 years (excluding Human Immunodeficiency Virus (HIV)-positive
individuals) are caused by S. pneumoniae (O’Brien et al., 2009).
Serotype distribution in the population is constantly fluctuating and depends on
many factors including (but not exclusively); age, gender, geographic location,
vaccine coverage, antibiotic usage, pre-existing illness and HIV status (Imöhl et al.,
2010; Klugman et al., 2004; Cui et al., 2017; Mendez-Lage et al., 2015; Feikin and
Klugman, 2002; Geno et al., 2015). However, the severity and outcome of invasive
pneumococcal disease is not serotype specific and is instead dependent upon host
factors such as age, immunosuppression and underlying disease (Group et al., 2007).
In 2000, a 7-valent pneumococcal vaccine was licensed for young children and
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studies showed that between 1998 and 2003 the number of hospitalisations due to
invasive pneumococcal disease decreased significantly (Shah and Ratner, 2006). The
introduction of the vaccine directly reduced the rate of pneumococcal disease in
children, with the greatest reduction in children <2 years of age, and conferred an
additional indirect effect on the older population due to herd immunity (Whitney
et al., 2003; Lexau et al., 2005).
Figure 1.1: Estimated number of deaths from IPD in the United States of America
between 1997 and 2016. Number of survivals (blue) and number of deaths (green). Image
obtained from Centers for Disease Control and Prevention (Centers for Disease Control and
Prevention Contributors, 2019).
1.2 Antibiotic discovery and the development of resistance
Antibiotics are medicines which inhibit or prevent bacterial growth at low
concentrations. A number of different bacteria have been shown to be natural
producers of antibiotics and for many years this was believed to provide a
competitive advantage against other microorganisms within the same niche
(Waksman and Woodruff, 1941; Schatz et al., 1944). However recent studies
indicate that antibiotics may act as signalling molecules, regulating homeostasis of
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microbial communities by affecting bacterial motility, biofilm formation and protein
expression (Linares et al., 2006). There are several historical cases which indicate that
humans have exploited and benefited from the use of antibiotics throughout history.
These include traces of tetracycline found in skeletal remains from 350-550 BC, the
identification of antibiotic-producing bacteria in the red soils of Jordan (used to treat
skin infections) and the anti-malarial qinghaosu (artemisinin) in traditional Chinese
medicine used for many ailments (Aminov, 2010; Falkinham et al., 2009). Alexander
Fleming discovered the β-lactam antibiotic penicillin and the first antibiotic to be
used in a clinical setting was Prontosil (a sulphonamide) which was produced in
1931 and used to cure a boy dying of staphylococcal septicaemia in 1933 (Gould,
2016). These discoveries marked the beginning of the ’Antibiotic Golden Era’ (1940 -
1970) and during World War 2, the War Production Board established large-scale
production of penicillin to assist the war efforts (Quinn, 2013). Subsequently there
was a boom in the discovery of new antibiotic classes (Figure 1.2), antibiotics were
described as wonder drugs and were used widely, with many developed and
developing countries recording improved outcomes for infectious disease and,
simultaneously, increased life expectancy (Adedeji, 2016).
Antibiotics can act by inhibiting bacterial growth (bacteriostatic), killing the
bacterium (bacteriocidal), or by inducing cell lysis (bacterolytic). Figure 1.3,
highlights the three key areas of metabolism which antibiotic classes can target; cell
wall biosynthesis, nucleic acid synthesis and protein synthesis. Some antibiotics
target additional biosynthesis pathways such as mycolic and folic acid synthesis.
Antibiotic resistance is driven by evolution and arises when mutations in DNA
result in the bacteria no longer being affected by specific antibiotic compounds,
thereby providing an evolutionary advantage for those bacteria that have developed
resistance. There are two mechanisms which are the genetic basis for development
of resistance; i) random mutations and ii) horizontal gene transfer. Bacteria carrying
random mutations which permit survival in the presence of the antibiotic persist
and become the predominant species, whilst susceptible bacteria are eliminated
4
Figure 1.2: Timeline of antibiotic discovery and the discovery void. Dates indicated are
those of reported initial discovery or patent. Naturally occurring antibiotics are shown in
green whilst synthetic antibiotics are shown in yellow. Figure from Silver (2011).
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Figure 1.3: Diagram illustrating the cellular mechanisms which are targets for antibiotics
by the antibiotic. There is often a fitness cost incurred due to mutations like
this and so often they are only maintained in the presence of the antibiotic (Blair
et al., 2015). Horizontal gene transfer is where bacteria exchange DNA through
transformation, transduction or conjugation. It is one of the most important
drivers of bacterial evolution and is a significant cause of antibiotic resistance
(Blair et al., 2015). The three key mechanisms which generate bacterial resistance
are; preventing access of the antibiotic to the bacterial target, inactivation of the
antibiotic and modification of the antibiotic target (Figure 1.1). Preventing access of
the antibiotic to its target can occur by either decreasing or replacing non-specific
porins, which are responsible for antibiotic uptake, or by increasing efflux pumps,
which export antibiotics out of the cell. Enzymes such as β-lactamases, imipenemase,
oxacilinase and carbapenemase hydrolyse the antibiotic thus causing its inactivation,
furthermore, aminoglycosides and chloramphenicol are particularly susceptible
and can be modified by enzymes such as acetyltransferases, phosphotransferases
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and nucleotidyltransferases. Modification of the antibiotic target prevents binding
of the antibiotic but without affecting the normal activity of the target. This has
been observed in S. pneumoniae penicillin binding proteins (PBPs) acquire mutations
which prevent the binding of penicillin, generating resistance. Modifications which
do not require mutations can also be used to protect the target from antibiotic
binding. For more detailed reviews of these mechanisms the author refers the reader
to Walsh (2000), Blair et al. (2015) and Kapoor et al. (2017).






























































Table 1.1: The cellular target and mode of action, and mechanism of bacterial resistance
for the main classes of antibiotics. Figure adapted from Walsh (2000).
The use of antibiotic compounds throughout history has contributed to the
accumulation of resistance genes in the human population, and so antibiotic
resistance has likely always existed to a greater or lesser extent. Enzymes, known
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as β-lactamases, which hydrolyse β-lactam antibiotics, originated more than two
billion years ago (Aminov, 2010). In his Nobel Prize lecture, Alexander Fleming
noted that incorrect use of antibiotics could render them ineffective. This was due
to his observation that bacteria could become resistant to antibiotics if exposed to
sub-inhibitory concentrations. However, despite this warning, antibiotics have been
overused and misused due to inappropriate prescribing in humans, under-dosing
through lack of course completion, extensive use in agriculture and possibly by
additional factors such as increased use in cleaning products (Ventola, 2015). As a
result, antibiotic resistance has risen dramatically since their clinical introduction
and a crisis looms. At present there are an estimated 700,000 deaths globally that
occur due to resistant bacterial infections; at the current rate of progression this is
predicted to rise to 10 million per year by 2050, making antibiotic resistance a global
health priority (O’Neill, 2016).
Antibiotic Resistance in S. pneumoniae
Penicillin resistance is a major concern in S. pneumoniae, with resistance rates varying
between 25-50 % throughout Europe. Interestingly high-level penicillin resistance
appears to develop in only a few serotypes; out of the 147 high-level penicillin
resistant isolates studied, 90.5 % belong to one of six serotypes (Rauch et al., 1998).
β-lactams such as penicillin covalently bind and inhibit the active site serine of
penicillin binding proteins (PBPs). PBPs are involved in the polymerisation and
cross-linking of precursors to create the peptidoglycan (PG) layer in the bacterial
cell wall. PBP genes have acquired heterologous DNA sequences (some conferring
resistance) by horizontal gene transfer, from other bacteria which are indigenous to
the upper respiratory tract such as Streptoccocus mitis and Streptococcus oralis (Ola
et al., 2007). This results in mosaic PBPs whose binding site has a reduced affinity
for penicillin binding. This is a prime example of antibiotic target modification and
shows how the natural competence of S. pneumoniae confers an advantage to the
bacterium.
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Other antibiotics used to treat S. pneumoniae infections also show varying levels
of resistance. Cephalosporin resistance occurs due to alterations in PBP 2x,
2a and 1a; such resistance increases in parallel with penicillin resistance, with
resistance to cefotaxime and ceftriaxone reported for up to 40 % of S. pneumoniae
strains. Worryingly, resistance to trimethoprim-sulfamethoxazole occurs in 20-60
% of pneumococcal isolates. Whilst resistance to erythromycin and tetracyclines
has increased worldwide, prevalence in individual countries is highly variable.
Clindamycin resistance is less common than macrolide resistance, but high-level
resistance of clindamycin is correlated to macrolide resistance. The mef(A) gene,
encoding an antibiotic efflux pump, is commonly acquired in these bacteria and
leads to macrolide resistance (Reinert, 2009). The original fluoroquinolones had a
marginal minimum inhibitory concentration (MIC) against S. pneumoniae and were
a poor choice of drug for CAP; however, the newer fluoroquinones have improved
activity against S. pneumoniae, with penicillin resistance having no effect. All strains
of S. pneumoniae are susceptible to vancomycin and most strains are susceptible to
carbapenems, including those resistant to penicillin, making these a viable treatment
choice. However, vancomycin tolerance has been observed, and all isolates were
also resistant to penicillin (Chenoweth et al., 2000).
Multidrug resistance (MDR) is now endemic in many countries, with 9-25 % of
pneumococci in the US found to be multidrug resistant (Chenoweth et al., 2000). It
is therefore clear that whilst some treatments for CAP remain effective, resistant
strains are increasing at an alarming rate. Therefore there is an urgent need for the
development of new antimicrobials.
1.3 Peptidoglycan and cell wall biosynthesis
As mentioned previously, cell wall synthesis is one of the main targets for antibiotics.
In Gram-positive organisms which lack an outer membrane, the PG is an essential
component of the bacterial cell wall which provides strength and rigidity, flexibility
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during growth and division, and protects the cell from high osmotic pressures. It is
a polymer consisting of alternating carbohydrate residues of N-acetyl glucosamine
(GlcNAc) and N-acetylmuramic acid (MurNAc) with an appended peptide chain
that is cross-linked either directly or indirectly, resulting in the formation of a
mesh-like structure (Figure 1.4) (Bugg et al., 2011). PG acts as an anchor for other
cell wall components such as surface proteins, CPS and Type I pilus (Dramsi et al.,
2008; Larson and Yother, 2017; Shaik et al., 2014).
Figure 1.4: Diagram illustrating the mesh-like structure of peptidoglycan. Alternating
residues of N-acetylmuramic acid (MurNAc) (blue) and N-acetylglucosamine (GlcNAc)
(red) with direct and indirect cross-links occurring between peptide stems.
Inhibition of cell wall biosynthesis is a key mechanism for many antibiotics,
including the most widely used class of antibiotics known as the β-lactams, as
well as glycopeptides and amino acid analogues (Schneider and Sahl, 2010). Figure
1.5 demonstrates the 3 main stages of PG biosynthesis; cytoplasmic, internal face
of cytoplasmic membrane and external face of cytoplasmic membrane (Bugg et al.,
2011).
Whilst the PG pathway shares similarities in most bacteria, there are minor
differences between Gram-positive and Gram-negative bacteria plus additional
variations which occur between different species. This section will therefore describe























































































































































































































































































































































































































































































































































































those occurring in S. pneumoniae.
The cytoplasmic stages of PG synthesis are well characterised, and
can be summarised as the production of Park Nucleotide or uridine
diphosphate-N-acetylmuramyl pentapeptide (UDP-MurNAc-5P), by formation
of UDP-N-acetylmuramic acid (UDP-MurNAc) by MurA and MurB, and the
subsequent addition of amino acids by Mur ligases MurC, D, E and F to form a
pentapeptide (5P) chain (Barreteau et al., 2008). The pentapeptide chain at this stage
of the pathway is most commonly L-Ala-γ-D-Glu-X-D-Ala-D-Ala, whereby X is
L-Lys in Gram-positive bacteria or meso-DAP (where DAP denotes diaminopimelic
acid) in Gram-negative bacteria. However, other less frequently observed variations
of this residue have been documented and are discussed in more detail by Vollmer
et al. (2008). MraY and MurG subsequently catalyse the conversion of Park
Nucleotide into Lipid II(X) (where X can be omitted to refer to all Lipid II molecules,
or used to indicate the specific amino acid residue present at the third position of
the 5P).
A number of modifications to the 5P of Lipid II can occur, during this stage at the
internal face of the cytoplasmic membrane.
The PG of a number of Gram-positive bacteria (including Mycobacterium tuberculosis,
S. pneumoniae and Clostridium perfringens) is amidated to contain D-iso-glutamine
(iGln) at the second position of the pentapeptide. In Staphylococcus aureus, the
GatT/MurD enzyme complex was identified to be responsible for the amidation
of D-Glu, and homologous transcriptional units have also been identified in other
Gram-positive bacteria (Munch et al., 2012; Liu et al., 2017). In S. pneumoniae 100 %
of the PG contains iGln at the second position of the 5P, which is consistent with the
findings that GatT/MurD are essential genes (Liu et al., 2017).
An additional modification which commonly occurs in Gram-positive bacteria is
branching, by addition of amino acids to the ε-amino group of the third position
lysine of the 5P. With the exception of Weissella viridescens and Enterococcus faccium,
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for which branching occurs to the UDP-MurNAc-5P, this modification occurs to
the Lipid II(Lys) (Hegde and Blanchard, 2003; Bellais et al., 2006). The composition
and extent of branching varies greatly between species, and as such, there are
a number of homologous proteins which are responsible for these amino acid
additions (Table 1.2) (Vollmer et al., 2008). The PG of wild type S. pneumoniae is
heterogeneous, containing branched and unbranched PG. MurM and MurN are the
enzymes responsible for the sequential addition of amino acids to generate branched
PG precursors (Severin and Tomasz, 1996). MurM aminoacylates the lysine of the
5P with L-Ser or L-Ala and MurN acylates the free amino group of the first amino
acid, with an invariable L-Ala. Peptide bond formation occurs in a direction that is
reversed compared to peptide bond formation in ribosomal protein synthesis (Filipe
et al., 2000a).
Enzyme Bridge Species
FemX, FemA, FemB (Gly)5 Staphylococcus aureus




MurM, MurN (L-Ala/L-Ser)-L-Ala Streptococcus
pneumoniae
Aslfm D-Asp Enterococcus faecium




FemX and VanK Gly S. coelicolor
Table 1.2: Enzymes responsible for branching of peptidoglycan precursors, the nature
of the branch and the species to which they belong. Adapted from (Vollmer et al., 2008;
Shepherd and Ibba, 2013b).
The order of amidation and branching reactions has yet to be determined; in S.
pneumoniae all previous experiments on MurM have utilised non-amidated Lipid
II(Lys).
Following synthesis of Lipid II on the internal face of the cytoplasmic membrane it
must be transported across the membrane to the external face for incorporation into
the PG. There has been much controversy in the field with regards to identification
of the flippase, and a number of candidate proteins have been investigated; MurJ,
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FtsW and AmJ (Ruiz, 2015). In Escherichia coli the flippase has been identified
as MurJ, which belongs to the Multidrug/oligosaccharideyl-lipid/polysaccharide
exporter family. Structural studies of MurJ show two conformations; inward-open
and outward-open which indicate an alternating-access mechanism of transport
(Kumar et al., 2019; Kuk et al., 2017; Zheng et al., 2018). YtgP is the MurJ ortholog in
Gram-positive bacteria and is essential in S. pneumoniae and S. aureus. However, B.
subtillis also encodes the functionally redundant AmJ protein, and so YtgP is not
essential (Ruiz, 2015).
Once Lipid II(Lys) is on the external face of the membrane it is incorporated into the
PG by the PBPs. PBPs bind penicillin due to the similarity between penicillin and
the terminal D-Ala D-Ala of the Lipid II (the PBPs natural substrate) (Figure 1.6).
Figure 1.6: Comparison of Penicillin and D-Ala D-Ala structures. a) Penicillin and b)
D-Ala D-Ala. Figure prepared in ChemDraw (Version 17.1)
The PBPs can be divided into high molecular mass (HMM) and low molecular
mass (LMM) PBPs. The HMM PBPs are responsible for PG polymerisation and
insertion of PG into an existing wall, and they are divided into Class A and Class B
PBPs. Both Class A and B have C-terminal domains with transpeptidase activity.
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The N-terminal domain of Class A PBPs is responsible for transglycosylase activity.
Class B PBPs interact with cell cycle proteins such as RodA and FtsW which have
been shown to possess transglycosylase activity (Meeske et al., 2016; Taguchi et al.,
2019). As such the Class A and B PBPs are often referred to as bi-functional and
monofunctional respectively. Some bacteria have monofunctional enzymes, with
transglycosylase activity, which are similar to the N-terminal domain of Class A
PBPs (Sauvage et al., 2008). The LMM PBPs make additional modifications to the
PG and are involved in cell separation, peptidoglycan maturation or recycling.
LMM PBPs include endopeptidases which separate glycan strands by cleaving
cross-bridges, and D,D-carboxypeptidases which act in concert with autolysins to
continually remodel and maintain the PG layer (Typas et al., 2011; Sauvage et al.,
2008).
Transglycosylation (TG) is the polymerisation of multiple Lipid II precursors to
form a glycan chain, whilst transpeptidation (TP) is the formation of cross-bridges
between the pentapeptides of individual Lipid II molecules. TP between unbranched
or branched Lipid II PG precursors generates direct cross-links or indirect cross-links
respectively (Filipe and Tomasz, 2000).
TP between two peptide stems occurs when the peptide bond of D-Ala-D-Ala on the
Lipid II (donor) undergoes nucleophilic attack by the active site serine of the PBP
forming an acyl-enzyme intermediate. A second Lipid II molecule (acceptor) then
attacks the acyl-enzyme intermediate. The nucleophile for this reaction is either
the primary amine of lysine (for a direct cross-link) or the amine of the dipeptide
branch (for an indirect cross-link). This results in the cross-linking of two Lipid II
molecules within the PG (Sauvage et al., 2008).
S. pneumoniae contains three bi-functional Class A PBPs; PBP1a, PBP1b and PBP2a.
None of these are essential but double mutants (PBP1a and PBP2a) are not viable.
Interestingly, whilst the PBPs are able to utilise both Lipid II and iGln Lipid II for
TG, the essentiality of MurT/GatD appears to be due to the inability of PBPs to
cross-link the peptide stems of Lipid II in the absence of iGln at position 2 (Gisch
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et al., 2015).
1.4 MurM and branching of peptidoglycan in S.
pneumoniae
1.4.1 Function of MurM
In S. pneumoniae the MurMN operon encodes two aminoacyl ligases, MurM and
MurN, which are responsible for the formation of dipeptide branched Lipid II(Lys)
which results in indirectly cross-linked PG. MurM is responsible for the addition of
L-Ser or L-Ala to the ε-amino group of the third position lysine in the pentapeptide
of the Lipid II(Lys). MurN subsequently appends an invariable L-Ala to this amino
acid, generating a dipeptide branched Lipid II(Lys) (Fiser et al., 2003; Lloyd et al.,
2008). Neither MurM or MurN are essential; the deletion of MurN generates an
unusual mono-branched phenotype, whilst deletion of MurM completely abolishes
all indirect cross-linking. Whilst MurN is well conserved, MurM is highly mosaic
with many different allelic variations between strains. Unlike most bacteria, the PG
of S. pneumoniae is highly heterogenous and is comprised of both direct and indirect
cross-links, in proportions which vary from strain to strain. The key determinant
of MurM bias towards incorporation of L-Ala or L-Ser was found to be a 30 amino
acid sequence at position 244-274, with particular importance placed on the residue
at 260. MurM alleles containing a threonine or lysine at position 260 were found to
more commonly incorporate L-Ser or L-Ala into the pneumococcal wall respectively
(Filipe et al., 2001b). In vitro comparison of MurM alleles from S. pneumoniae (159) and
S. pneumoniae (Pn16) supported this, and confirmed that the amino acid selectivity
was not influenced by strain specific differences in the transfer ribonucleic acid
(tRNA) pool (Lloyd et al., 2008).
MurM is a ∼45 kDa cytoplasmic protein, however in order to access its Lipid
II(Lys) substrate it must come into very close proximity with the membrane.
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Although the substrate for MurM is Lipid II(Lys) it is important to remember
that the hydrophobic lipid tail is embedded in the membrane and the part of the
substrate which interacts with MurM is the pentapeptide chain. All previous
studies on MurM have been conducted using Lipid II(Lys) so it is unknown
whether iGln Lipid II(Lys) is also a substrate. In contrast to the Lipid II(Lys),
the second substrate of MurM is a large (Molecular Weight (MW) = 25-30 kDa)
hydrophilic tRNA. The different molecular environments and requirements of these
two substrates indicate that MurM is a complex and versatile protein. It remains
unclear whether MurM carries bound tRNA directly to the membrane or whether
it follows a ping-pong mechanism of action, whereby it interacts with the tRNA
in the cytoplasm, forming a stable aminoacyl-intermediate which subsequently
localises to the membrane to act upon the Lipid II(Lys). MurM has been shown to
utilise cognate alanyl-tRNAAla and seryl-tRNASer but interestingly, demonstrated
a catalytic preference to seryl-tRNAAla (Shepherd, 2011). In addition, a minihelix
tRNA comprising the acceptor stem and TψC loop and stem, was enough to support
MurM activity (Lloyd et al., 2008). Due to the highly mosaic nature of MurM
it is not surprising that the enzyme activity varies between strains; Lloyd et al.
(2008) demonstrated that aminoacylation of MurM159 was ∼ 5-fold more active than
MurMPn16.
1.4.2 Structure of MurM
In S. aureus, functional homologues of MurMN such as FemXAB are involved in
the synthesis of the pentaglycine cross-bridge. These homologues can provide a
useful comparison for both structural modelling and functional elucidation of S.
pneumoniae MurM. The crystal structure of MurM has not yet been solved, however
its predicted structure consists of two domains; the first is a globular domain
comprising two twisted β-sheets surrounded by helices and the second domain
is an α-helical coiled-coil arm (Figure 1.7). The overall predicted structure shows
some similarities to seryl-tRNA synthetases (SerRS) (Fiser et al., 2003) which is
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unsurprising, given that tRNA is a common substrate. A crystal structure of
Thermus thermophilus (T. thermophilus) SerRS complexed with tRNA showed that
the coiled-coil region made contact with the TψC loop of the tRNA, directing the
acceptor stem into the active site of the synthetase (Biou et al., 1994). The coiled-coil
domain of MurM has therefore been suggested to serve an analogous function.
However, interestingly, the coiled-coil domain is not essential for tRNA binding in
all homologues, since Weissella viridescens (W. viridescens) FemX does not possess this
domain but still utilises tRNA as a substrate (Biarrotte-Sorin et al., 2004). Whilst the
second substrate for MurM is Lipid II(Lys), for the W. viridescens FemX homologue
the second substrate is the soluble UDP-MurNAc-5P precursor. This suggests
that the coiled-coil region in MurM and other FemXAB family members may be
important for targeting the protein to the membrane, and hence is not required in
W. viridescens FemX (Maillard et al., 2005).
Figure 1.7: Predicted structure of MurM. MurM is comprised of a globular domain and a
coiled-coil domain linked by a flexible unstructured region. Figure adapted from (Fiser et al.,
2003).
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1.4.3 MurM and penicillin resistance
The product of MurM is the substrate for the downstream PBPs, therefore it is
unsurprising that MurM has been identified as a non-PBP penicillin resistance
determinant (Smith and Klugman, 2001). Whilst the proportion of overall cross-links
in the PG varies very little between susceptible and resistant strains of S. pneumoniae,
the proportion of indirect cross-links (branched PG) correlates strongly with
resistance (Garcia-Bustos and Tomasz, 1990). In many penicillin susceptible strains
>70 % of the PG contains linear peptides, whilst in contrast, many penicillin
resistant strains primarily consist of branched stem peptides (Garcia-Bustos and
Tomasz, 1990). However, the presence of highly branched PG does not confer
resistance, as demonstrated by S. pneumoniae R6 which is a susceptible strain with a
high proportion (40 %) of branched peptides in its PG (Garcia-Bustos and Tomasz,
1990). It was proposed that remodelling of the PBP active site, which results in
low-affinity PBPs, may also drive a change in substrate preference, promoting the
use of hydrophobic branched muropeptides over the more common linear ones
(Garcia-Bustos and Tomasz, 1990). Therefore the presence of a functional MurM is
important to the development of resistance.
Studies that have investigated the effect of transforming susceptible strains with
PBPs and/or MurM from resistant strain donor DNA, all demonstrate that MurM
alone is not sufficient for resistance, and that low-affinity PBPs are required. It has
been demonstrated that deletion of MurM from penicillin resistant pneumococci
results in a dramatically reduced MIC (from resistant to sensitive), and that
this resistance can be restored by transformation with plasmid encoded MurM.
Additionally, MurM does not show strain specificity, i.e. a MurM from another
resistant strain can fully restore the MIC (Filipe et al., 2002). Some studies
investigating high-level penicillin resistance (MIC of 16 µg.mL-1) show that
transforming PBPs from a highly resistant strain alone is sufficient to convert a
sensitive R6 strain to high level penicillin resistance (Dowson et al., 1995), whilst
other studies demonstrate that transforming PBPs alone can only partially restore
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resistance, and that MurM is required to achieve full levels of resistance (Smith and
Klugman, 2000, 2001).
These conflicting results may have arisen because these experiments were all
conducted with different strains, for which both PBPs and MurM are highly mosaic.
Categorising MurM alleles as ’altered’ MurM and ’standard’ MurM, whereby
’altered’ can enhance resistance levels in the presence of low-affinity PBPs and
’standard’ does not, may be useful. It is possible that the strain that achieved full
resistance in the absence of MurM, possessed a ’standard’ MurM allele, whilst
the strain that demonstrated MurM dependence for restoring high level penicillin
resistance, possessed an ’altered’ MurM. This may also explain why MurM from
R36A (sensitive) can substitute for Pen6 (resistant) MurM (Filipe et al., 2000b). It
is possible that, whilst R36A does not contain low-affinity PBPs, and is therefore
a sensitive phenotype, it possesses an ’altered’ MurM, and so, has the potential to
support a resistant phenotype.
Previous studies demonstrated that inactivation of the MurMN operon not only
resulted in the disappearance of cross-bridges from pneumococci but also a complete
loss of penicillin resistance (Fiser et al., 2003). Taken together, these results suggest
that whilst MurM alone is not sufficient for penicillin resistance, the presence of a
functional MurM allele is required for the development of penicillin resistance, and
an ’altered’ MurM allele may provide additional protection against high-levels of
penicillin. Reduction in β-lactam resistance by inactivation of cell wall branching
enzymes has also been identified in S. aureus (Berger-Bächi and Tschierske, 1998)
and Enterococcus faecalis (Bouhss et al., 2002). This presents a new paradigm for
the development of novel antibiotics, since the inhibition of cell wall branching
enzymes such as MurM may restore penicillin sensitivity to previously resistant
strains (Fiser et al., 2003).
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1.5 tRNA and aminoacyl-tRNA synthetases
1.5.1 The role of tRNA in protein synthesis and beyond
tRNA is a large macromolecule comprised of 70-96 nucleosides (adenosine (A),
guanosine (G), uridine (U) and cytosine (C)), and modified versions thereof (Björk
et al., 1987). tRNA is folded into multiple stem-loop structures, whereby nucleotides
in the stems are stabilised by Watson-Crick base pairing. The tertiary structure
is often represented as a cloverleaf (Figure 1.8a) but actually forms an L-shape in
3D space (Figure 1.8b). Nucleotide positions which are common to all tRNAs are
numbered, some of these were identified as invariant and semi-invariant positions,
and additional nucleotides can be added in the D-loop or variable loop (Sprinzl et al.,
1989). The function of tRNA is to ’carry’ amino acids to specific cellular locations
for use in metabolic processes. The sequence at the 3’ end of all tRNAs is CCA; this
is the site where an amino acid is covalently attached to the 2’ hydroxyl (OH) or
3’OH of the terminal ribose of the specific tRNA. This reaction is catalysed by the
corresponding aminoacyl-tRNA synthetase (aaRS).
During protein synthesis, genetic information encoded on messenger ribonucleic
acid (mRNA), in the form of codons, is translated into amino acids by the ribosome.
The ribosome matches each mRNA codon with the corresponding anticodon
of an aminoacyl-tRNA (aa-tRNA). The ribosome is a large molecular complex
made up of ribosomal ribonucleic acid (rRNA) and proteins; upon establishing
a codon-anticodon match, the amino acid is transferred from the aa-tRNA to the
preceding amino acid generating a polypeptide chain (Figure 1.9). There are many
codons in the genome which represent the same amino acid, and the genetic code is
therefore referred to as degenerate. These synonymous codons are often used with
different frequencies within the genome, which is referred to as codon bias. There are
more tRNAs than there are amino acids because some tRNAs exist as isoacceptors
(tRNAs possessing alternate anticodons which encode the same amino acid) (Novoa
and de Pouplana, 2012). However, whilst there are 61 codons in the universal genetic
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Figure 1.8: Structure of tRNA a) The secondary structure of tRNA as represented by
a cloverleaf diagram b) The tertiary structure of Yeast phenylalanine tRNA (1EHZ) as
determined by X-ray crystallography (Shi and Moore, 2000).
code, there are fewer than 45 different tRNAs in most organisms. Some tRNAs
possess anticodons which can recognize multiple, but not necessarily every, codon
corresponding to a specific amino acid (Lodish et al., 2008). This phenomonen is
explained by the ’wobble hypothesis’, for which the third (3’) residue of mRNA and
the first (5’) residue of the anticodon have flexibility in their binding interaction
(Crick, 1966).
Figure 1.9: Elongation and termination steps of bacterial translation. Figure from Zaher
and Green (2009).
The fidelity of protein synthesis must be maintained to ensure that proteins fold
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and function correctly. Cells have evolved a number of mechanisms to ensure that a
high enough fidelity can be maintained whilst minimising the energy expenditure
required to do so. Two processes a) codon-anticodon recognition by the ribosome
(not discussed here) and b) correct pairing of an amino acid to cognate tRNA by
aaRSs, dictate the overall fidelity of protein synthesis, which is estimated to be 10-4 -
10-3 (Ibba and Söll, 2000; Bouadloun et al., 1983; Edelmann and Gallant, 1977; Kramer
et al., 2010; Kurland, 1992; Yadavalli and Ibba, 2012).
Whilst protein synthesis is the most widely known function for tRNAs, they serve
many other non-canonical biological functions. These were classified into 4 main
groups; translation, tRNA dependent regulation, genomic interactions and synthetic
functions (Katz et al., 2016). Amino acids are provided by aa-tRNAs for a range of
non-translational synthetic functions including modification of cellular envelopes,
porphyrin biosynthesis, protein degradation pathways, antibiotic synthesis and
PG synthesis (Banerjee et al., 2010). Whilst some tRNA isoacceptors can be
utilised in both translation and non-canonical functions, some organisms possess
specific non-proteogenic isoacceptors. In S. aureus unusual tRNAGly isoacceptors
which support PG biosynthesis but not protein synthesis have been identified and
demonstrated to bind weakly to elongation factor thermo unstable (EF-Tu) (Bumsted
et al., 1968; Giannouli et al., 2009; Levicán et al., 2005). For more information on
synthetic or non-synthetic functions of tRNA the author refers the reader to Katz
et al. (2016).
A significant amount of research has been focused on identifying exactly which
elements of tRNA allow aaRSs to discriminate between different tRNAs. These
so called ’identity elements’ can be positive (determinants) assisting recognition
by cognate aaRSs, or negative (anti-determinants) which prevent interactions with
non-cognate aaRSs. Identity elements most commonly form direct interactions with
aaRSs and are located in the 3’ terminus of the acceptor stem and anticodon loop. A
total of 40 positions, none of which are found in the continuous acceptor stem or
TψC-loop, have been demonstrated to act as identity elements (Giegé et al., 1998).
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Location and extent of identity determinants varies significantly between tRNAs;
some are single nucleotide variations such as the discriminator base at position
73, or a unique base pair which is sufficient for recognition (Hou and Schimmel,
1988), others occur as combinations occurring in the anticodon and acceptor stem.
In some cases the discriminator base is critical (Pallanck et al., 1992) and in others it
is unimportant (Hasegawa et al., 1992). Likewise, whilst most aaRSs require distal
interactions with the anticodon for recognition, a few exceptions exist where there
are too many isoacceptors with different anticodon nucleotide combinations to
provide a unique anticodon:aaRS match (Pang et al., 2014). In addition to direct
interactions of identity elements, aaRSs can also recognise specific architectural
features belonging to the tRNAs (Giegé et al., 1998).
In addition to the aaRSs, identity elements of tRNAs are also used for recognition by
other proteins. For example base-pairing at position 51-63 of tRNA has been shown
to modulate affinity to T. thermophilus EF-Tu; a protein which facilitates the binding
of aa-tRNA to the ribosome (Sanderson and Uhlenbeck, 2007).
1.5.2 Aminoacylation by aaRS
The aminoacyl-tRNA synthetases (aaRSs) are proteins responsible for
aminoacylating the specific amino acid to its cognate tRNA (also referred
to as charging the tRNA). Whilst most aaRS are highly specific for aminoacylation
of a single amino acid (aa) to its cognate tRNA, some aaRSs have dual activity and
are capable of charging two tRNAs with their cognate amino acids (Lipman et al.,
2002). This occurs in a two step process; amino acid activation and transfer (where
aa is amino acid):
aa + ATP −→ aa-AMP + PPi
aa-AMP + tRNA −→ aa-tRNA + AMP
In amino acid activation, the carboxyl group of the amino acid attacks the
adenosine 5’triphosphate (ATP), forming an aminoacyl-adenylate (aa-AMP) and
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releasing inorganic pyrophosphate (PPi). In the second step the aa-AMP undergoes
nucleophilic attack by the 2/3’OH on the ribose of the 3’ terminal nucleotide of the
tRNA (Berg et al., 2002; Li et al., 2015).
Figure 1.10: Mechanism of aminoacylation by aminoacyl-tRNA synthetases. Figure from
Li et al. (2015)
The aaRS’s can be categorised into two major classes based on structural similarities
and sequence motifs. The Class I synthetases are mostly monomeric whilst the
Class II synthetases are mainly dimeric or multimeric. Class I and II contain 2 and 3
conserved motifs respectively; the motifs are shared within the class but completely
absent in the other class (Burbaum et al., 1990; Eriani et al., 1990). Additionally,
the OH group on the ribose of the tRNA which catalyses nucleophilic attack on
the adenylate is strongly correlated with the Class system, with Class I using
the 2’OH and Class II using the 3’OH. There are aaRSs that are exceptions to
these classifications, alanyl-tRNA synthetase (AlaRS) and glycyl-tRNA synthetase
(GlyRS) only possess one of the three Class II motifs, and whilst phenylalanyl-tRNA
synthetase (PheRS) and phosphoseryl-tRNA synthetase (SepRS) possess the Class II
motifs, they aminoacylate tRNA at the 2’OH of ribose (Eriani et al., 1990; Englert
et al., 2013) (Table 1.3). Despite the Class I and II aaRSs aminoacylating at 2’OH
and 3’OH respectively, once appended, the amino acid can migrate back and forth
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between the two positions (Schimmel and Söll, 1979). However, interestingly the
position of the amino acid can be an important determinant for usage in protein of
PG synthesis; the A site of the ribosome is specific for the 3-O-aminoacyl isomer
whilst MurM (and homologues from other species) accept only 2’-O-aminoacyl
isomers (Fonvielle et al., 2010; Shepherd, 2011).
Class I Class II
arginyl-tRNA synthetase (ArgRS) aspartyl-tRNA synthetase (AspRS)
cysteinyl-tRNA synthetase (CysRS) asparaginyl-tRNA synthetase (AsnRS)
glutamyl-tRNA synthetase (GluRS) histidyl-tRNA synthetase (HisRS)
glutaminyl-tRNA synthetase (GlnRS) lysyl-tRNA (LysRS)
isoleucyl-tRNA synthetase (IleRS) phenylalanyl-tRNA synthetase
(PheRS)b
leucyl-tRNA synthetase (LeuRS) prolyl-tRNA synthetase (ProRS)




tyrosyl-tRNA synthetases (TyrRS) alanyl-tRNA synthetase (AlaRSa)




Table 1.3: Class I and class II synthetases. Class I enzymes contain 2 conserved motifs (not
found in Class II aaRS’s) and aminoacylate at the 2’OH of the terminal nucleotide ribose of
the tRNA. Class II enzymes contain 3 conserved motifs (not found in Class I aaRSs) and
aminoacylate at the 3’OH of the tRNA’s terminal nucleotide ribose. There are however
some exceptions (a) indicates synthetases which only have one of the three sequence motifs
and (b) indicates Class II enzymes which aminoacyate at the 2’OH of the tRNA’s terminal
nucleotide ribose. Table modified from Schimmel (1991).
1.5.3 Substrate selection by aaRSs
tRNA selection by aaRSs
In order to differentiate between cognate and non-cognate tRNAs, aaRSs largely
rely on direct interaction with, and recognition of specific identity elements of the
tRNA, however recognition of structural features of tRNA have also been observed
(Giegé et al., 1998). The coiled-coil region of T. thermophilus SerRS was shown to
make direct contact with the TψC loop of the tRNA, directing the acceptor stem into
the active site (Biou et al., 1994). Interestingly, successful recognition of the correct
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tRNA by the aaRS has also been shown to modulate the affinity for cognate amino
acid recognition (Ibba et al., 1996).
Selecting the cognate amino acid and editing mechanisms
As mentioned previously correct pairing of an amino acid to its cognate tRNA
by the aaRSs is key to maintaining the fidelity of protein synthesis. aaRSs have
had to overcome the fact that smaller or isosteric amino acids may also bind
in a pocket designed for the cognate amino acid. Examples include, binding
of serine and glycine (noncognate) in AlaRS, serine (noncognate) in ThrRS and
LysRS, valine (noncognate) in IleRS and threonine (noncognate) in ValRS. Under
normal conditions the overall error rate of misaminoacylation by the aaRSs is
very low (∼10-6) which is 100-1000 times more accurate than protein synthesis
(Francklyn, 2008). The double sieve mechanism was proposed to explain how
aaRS are able to select for their cognate amino acid and deselect for non-cognate
amino acids, in order to maintain this high fidelity. Amino acids larger than the
substrate were proposed to be excluded at the amino activation site (coarse sieve),
but smaller isosteric amino acids may be incorrectly activated. The fine sieve was
proposed to be a hydrolytic editing mechanism to remove mis-activated amino
acids, whilst retaining the cognate amino acid (Pang et al., 2014). Since some
aaRSs are able to activate non-cognate amino acids that are larger, the double sieve
mechanism does not provide an accurate representation of this issue. In contrast
to a simple sieve mechanism, it is instead a complex interplay of steric, hydrogen
bonding and electrostatic forces which regulates the production of correctly acylated
tRNA (Francklyn, 2008). For example threonine, serine and valine have very
similar molecular weights and side chain stereochemistry; whilst ThrRS commonly
mis-aminoacylates with serine, it is able to successfully discriminate between
threonine and valine due to the absence of the hydroxyl required for zinc ion
coordination on the latter (Berg et al., 2002).
If a non-cognate amino acid is activated cis-editing by aaRSs can either occur in
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the catalytic site, after activation but before transfer to tRNA (pre-transfer editing)
or in a distinct editing site following the transfer of amino acid to the 3’ CCA
of the cognate tRNA (post-transfer editing). The requirement for editing varies
significantly between different synthetases, and the pre- and post-transfer editing
ability of different aaRSs is variable. The rate of amino acid transfer to tRNA has
been found to be inversely correlated with the occurrence of pre-transfer editing
(Dulic et al., 2010). Additionally, the rate of translocation to the editing site does
not vary between tRNA mis-acylated with different amino acids (Nomanbhoy and
Schimmel, 2000).
AlaRS and ThrRS mis-acylate serine and so rely on editing activities to maintain the
fidelity of protein synthesis. Mis-aminoacylation with serine or glycine by AlaRS
occurs at an error rate of 1/500 or 1/250 respectively. As a result many aaRSs have
a distinct editing domain which can correct mis-acylation. The editing domain
of AlaRS weakly aligns with that of ThrRS; in AlaRS, but not ThrRS, the editing
domain is found in all kingdoms of life, and so may have been acquired by ThrRS
during evolution (Beebe et al., 2003). Cys666 and Cys182 have been identified as
critical for hydrolytic editing in AlaRS and ThrRS respectively (Beebe et al., 2003;
Ling and Söll, 2010; Wu et al., 2014). Cys443 was also identified as necessary for
editing of alanine in ProRS, and additional sites (His73, His77 and His186) proposed
to be important in zinc coordination, are important for editing in ThrRS (Beuning
and Musier-Forsyth, 2000; Dock-Bregeon et al., 2000).
Additional free-standing editing domain homologues have been identified for some
aaRSs (An and Musier-Forsyth, 2005; Ahel et al., 2003). Whilst the AlaXs are the most
widespread trans-editing factors, interestingly, S. pneumoniae does not encode any
known AlaXs. It is therefore likely that another mechanism exists to help maintain
the fidelity of protein synthesis in this bacteria (Shepherd and Ibba, 2013a).
Despite numerous quality control mechanisms, decreased translational fidelity can
arise as a result of a genetic mutation, aminoglycoside antibiotics, and a variety of
environmental stresses such as nutrient deprivation and oxidative stress (Mohler
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and Ibba, 2017). Treatment of ThrRS with H2O2 has been shown to abolish editing
activity, resulting in an increase in seryl-tRNAThr (Wu et al., 2014).
1.6 Oxidative stress in S. pneumoniae
Obligate anaerobes and microaerophiles cannot grow in the presence of oxygen (O2),
in addition, the growth of aerobic bacteria may be severely affected during hypoxia.
This demonstrates that molecular (O2) is highly toxic; whilst (O2) itself does not react
with most bio-molecules, toxicity arises from its partial reduction, by the progressive
addition of electrons (e-), into (O2) species that are more reactive than itself (Figure
1.11) (Imlay, 2003; Mishra and Imlay, 2012). Almost all organisms possess enzymes
that scavenge superoxide (O2-) and H2O2 to provide protection from oxidative stress
(Mishra and Imlay, 2012). Oxidative stress can come from a range of exogenous
sources including H2O2-secreting lactic acid bacteria, NADPH oxidase responses
of plants and macrophages, and redox reactions from phytochemistry (Mishra and
Imlay, 2012).
Figure 1.11: The reduction of oxygen to form reactive oxygen species (ROS). Oxygen
is reduced by sequential addition of electrons to form superoxide, hydrogen peroxide,
hydroxyl radical and finally water. Figure from Mishra and Imlay (2012).
Under aerobic conditions, bacteria convert glucose into lactic acid with the
concomitant generation of ATP. Lactate oxidase (Lox) converts lactic acid to
pyruvate, generating H2O2 as a metabolic biproduct (Seki et al., 2004). Pyruvate can
subsequently be converted to acetate via the thioclastic pathway, or by pyruvate
oxidase generating additional ATP. NADH oxidase (NOXase) directly catalyzes the
four-electron reduction of O2 to water (H2O) and is important for aerobic growth
(Gibson et al., 2000). In many lactic acid bacteria, Lox NOXase and pyruvate oxidase
are only active when the glucose source has been exhausted (Taniai and Yoshida,
2008).
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H2O2 can also be converted into a highly reactive, and dangerous, hydroxyl radical
(HO by the Fenton-reaction:
Fe2+ + H2O2 −→ Fe3+ + HO + OH-
Fe3+ + H2O2 −→ Fe2+ + HOO + H+
O2- is also formed during aerobic growth by autoxidation of the respiratory
dehydrogenases. During normal turnover of dehydrogenases, if O2 collides with
a reduced flavin before it has transferred the electron to the next carrier, the e- can
partially reduce oxygen. The concentration of O2 will therefore dictate how quickly
O2- is produced (Imlay, 2003).
Reactive oxygen species (ROS) target many biological molecules including DNA,
RNA, proteins and lipids resulting in high mutation rates, growth defects and cell
death (Imlay, 2003; Mishra and Imlay, 2012).
Due to high prevalence of ROS, there are a number of major response regulators
that provide mechanisms to protect against oxidative stress. OxyR, SoxRS, and
RpoS in E. coli have been shown to be functionally conserved in proteobacteria
to Actinobacteria (Chiang and Schellhorn, 2012). Antioxidant enzymes such as
superoxide dismutases (SOD), catalase and hydroperoxidases, as well as DNA
repair mechanisms, provide protection against ROS in many bacteria. However, if
the oxidative stress exceeds the capacity of the bacterial response then the effects
will be toxic. In E. coli, low concentrations of H2O2 activate OxyR, resulting in
the expression of catalase, a protein that converts H2O2 to H2O and O2, and
transcriptional chaperones such as DnaK, which increase tolerance to aberrant
proteins.
However, despite these responses, under severe oxidative stress, bimodal killing of
E. coli is observed by H2O2 (Ling and Söll, 2010). 0.2-0.5 mM H2O2 can induce protein
mistranslation, and in E. coli H2O2 has been shown to cause oxidation of Cys182
of the ThrRS, impairing its editing capacity and increasing mis-aminoacylation of
tRNAThr with serine (Ling and Söll, 2010).
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S. pneumoniae is unique in that its Lox and Streptococcus pyruvate oxidase (SpxB)
genes are constitutively expressed, resulting in generation of more ATP but at the
expense of producing copious amounts of H2O2. Figure 1.12 shows the proposed
pathway of aerobic metabolism in S. pneumoniae (Taniai and Yoshida, 2008).
Figure 1.12: Proposed pathway of aerobic metabolism of glucose in S. pneumoniae.
Figure from Taniai and Yoshida (2008)
S. pneumoniae produces high levels (∼1.0 mM) of exogenous H2O2, killing or
inhibiting growth of other organisms such as S. aureus, Haemophilus influenza,
Morexella catarrahais and Neisseria meningitidis that are inhabiting the same
microenvironment (Pericone et al., 2000; Sel, 2009). It is intriguing therefore that
S. pneumoniae does not possess the global regulators (OxyR or PerR), or either of
the H2O2 scavenging enzymes (catalase and NADH peroxidase) that are present in
other species (Pericone et al., 2003). The mechanism by which S. pneumoniae survives
in high exogenous levels of H2O2 remains largely unknown, however pyruvate
oxidase (SpxB) is required for resistance to exogenous H2O2 and an aquaporin
(So-aqpA) is important for H2O2 detoxification (Pericone et al., 2003; Tong et al.,
2019).
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1.7 Hypothesis and Aims
High levels of H2O2 stress experienced by S. pneumoniae, along with few protective
mechanisms against oxidative stress have been characterised. S. pneumoniae has
been shown to experience high levels of H2O2 stress, and very few protective
mechanisms against oxidative stress have been characterised. In addition H2O2
has been shown to increase mis-aminoacylation and translational error in other
organisms. Therefore we propose that MurM shows a preference for mischarged
tRNAs, such as seryl-tRNAAla and seryl-tRNAThr as a mechanism for maintaining
translational fidelity during H2O2 stress, by directing mischarged tRNAs away from
protein synthesis into PG synthesis (Figure 1.13).
Figure 1.13: Proposed hypothesis of how MurM helps maintain the fidelity of protein
synthesis in the presence of oxidative stress. The presence of hydrogen peroxide (H2O2)
results in the oxidation of the cysteine residue in the editing domain of the aaRS. This causes
an increase in mis-aminoacylated tRNA species which are eliminated by incorporation into
the peptidoglycan by MurM. This diagram uses AlaRS and mis-aminoacylation with serine
as an example. AS = active site, ES = editing site. Figure created with BioRender.com
The main aims were to characterise the effect of H2O2 on AlaRS and ThrRS, to
investigate substrate specificity of MurM for cognate versus non-cognate aa-tRNAs
and Lipid II(Lys) versus iGln Lipid II(Lys). Computational modelling aimed to
provide a better understand of the structure of MurM and any possible sites of




The author would like to acknowledge the help of the Media Preparation Facility in
the School of Life Sciences at the University of Warwick, for providing media, and
standard buffers or solutions.
This chapter will outline the final, fully optimised protocols used to conduct
the research reported here. Where optimisation was required, the experimental
procedures and any interim results will be detailed and discussed in the appropriate
results chapter.
Many protocols and methods remain constant despite their broad range of
application. These standard methods will be outlined initially and any adjustments
or modifications to such methods will be discussed subsequently in direct reference
to the specific experiment.
All cell culture manipulations were conducted using appropriate aseptic techniques
inside a biological safety cabinet (Richmond Scientific).
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2.1 Chemicals, reagents, buffers and growth media
2.1.1 Chemicals and reagents
Unless otherwise stated all chemicals were supplied by Sigma-Aldrich (UK), Fisher
Scientific (UK) or Melford Laboratories Ltd.
2.1.2 Buffers
Buffers were prepared using MilliQ H2O and pH was adjusted using a SevenEasy
pH meter (Mettler Toledo) calibrated with pH 4.01, 7.01 and 10.01 buffer solution
standards (Thermo Scientific). Buffers used for protein purification were filtered
using a 0.2 µm MF-Millipore Membrane Filter, and buffers used for tRNA
preparations were autoclaved at 15 psi for 20 minutes (mins) at 120 ◦C prior to
use.
2.1.3 Growth media
Unless stated otherwise, where required antibiotics were used at a final
concentration of 100 µg.mL-1, 50 µg.mL-1 and 35 µg.mL-1 for Ampicillin (Amp),
Kanamycin (Kan) and Chloramphenicol (Cam) respectively in both solid and liquid
media cultures.
Liquid culture media
All liquid culture media used throughout this project were prepared as detailed
below:
• Luria-Bertani (LB) media (Bertani, 1951): 1.25 % (w/v) Bacto-tryptone, 0.625
% (w/v) yeast extract and 1.25 % (w/v) sodium chloride (NaCl) at pH 7.5.
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• Super Optimal Broth with Catabolite repression (SOC) media: 2 % (w/v)
Bacto-tryptone, 0.5 % (w/v) Bacto-yeast extract, 0.05 % (w/v) NaCl, 2.5 mM
potassium chloride (KCl) and 20 mM glucose at pH 7.0.
• Tryptic Soy Broth (TSB) media: 17 g.L-1 casein peptone (pancreatic), 2.5 g.L-1
dipotassium hydrogen phosphate (K2HPO4), 2.5 g.L-1 glucose, 5 g.L-1 NaCl
and 3 g.L-1 soya peptone.
• Brain Heart Infusion Media (BHI): 37 g.L-1 of BHI broth.
• Auto Induction Medium (AIM) 2YT Broth base including trace elements:
4.6 % (w/v) of dehydrated AIM medium (FORMEDIUMTM).
All media was sterilised by autoclaving at 120 ◦C for 15 mins.
Solid growth media
All solid media used throughout this project were prepared as detailed below:
• LB agar (LBA): LB medium with 1.5 % (w/v) bacto-agar.
• Muller-Hinton horse blood agar: 38 g.L-1 Muller-Hinton agar (Merck) with 5
% (v/v) defibrinated horse blood (EO Laboratories Limited).
• TSB agar: TSB media with 1.5 % (w/v) bacto-agar.
• BHI agar: BHI media with 1.5 % (w/v) bacto-agar.
Agar was sterilised by autoclaving at 120 ◦C for 15 mins. Agar was cooled to <50
◦C, appropriate antibiotics were added and plates were poured and left to dry in a
biological safety cabinet.
2.2 Characterising S. pneumoniae strains
All antimicrobial susceptibility testing was conducted in collaboration with John
Moat at the Antimicrobial Screening Facility, University of Warwick.
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2.2.1 Susceptibility testing by disk diffusion method
Glycerol stocks of S. pneumoniae (159) and S. pneumoniae (Pn16) were single colony
streaked onto Muller-Hinton horse blood agar plates and a single Oxacillin disk
(Oxoid
TM
) was placed on top of the area with the highest microbial load using
tweezers. Plates were incubated at 37 ◦C, overnight with 5 % (v/v) carbon
dioxide (CO2). The zone of inhibition surrounding the disk was measured and
the susceptibility determined in accordance with the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) disk diffusion method (EUCAST).
2.2.2 Minimum inhibitory concentration determination
Preparation of inoculum
Glycerol stocks of S. pneumoniae (159) and S. pneumoniae (Pn16) were plated onto
Muller-Hinton horse blood agar plates and incubated at 37 ◦C with 5 % (v/v) CO2
for 18 hours. ATCC S. aureus 29213 (for use as a positive control) was plated onto
LBA plates and incubated at 37 ◦C overnight. Cells were harvested using a cotton
swap and resuspended in phosphate-buffered saline (PBS) to a turbidity matched to
a McFarland standard 1.
Minimum inhibitory concentration determination by E-strip method
Inoculum was plated onto Muller-Hinton horse blood agar plates and a Penicillin G




) was applied to the centre of
the plate using tweezers. As a positive control a PenG E-strip was applied to ATCC
Staphylococcus aureus 29213. Plates were photographed and the zones of inhibition
were interpreted in accordance with Clinical Laboratory Standards Institute (CLSI)
(CLSI).
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Minimum inhibitory concentration determination by broth microdilution
method
A standard broth microdilution method was used in accordance with CLSI
protocol (CLSI). MIC values were determined using standard methods and data
was interpreted in accordance with the EUCAST breakpoints (EUCAST). ATCC
Staphylococcus aureus 29213 was used as a positive control. Strains were classified as
resistant or sensitive in accordance with EUCAST (EUCAST).
2.2.3 Whole genome sequencing of S. pneumoniae strains
The work outlined in this section was conducted in collaboration with Catherine
Rowland (University of Warwick). All sequencing was conducted at Micropathology
Ltd with the guidance and supervision of Dr Daniel Hand, and the bioinformatics
analysis was conducted by Dr Daniel Hand (Micropathology Ltd.)
S. pneumoniae growth and DNA extraction
10 mL BHI medium with 5 % (v/v) defibrinated Horse Blood (EO Laboratories
Limited) was innoculated with 500 µL glycerol stocks of S. pneumoniae (159) and
S. pneumoniae (Pn16). Cultures were incubated at 37 ◦C overnight, with 5 % (v/v)
CO2. Genomic DNA was prepared using Maxwell R© 16 DNA Purification Kits in
accordance with the manufacturers protocol.
Next generation sequencing
Deoxyribonucleic acid (DNA) was size and purity analysed using Fragment
Analyzer (Advanced Analytical) and quantified using an InvitrogenTMQubiTM 3.0
Fluorometer. Library preparation was conducted in accordance with Nextera R© XT
DNA Library Prep Kit Reference Guide. Next generation sequencing (NGS) was
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De novo genome assembly
Genomes were de novo assembled using SPAdes (Version 3.11.1) (Bankevich et al.,
2012), assessed using QUAST (Version 4.1) (Gurevich et al., 2013) and annotated
with Prokka (Version 1.12) (Seemann, 2014).
The de novo assembled sequences of MurM from S. pneumoniae (159) and S.
pneumoniae (Pn16) were aligned with the previously published sequences (Lloyd
et al., 2008) using CLUSTAL OMEGA (Version 1.2.4) multiple sequence alignment
tool (Sievers et al., 2011).
2.3 Manipulation of DNA
All construct details are presented in Table 2.1. All primers were synthesised by
Integrated DNA Technologies (IDT) and details can be found in Appendix 7.1.
All polymerase chain reactions (PCRs) were conducted using a SureCycler 8800
thermocycler (Agilent Technologies). Annealing temperatures for PCR conditions
were calculated using New England Biolabs (NEB) Tm Calculator (Version 1.9.13)
(https://tmcalculator.neb.com).
2.3.1 DNA sequencing of plasmid constructs
All sequencing was conducted by GATC Biotech (Eurofins) with 80 - 100 ng.µl-1
plasmid or 20 - 80 ng.µl-1 PCR product and 5 pmol.µl-1 primer. The quality of
sequence reads was analysed and assembled manually using A plasmid Editor
(ApE) (Version 2.0.55). The final sequence was translated to the corresponding
amino acid code using ExPASy Translate Tool (Gasteiger E., 2003) and aligned to
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the construct reference sequence using CLUSTAL OMEGA (Version 1.2.4) multiple
sequence alignment tool (Sievers et al., 2011).
Construct Name Description Antibiotic
selection
Affinity Tag
pET28a::MurA E. coli MurA in pET28 vector Kan C-terminal 6-His
pET26a::MurB P. aeruginosa 01293 MurB in
pET26a vector (El Zoeiby et al.,
2001)
Kan C-terminal 6-His
pET30a::MurC P. aeruginosa01 MurC in
pET30a vector (El Zoeiby
et al., 2000)
Kan C-terminal 6-His
pET21b::MurD P. aeruginosa01293 MurD in
pET21b (El Zoeiby et al., 2001)
Amp C-terminal 6-His
pET21b::MurE S. pneumoniae (Pn16) MurE in
pET21b (A.J. Lloyd, Warwick)
Amp C-terminal 6-His




pET26b::AlaRS S. pneumoniae (159) AlaRS in





S. pneumoniae (159) AlaRS




pET21b::SerRS S. pneumoniae (Pn16) SerRS in











gBlock of S. pneumoniae (159)
MurM sequence (Lloyd et al.





gBlock of S. pneumoniae (Pn16)
MurM sequence (as published











Table 2.1: Gene constructs used in this project. All constructs will be referred to as detailed
in the construct name.
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2.3.2 Colony PCR
Single colonies were re-streaked on LBA plates containing the appropriate antibiotic
selection and incubated at 37 ◦C overnight. Half of the re-streaked colonies were
harvested into 50 µL H2O and incubated at 100 ◦C for 10 mins. PCR mixes comprised
1 x Standard Taq Reaction Buffer (NEB), 1.5 mM magnesium chloride (MgCl2), 0.5
mM dNTPs, 0.5 µM Forward Primer, 0.5 µM Reverse Primer, 1.25 units (U) Taq
Polymerase, and 5 µL Template DNA (boiled colony mix). Final PCR conditions can
be found in Table 2.2.









Final Extension 72 05:00
Hold 4 8
Table 2.2: Colony PCR conditions
2.3.3 Visualisation of DNA
0.8 - 2 % (w/v) electrophoresis grade agarose (Invitrogen) was suspended in 40 mM
Tris, 20 mM acetic acid, and 1 mM ethylenediaminetetraacetic acid (EDTA) (pH 8.3)
and solubilised by microwaving. When cooled to ∼50 ◦C, 1 x GelRed R© nucleic acid
stain was added to the mixture which was cast as a flat bed gel and left to set at 4
◦C.
Samples were prepared using 1 x NEB Gel Loading Dye (no sodium dodecyl sulfate
(SDS)) and an appropriate ladder (Quick-Load R© 1 kb DNA Ladder, Quick-Load R©
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100 bp DNA Ladder (NEB)) prepared in accordance with the manufacturers protocol.
Gels were assembled in a MultiSUB Midi Horizontal Gel System (Cleaver Scientific).
Samples were loaded to each well and the gels were run at 100 volts (V) for 60 mins
in 40 mM Tris, 20 mM acetic acid, and 1 mM EDTA (pH 8.3). Gels were visualised
using Syngene G:Box and GeneSnap software (Version 7.12).
2.3.4 Gel extraction of DNA
Gels were visualised using a UVP Benchtop UV Transilluminator, bands of interest
were cut from the gel using a scalpel and extracted using Monarch R© DNA Gel
Extraction Kit as per the manufacturers protocol.
2.3.5 Purification of PCR products
PCR products were purified using Monarch R© PCR and DNA Cleanup Kit as per
the manufacturers protocol.
2.3.6 Quantification of DNA
1 µL sample of DNA was quantified using IMPLEN NanoPhotometer R©.
2.3.7 Plasmid purification
A single colony, from a transformation plate (Section 2.4.2) was used to inoculate
5 mL LB media, containing appropriate antibiotic selection, and incubated at 37
◦C, shaking at 180 revolutions per minute (rpm), overnight. Cells were pelleted by
centrifugation at 1,800 xg for 10 mins. Plasmid was isolated from cell pellets using
Monarch R© Plasmid Miniprep Kit in accordance with the manufacturers protocol.
Plasmid DNA was isolated from 5 mL LB media cultures using Monarch R© Plasmid
Miniprep Kit as per the manufacturers protocol.
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2.3.8 Gibson cloning of proteins
MurMPn16 and MurM159 gBlocks R© gene fragments containing a 5’ Ndel
and 3’ XhoI restriction sites, a C-terminal Tobacco Etch Virus (TEV)
protease cleavage site and a C-terminal hexa-histidine (6-His) tag were
designed, codon optimised using the GenScript Rare Codon Analysis Tool
(https://www.genscript.com/tools/rare-codon-analysis) and synthesised by IDT
(Appendix 7.1). PCR mixes comprising 1 x Q5 Master Mix, 0.5 µM Forward Primer,
0.5 µM Reverse Primer, 20 ng template DNA and 3 % (v/v) dimethyl sulfoxide
(DMSO) were used to amplify gBlocks R© and pET22b. Final PCR conditions can be
found in Table 2.3 and annealing temperatures of MurMPn16 and MurM159 gBlocks R©,
and pET22b amplifications were 65.5 ◦C, 64.5 ◦C and 64.5 ◦C respectively. PCR
products were purified and quantified as per Section 2.3.5 and 2.3.6.
Component Temperature (◦C) Time (min:sec)
Initial Denaturation 98 00:10





Final Extension 72 03:00
Hold 4 8
Table 2.3: PCR conditions for Gibson cloning of MurM. Conditions used for amplification
of gBlocks R© gene fragments and the pET22b vector.
Primers were designed using NEBuilder Assembly Tool and gBlocks R© were cloned
into pET22(b) using the NEBuilder HiFi DNA Assembly Master Mix in accordance
with the manufacturers protocol.
Following assembly, the reaction mix was used to directly transform NEB-5α
competent cells (Section 2.4.2). A colony PCR (Section 2.3.2) was conducted
42
and products analysed were using a 1 % (w/v) agarose gel (Section 2.3.3).
Plasmid stocks, from positive colonies, colonies were prepared (Section 2.3.7) and
sequenced. Constructs created using the Gibson method will be referred to as
pET22b::gMurMPn16 and pET22b::gMurM159 and the proteins expressed from these
will be referred to as gMurMPn16 and gMurM159 respectively from hereon in.
2.3.9 Site-directed mutagenesis of gMurMPn16
Primers were designed using the NEBaseChanger (Version 1.2.7) and synthesised by
IDT. Site directed mutagenesis was conducted using Q5 R© Site-Directed Mutagenesis
Kit as per the manufacturers protocol. In addition 3 % (v/v) DMSO was added
to the PCR reaction and the cycling conditions were modified slightly (Table 2.4).
Reactions were directly transformed into NEB R©5-α competent cells (Section 2.4.2),
from which plasmid stocks were miniprepped, quantified and sequenced (Section
2.3.7, 2.3.6 and 2.3.1).
Component Temperature (◦C) Time (min:sec)
Initial Denaturation 98 00:30





Final Extension 72 02:00
Hold 4 8
Table 2.4: PCR conditions for site directed mutagenesis of gMurMPn16
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2.4 Protein expression
During cell culture, the optical density at 600 nm (OD600nm) was monitored using a
Jenway 6306 UV-visible spectrophotometer.
All competent cell lines used throughout this project are detailed in Table 2.5. MurG,
porcine heart isocitrate dehydrogenase (IDH), yeast inorganic pyrophosphatase
(IPP) and DacB proteins used throughout this project were provided by Julie Tod
and Anita Catherwood (University of Warwick).




















F-ompT hsdSB(rB-, mB-) gal
dcm (DE3) pLysSRARE[T7p20
ileX argU thrU tyrU glyT




JM109 endA1 glnV44 thi-1 relA1
gyrA96 recA1 mcrB+





Table 2.5: Competent bacterial strains used for cloning and protein expression.
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2.4.1 Competent cell preparation
Competent cell glycerol stocks were streaked for single colonies on LBA plates and
incubated at 37 ◦C overnight. A single colony was inoculated into 2.5 mL of LB
media and incubated at 37 ◦C, shaking at 180 rpm overnight (overnight culture).
250 mL of LB media (supplemented with 20 mM magnesium sulphate (MgSO4))
was inoculated with 2.5 mL of overnight culture and incubated at 37 ◦C, shaking at
180 rpm. At an OD600nm of 0.4 - 0.6 absorbance units (AU) was achieved. Cells were
pelleted by centrifugation at 4,500 xg for 5 mins at 4 ◦C. Cells were kept on ice and all
equipment was pre-chilled for remaining manipulations. The cell pellet was gently
re-suspended in 100 mL ice-cold 30 mM potassium acetate, 10 mM calcium chloride
(CaCl2), 50 mM manganese chloride (MnCl2), 100 mM rubidium chloride (RbCl2)
(pH 8.0), 15 % (v/v) glycerol and incubated for 5 mins. Cells were pelleted by
centrifugation at 4,000 xg for 5 mins at 4 ◦C. The cell pellet was gently re-suspended
in 10 mL of 10 mM 3-(N-morpholino)propanesulfonic acid (MOPS), 74 mM CaCl2,
10 mM RbCl2 (pH 6.5), 15 % (v/v) glycerol and incubated for 15-60 mins. 50 µL
aliquots were flash-frozen in liquid nitrogen and stored at -80 ◦C.
2.4.2 Bacterial transformation
50 µL aliquots of competent cells were transformed with 50 - 100 ng plasmid, mixed
and left on ice for 30 mins. Competent cells were heat shocked at 42 ◦C for 45
seconds (s) and returned to ice for 2 mins. 200 µL of SOC was added and cells left to
recover at 37 ◦C, 180 rpm for 60 mins. 50 µL of recovered cells were plated onto LB
+ appropriate antibiotic and incubated at 37 ◦C overnight.
2.4.3 Starter culture preparation
For use in trial expressions, a single colony was used to inoculate 3 mL LB media +
appropriate antibiotic and incubated at 37 ◦C, shaking at 180 rpm for 5.5 hours.
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For use in large scale expressions, a single colony was used to inoculate 200 mL
of LB media + appropriate antibiotic and incubated at 37 ◦C, shaking at 180 rpm,
overnight.
2.4.4 Expression trials
Variables that may be altered during an expression trial include; cell line;
growth media; expression temperature and time; and concentration of isopropyl
β-D-1-thiogalactopyranoside (IPTG).
100 µL of starter culture was used to inoculate 10 mL of LB or AIM + appropriate
antibiotic. Cultures were incubated at 37 ◦C, shaking at 180 rpm. When the OD600nm
reached 0.6 AU, the temperature was reduced to the desired temperature (15 ◦C
upwards), in addition, cells in LB media were induced by the addition of 0.5 mM
IPTG. Cultures were incubated at the desired temperature, for the desired time,
shaking at 180 rpm. 1 mL samples were taken at regular time points for analysis.
Time course samples were harvested by centrifugation at 13,000 rpm for 5 mins.
Pellets were resuspended in 50 mM sodium phosphate, 300 mM NaCl (adjusted to
pH 7.5 using sodium hydroxide (NaOH)) and sonicated twice for 5 s at 10 % power
using a Bandelin Sonoplus sonicator. Cell debris was pelleted by centrifugation
at 16,000 (xg) for 5 mins. The supernatant was retained (soluble protein fraction)
and the pellet was resuspended in 500 µL of 0.1 % (v/v) Tween 20, 1 mM EDTA
(pH 8.0) and centrifuged at 16,000 xg. The supernatant was discarded and pellet
resuspended in 150 µL of 0.1 % (v/v) Tween 20, 1 mM EDTA (pH 8.0) (insoluble
protein fraction).
The soluble and insoluble fractions were analysed by SDS-PAGE (Section 2.5.5).
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2.4.5 Large scale protein expression
10 mL of a 200 mL starter culture was used to inoculate 1 L LB media supplemented
with 0.2 % (v/v) glucose and appropriate antibiotics in 2 L baffled flasks. The
cultures were incubated at 37 ◦C, shaking at 180 rpm. At an OD600nm of 0.6 AU,
protein expression was induced by the addition of 0.5 mM IPTG with a concurrent
reduction in temperature to 25 ◦C, cultures were incubated under these conditions
for the desired expression period (Section 2.4.6). Cells were pelleted at 10,000 xg for
20 mins and stored at -80 ◦C overnight.
2.4.6 Specific protein expression conditions
Following IPTG induction, AlaRS, AlaRS(mutant) and SerRS were expressed for 3
hours whilst Mur ligases (A-F), ThrRS and gMurM159 were incubated for 4 hours.
2.5 Protein purification
2.5.1 Standard protein purification methods
Unless otherwise stated purifications were conducted using an AKTATM pure
protein purification system (GE Healthcare) with UNICORN software (Version 6.3),
absorbance at 280 nm was monitored for identification of protein peaks. Cleaning,
stripping and storage of chromatography columns was conducted in accordance
with the manufacturers recommendations.
Immobilised metal affinity chromatography
Immobilised metal affinity chromatography (IMAC) was conducted at room
temperature (RT) and used to purify proteins containing C- or N-terminal
6-His tags. A 5 mL HisTrap
TM
HP column (GE Healthcare) or a 30 mL
TALON R© SuperflowTM (Clontech) column (poured and packed in house as per the
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manufacturers recommendations), were used throughout these methods. Columns
were equilibrated in 10 column volumes (CV) 0.2 µm filter sterilised MilliQ H2O,
followed by 10 CV of Buffer A (containing no/low Imidazole). Protein samples were
loaded directly onto the column via a sample loading loop (unless protein binding
was poor, in which case, the sample was allowed to recirculate over the column
using a P-1 peristaltic pump (Pharmacia Biotech)) at 4 ◦C. The column was washed
with 10 CV Buffer A and eluted using either a continuous gradient or step-wise
increases of Buffer B (high imidazole). Equilibration and elution were conducted at
a flow rate of ≤ 4 mL.min-1, whilst sample loading was conducted at a flow rate of
1 mL.min-1. The maximum back pressure for all steps was 0.3 MPa and the sample
loaded did not exceed the binding capacity of 200 mg His-tagged protein.
Size exclusion chromatography
Size exclusion chromatography (SEC) was used at RT to separate proteins based
on size. A Superdex S-200 column (26/60) (poured and packed in house as per
the manufacturers recommendations) or a HiPrepTM26/60 SephacrylTM S-200 HR
column (GE Healthcare) were used throughout these methods. Columns were
equilibrated in 1 CV H2O and 1 CV equilibration buffer. Sample was loaded in ≤ 2
mL using a sample loading loop. A flow rate and maximum pressure of 1 mL.min-1
and 0.5 MPa and ≤ 1.3 mL.min-1 and 0.15 MPa were used for Superdex 200 and
Sephacryl S-200 respectively.
2.5.2 Specific protein purification methods
Large scale expression and purification of Mur ligases
Pellets were thawed on ice and resuspended in 3 mL.g-1 50 mM
4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), 1 mM MgCl2
(pH 7.5), 2 mM β-mercaptoethanol, 1 µM pepstatin, 1 µM leupeptin and 0.2 mM
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phenylmethane sulfonyl fluoride (PMSF) and 2.5 mg.mL-1 lysozyme on a rolling
platform for 10 mins at 4 ◦C. The sample was sonicated on ice for 10 times for 15 s at
70 % power using a Bandelin Sonoplus sonicator, and centrifuged at 10,000 xg for 15
mins. The supernatant was subsequently centrifuged at 50,000 xg for 45 mins. A 5
mL HiTrap IMAC HP column (GE Healthcare) was equilibrated in 50 mM HEPES,
1 mM MgCl2, 500 mM NaCl (pH 7.5), 5 % (v/v) glycerol, 1 µM pepstatin, 1 µM
leupeptin and 0.2 mM PMSF. A gradient elution was performed between 0 and 500
mM imidazole in a buffer composed of 50 mM HEPES, 1 mM MgCl2, 500 mM NaCl
(pH 7.5), 5 % (v/v) glycerol, 1 µM pepstatin, 1 µM leupeptin and 0.2 mM PMSF
over 60 mins. Fractions were analysed by SDS-PAGE and fractions containing the
protein of interest were pooled and dialysed against 50 mM HEPES, 1 mM MgCl2,
50 mM NaCl (pH 7.5), 3 mM 1,4-dithiothreitol (DTT), 50 % (v/v) glycerol, 1 µM
pepstatin, 1 µM leupeptin and 0.2 mM PMSF overnight at 4 ◦C (Section 2.5.3).
Large scale expression and purification of aminoacyl-tRNA synthetases
Pellets were thawed on ice and resuspended in 3 mL.g-1 50 mM HEPES, 500 mM
NaCl (pH 7.0), 1 mM β-mercaptoethanol, 1 µM pepstatin, 1 µM leupeptin, 0.2 mM
PMSF and 2.5 mg.mL-1 lysozyme on a rolling platform for 30 mins at 4 ◦C. Sample
was sonicated 10 times for 15 s at 70 % power using a Bandelin Sonoplus sonicator,
and centrifuged at 10,000 xg for 20 mins. The supernatant was subsequently
centrifuged at 50,000 xg for 45 mins.
A 5 mL HiTrap IMAC HP column was equilibrated in 50 mM HEPES, 500 mM
NaCl, 10 mM Imidazole (pH 7.0), 1 mM β-mercaptoethanol, 1 µM pepstatin, 1 µM
leupeptin, 0.2 mM PMSF. Supernatant was loaded using a peristaltic pump and
purified using stepwise elutions of 50 mM HEPES, 500 mM NaCl (pH 7.0), 1 mM
β-mercaptoethanol, 1 µM pepstatin, 1 µM leupeptin, 0.2 mM PMSF containing 50,
100, 200 and 500 mM imidazole. Fractions were analysed by SDS-PAGE, appropriate
fractions were pooled and concentrated using a Vivaspin R©20 10 kDa molecular
weight cut off (MWCO) (Sartorius).
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Superdex 200 (26/60) SEC was implemented for additional purification of
AlaRS(mut), SerRS and ThrRS. The column was equilibrated in 50 mM HEPES,
500 mM NaCl (pH 7.0), 1 mM β-mercaptoethanol, 1 µM pepstatin, 1 µM leupeptin,
0.2 mM PMSF, and sample was loaded via a sample loading loop. Fractions were
analysed by SDS-PAGE, and fractions containing the protein of interest were pooled
and dialysed against 50 mM HEPES, 100 mM NaCl, 1 mM MgCl2 (pH 7.0), 1 mM
DTT, 1 µM pepstatin, 1 µM leupeptin and 50 % (v/v) glycerol.
Protein purification of gMurM159
During purification of this protein, all purification steps using an AKTATM pure
protein purification system (GE Healthcare) were conducted in a cold cabinet at 4
◦C.
Cells were resuspended in 3 mL.g-1 HEPES, 1 mM MgCl2 (adjusted to pH 7.0
with NaOH), 0.2 mM PMSF, 1 µM leupeptin and 1 µM pepstatin, and 2.5 mg.mL-1
lysozyme at 4 ◦C for 30 mins. Sample was sonicated 10 x 15 s at 70 % power and
centrifuged at 10,000 xg for 30 mins.
The pellet was resuspended in 50 mM sodium phosphate, 1 M NaCl, 0.5 mM
ethylene glycol-bis(β-aminoethyl ether)-N,N,N,N-tetraacetic acid (EGTA) (adjusted
to pH 7.0 with NaOH), 2 mM β-mercaptoethanol, 0.2 mM PMSF, 1 µM leupeptin,
1 µM pepstatin and incubated on a rolling platform for 30 mins at 4 ◦C to
solubilise MurM. The sample was centrifuged at 100,000 xg for 45 mins, at 4
◦C and supernatant retained. The solubilisation proceedure was repeated with
the pellet, and supernatants from each extraction were pooled. Supernatant was
sequentially fractionated between 25 and 50 % saturation ammonium sulfate
and centrifuged at 50,000 xg for 20 mins at 4 ◦C. The pellet was resuspended
in 50 mM sodium phosphate, 500 mM NaCl (adjusted to pH 7.0 with NaOH),
0.2 mM PMSF, 1 µM leupeptin and 1 µM pepstatin and purified by SEC on a
HiPrepTM 26/60 SephacrylTM S-200 HR column (GE Healthcare). Fractions were
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analysed by SDS-PAGE and fractions containing MurM were pooled. The sample
was subsequently loaded, via a sample loading loop, onto a 30 mL TALON R©
SuperflowTM column, equilibrated in IMAC 50 mM sodium phosphate, 500 mM
NaCl (pH 7.0), 0.2 mM PMSF, 1 µM leupeptin and 1 µM pepstatin. A gradient
elution was performed between 0 and 500 mM imidazole in a buffer composed
of 50 mM sodium phosphate, 500 mM NaCl, 500 mM Imidazole (adjusted to pH
7.0 with NaOH), 0.2 mM PMSF, 1 µM leupeptin and 1 µM pepstatin over 10 CV.
Fractions were analysed by SDS-PAGE, and fractions containing MurM were pooled
and dialysed against 50 mM HEPES, 1 mM MgCl2, 500 mM NaCl (pH 7.5), 2 mM
β-mercaptoethanol, 0.2 mM PMSF, 1 µM leupeptin and 1 µM pepstatin overnight
at 4 ◦C and subsequently against 50 mM HEPES, 1 mM MgCl2, 500 mM NaCl (pH
7.5), 3 mM DTT, 0.2 mM PMSF, 1 µM leupeptin, 1 µM pepstatin, 50 % (v/v) glycerol
overnight at 4 ◦C (Section 2.5.3).
2.5.3 Protein dialysis and storage
Prior to use, 15.9 mm diameter 12-14 kDa MWCO (Medicell International) dialysis
tubing was boiled for 30 mins in 2 % (w/v) sodium bicarbonate and 10 mM EDTA
(pH 7.5). Tubing was stored in 10 mM EDTA, 0.5 g sodium azide at 4 ◦C. Tubing
was rinsed with MilliQ H2O immediately before use.
Following purification, protein samples were dialysed overnight at 4 ◦C against
storage buffer and where necessary concentrated in a Vivaspin R©20 10 kDa molecular
weight cut off (MWCO) (Sartorius). The concentration of protein samples was
determined (Section 2.5.4) and samples were aliquotted and stored at -80 ◦C.
2.5.4 Protein quantification
In a plastic, semi-micro cuvette, 2 µL of protein was added to diluted Bio-Rad reagent
(as per manufacturers instructions), mixed and left to stand for 5 mins. Absorbance
at 595 nm was measured using a Jenway 6306 UV-visable spectrophotometer.
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Sample was diluted/concentrated as appropriate, until readings were within the
linear range. All concentrations were determined in triplicate.
A standard curve was generated using bovine serum albumin (BSA) and used to
generate the following formula for calculating the protein concentration:
[Protein] (mg.mL-1) = A595nm × 9.75× dilution factor
Protein extinction coefficient, molecular weight and pI were calculated using Expasy
ProtParam tool (Gasteiger et al., 2005).
2.5.5 Protein visualisation
To determine the protein purity following each purification step and at the end of
the purification process, protein samples were visualised by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE).
Discontinuous SDS-PAGE (Williams and Reisfeld, 1964; Laemmli, 1970) was used to
separate proteins based on molecular weight (MW) under denaturing conditions.
Unless otherwise stated, a 12 % resolving gel and a 4 % stacking gel were used
for analysis of proteins. Gels were cast using a Mini-PROTEAN R© Tetra handcast
system, the resolving gel was poured first (3/4 full) and overlaid with ethanol
and the gel was allowed to set. The ethanol was removed and a stacking gel
was poured, a comb inserted and was allowed to set. Resolving gel comprised
375 mM Tris (pH 8.8), 0.4 % (w/v) SDS, 12 % (w/v) acrylamide:bis acrylamide
(37.5:1) polymerised with 0.2 % (w/v) ammonium persulphate (APS) and 0.2 %
N,N,N’,N’-Tetramethylethylenediamine (TEMED). Stacking gel comprised 125 mM
Tris (pH 6.8), 0.4 % (w/v) SDS, 4 % acrylamide:bis-acrylamide (37.5:1) polymerised
with 0.25 % and 0.5 % TEMED.
For analytical gels, loading was standardised to 15 µg for crude extracts and 10 µg
for pure protein per well (maximum volume per well where protein concentration
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was limiting). Samples were prepared in loading buffer comprising 50 mM Tris
(pH 6.8), 0.1 % (w/v) SDS, 10 % (v/v) glycerol and bromophenol blue and heat
denatured at 98 ◦C for 10 mins, immediately before loading.
Gels were assembled in a Mini-PROTEAN R© Tetra Cell, samples were loaded to each
well and gels run at 170 V for 40 mins in running buffer comprising 25 mM Tris, 19
mM Glycine and 17.5 mM SDS (pH 8.3).
Gels were stained for 1 hour using Instant Blue Stain (Expedeon), washed briefly
in MilliQ H2O and imaged using Syngene G:Box with GeneSnap software (Version
7.12).
Silver staining
Gel was fixed using 50% (v/v) acetone, 1.2 % (v/v) trichloroacetic acid (TCA) and
0.015 % (v/v) formaldehyde for 15 mins. Gel was washed 3 x in dH2O, incubated
in dH2O for a further 5 mins and washed 3 x in dH2O again. The gel was soaked
in 50 % (v/v) acetone for 50 mins and subsequently in 1 mM sodium thiosulphate
(Na2S2O3) for 5 mins. Gel was washed 3 x in dH2O and stained using 15 mM silver
nitrate (AgNO3), 0.37 % formaldehyde for 8 mins. The gel was washed 2 x in dH2O
and developed for 10-20 s (or until visible) in 0.7 mM sodium carbonate (Na2CO3),
1 mM Na2S2O3 and 0.015 % formaldehyde. The reaction was quenched by addition
of 1 % acetic acid, rinsed in dH2O and imaged.
Western blots
Where required, the presence of His6-tagged proteins were confirmed by Western
blot. BioRad Mini-PROTEAN R©TGX Stain-Free
TM
pre-case gels were used for
SDS-PAGE.
Proteins were transferred from the gel onto a PVDF membrane using the
Trans-Blot R©Turbo
TM
transfer system. The membrane was incubated in 10 % milk
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in PBS overnight at 4 ◦C on a rotating platform. The primary antibody (mouse
anti-His6 (Roche)) at 0.2 µg.mL-1 in 0.1 % milk in PBS was added to the membrane
and incubated overnight at room temperature. The membrane was washed in 0.1 %
tween in PBS, 3 x for 20 mins. The secondary antibody (goat anti-mouse IgG horse
radish peroxidase conjugate (Promega)) was diluted 1:2500 in 0.1 % milk in PBS,
added to the membrane and incubated for 1-2 hours. The membrane was washed in
0.1 % tween in PBS, 3 x for 20 min. The western blot was developed using BioRad
Clarity Western ECL substrates were used at 1:1 ratio and imaged on the Image
Quant LAS4000.
2.6 Pentapeptide intermediate synthesis and purification
UDP-MurNAc-pentapeptide (UDP-MurNAc-5P) intermediates were synthesised as
described by Lloyd et al. (2008). D-Glu was replaced with D-isoGln for the synthesis
of the iGln UDP-MurNAc-5P variant.
2.6.1 Pentapeptide intermediate synthesis reactions
2 mL reactions comprising 50 mM HEPES, 10 mM MgCl2 in 200 mM
phosphoenolpyruvate (PEP) (pH 7.6), 1.2 µM MurA, 57.3 µM MurB, 1.47 U.mL-1
IDH, 5.53 U.mL-1 pyruvate kinase (PK), 4.3 µM MurC, 1.1 µM MurD, 4 µM MurE,
8.5 µM MurF, 1 mM DTT, 50 mM KCl, 0.2 mM nicotinamide adenine dinucleotide
phosphate (NADP), 8.2 mM UDP-GlcNAc, 26 mM D-L isocitrate, 6 mM adenosine
5’-triphosphate (ATP), 35 mM L-Ala, 55 mM D-Glu/105 mM D-iso-Gln (iGln), 35
mM L-Lys and 35 mM D-Ala-D-Ala were incubated at 37 ◦C overnight.
2.6.2 Pentapeptide intermediate purification methods
Anion exchange chromatography was used to separate pentapeptide intermediates
based on charge. Unless stated otherwise purifications were conducted using
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an AKTATM pure protein purification system (GE Healthcare) with UNICORN
software (Version 6.3). Cleaning, stripping and storage of chromatography columns
was conducted in accordance with the manufacturers recommendations.
A 75 mL Source 30Q column (poured and packed in house as per the manufacturers
recommendations) was used for purification of pentapeptide intermediates. The
column was equilibrated in 1.5 CV H2O, 1.5 CV 1 M ammonium acetate (adjusted
to pH 7.6 with acetic acid (CH3COOH) and 1.5 CV 10 mM ammonium acetate
(adjusted to pH 7.6 with CH3COOH). A flow rate and maximum pressure of 10
mL.min-1 and 0.5 MPa respectively were used throughout.
Sample was centrifuged at 1800 xg for 45 mins in a Vivaspin R©20 centrifugal
concentrator. The sample was loaded on to a Source 30Q anion exchange column
manually via the system pump, washed with 100 mL of 10 mM ammonium acetate
and eluted with a linear gradient from 0.01-1 M ammonium acetate (adjusted to pH
7.6 with CH3COOH) over 120 mins. Absorbance at 280 nm, 254 nm and 218 nm was
monitored for identification of the uridine containing pentapeptide peak. Fractions
containing the pentapeptide were pooled, lyophilised and resuspended in 500 mL
H2O at least six times using an ALPHA 2-4 LD PLUS Freeze Drier (CHRIST). The
product was finally resuspended in 1 mL H2O and stored at -80 ◦C
2.6.3 Pentapeptide intermediate quantification
180 µL sterile H2O added to a quartz cuvette and blanked on the Jenway 7305
UV-visible spectrophotometer at an absorbance of 260 nm. 2 µLof purified
UDP-MurNAc-5P sample was added and mixed thoroughly by pipetting (if sample
was highly concentrated it was diluted as required). This was conducted in triplicate,
an average reading for absorbance at 260 nm was used to calculate the concentration




× total cuvette volume
sample volume× dilution factor
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where the extinction coefficient (ε) at 260 nm of uridine was 10,000 M-1.cm-1.
2.6.4 Pentapeptide intermediate activity determination
A 200 µL reaction comprising 50 mM HEPES, 10 mM MgCl2 (pH 7.0), 270 µg DacB,
2.5 µM amplex red, 10 µg horse radish peroxidase and 66 µg D-amino acid oxidase
was initiated by addition of pentapeptide intermediate and monitored at 555 nm
using a Varian Cary 100 spectrophotometer at 37 ◦C. The rate of reaction varies
depending upon the volume and concentrations of pentapeptide added to the
reaction. A presence of any rate is considered a positive result, and the peptide
intermediate can be used for downstream synthesis reactions.
2.6.5 Intermediate purity determination
A MonoQ (5/50) column (GE Healthcare) was used for analysis of the purity
of pentapeptide intermediates. The column was equilibrated in 3 CV H2O, 3
CV 1 M ammonium acetate (adjusted to pH 7.6 with CH3COOH) and 3 CV 10
mM ammonium acetate (adjusted to pH 7.6 with CH3COOH). A flow rate and
maximum pressure limit of 0.5 mL.min-1 and 3 MPa were used throughout. 1 mL
of pentapeptide sample was diluted to ≤ 300 µM in 10 mM ammonium acetate
(adjusted to pH 7.6 with CH3COOH). Sample was loaded to the MonoQ (5/50)
column via a sample loading loop and eluted using a linear gradient of 0-100 %
1 M ammonium acetate (adjusted to pH 7.6 with CH3COOH) over 20 mins. The
absorbance at 280 nm and 254 nm was monitored for identification of pentapeptide
peaks and the peak integration function in UNICORN software (Version 6.3) was
used to determine the purity using the following equation:
Purity (%) =
area under the UDP-MurNAc-5P peak
area under all peaks
56
Intermediate identity confirmation
The identity of the product was confirmed by negative ion nanospray time-of-flight
(TOF) mass spectrometric analysis using a Waters SYNAPT G2-Si mass spectrometer
and MassLynxTM software (Version 4.1). The instrument was calibrated with NaI
clusters and the sample, in 50 % (v/v) acetonitrile, was introduced via a nanospray
needle at a capillary voltage of 1.5 kV. The expected exact mass of UDP-MurNAc-5P
and iGln UDP-MurNAc-5P were 1149.35 and 1148.37 respectively.
2.7 Lipid substrate synthesis
Throughout this section, where methods are identical, Lipid is used to refer to Lipid
II(Lys) or iGln Lipid II(Lys).
Lipid intermediates were synthesised using methods described by Breukink et al.
(2003). Minor modifications (detailed below) were used to maximise yield and allow
purification of the iGln Lipid II(Lys) variant.
Solvent A (SolA) comprising chloroform:methanol:water (2:3:1) was used
throughout this section.
2.7.1 Preparation of Micrococcus flavus membranes
Micrococcus flavus glycerol stocks were streaked onto TSB agar plates and incubated
at 37 ◦C overnight. A single colony was inoculated into 100 mL of TSB media and
incubated at 37 ◦C, shaking at 180 rpm overnight. 8 x 650 mL of TSB supplemented
with 0.1 % (v/v) glucose, in 2 L baffled flasks, was inoculated with 6.5 mL starter
culture and incubated at 37 ◦C, shaking at 180 rpm until an OD600nm of 9.0 AU
was achieved. Cells were pelleted at this point (or earlier if they are no longer
in exponential growth phase) by centrifugation at 8,000 xg for 20 mins. The
pellet was resuspended in 25 mL of 20 mM Tris, 1 mM MgCl2 (pH 7.5), 2 mM
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β-mercaptoethanol and centrifuged at 15,000 xg for 20 mins. Supernatant was
discarded and pellet was stored at -20 ◦C.
Pellet was resuspended in 3 mL.g-1 of 20 mM Tris, 1 mM MgCl2 (pH 7.5), 2 mM
β-mercaptoethanol plus 2.5 mg.mL-1 lysozyme and incubated on a rolling platform
at 4 ◦C for 20 mins. Sample was passed through a continuous cell disrupter
(Constant Cell Disruption Systems) at 30 kspi twice and centrifuged at 10,000 xg for
1 hour. Pellets were resuspended in 3 mL of supernatant, aliquoted and stored at
-80 ◦C.
2.7.2 Optimisation of iGln Lipid II(Lys) synthesis
The work outlined in this section was conducted in collaboration with Catherine
Rowland (PhD Student).
Small scale trial syntheses
Reactions comprising 0.23 mg undecaprenyl phosphate, 2 mM or 4 mM iGln
UDP-MurNAc-5P(lys), 6 mM UDP GlcNAc, 0.57 mg.mL-1 MurG, 5 mM MgCl2
and 0 µM or 5 µM moenomycin were made up to 200 µL with M. flavus membranes,
and incubated at 37 ◦C for 3 hours or overnight. Using this reaction as a template,
variation of the concentration of iGln UDP-5P(lys), the presence of moenomycin
and incubation length were tested for their impact on synthesis of the desired iGln
Lipid II(Lys). Samples were isolated and analysed by TLC as described in section
2.7.4 and 2.7.5 respectively.
Large scale time course experiments
2 mL reactions using the most promising conditions as established in Section 2.7.2
were tested on a large scale. 200 µL samples were taken and frozen at -20 ◦C every
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hour for 12 hours. Samples were isolated and analysed by TLC as described in
Sections 2.7.4 and 2.7.5 respectively.
2.7.3 Lipid synthesis reactions
In a glass vial, 2 mg undecaprenyl phosphate in 100 mM Tris-HCl (pH 8.0), 5
mM MgCl2, 1 % (w/v) Triton X-100 with 2 mM UDP-MurNac-5P or 4 mM iGln
UDP-MurNAc-5P, 6 mM UDP-GlcNAc, 0.57 mg.mL-1 MurG and 5 mM MgCl2 were
made up to 2 mL with M. flavus membranes and incubated at 37 ◦C overnight.
2.7.4 Isolation and purification of Lipid
Isolation of Lipid
Lipid synthesis reactions were terminated by the addition of 1 x incubation volume
of 6 M pyridinium acetate and 2 x incubation volume of N-butanol. Samples were
voretexed and centrifuged at 3,000 xg for 10 mins to seperate organic and aqueous
phases. The organic (top) phase was recovered and re-extracted in an equal volume
of H2O. The sample was vortexed and centrifuged at 3,000 xg for 10 mins, the
organic (top) phase was dried down using a Rotavapor R-210 (or Vacuum Pump
V-710 (Buchi) for small sample volumes). Dried samples were resuspended in 1.5 x
CV of SolA.
Column preparation
For a full scale synthesis (2 mL) a bed volume of 4 mL was used, this was scaled
accordingly for smaller syntheses. A diethylaminoethyl (DEAE)-sephacel (acetate
counter ion) gravity flow column was prepared using a glass burette containing a
small amount of glass wool in the tip, as a filter. The column was equilibrated with
10 CV 1 M ammonium acetate, 15 CV H2O and 10 CV Sol A.
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Purification of Lipid
The dried sample was resuspended in 1.5 x CV of Sol A. All fractions were collected
in glass bijoux tubes for analysis. Sample was loaded to the column and 3 CV
SolA used to wash the column. The Lipid was eluted using stepwise washes
of 12 mL chloroform:methanol:aqueous ammonium bicarbonate (2:3:1), whereby
the concentration of the ammonium bicarbonate component increased with every
wash. Washes whereby the aqueous component of the eluant contained 50, 75,
100, 150, 200, 250, 300, 500 mM and 1 M ammonium bicarbonate were used for
Lipid II(Lys) purifications. Additional washes where the aqueous component of
the eluant contained of 60, 65, 70, 80, 85, 90, 95 mM ammonium bicarbonate were
included for the purification of iGln Lipid II(Lys). 400 µL samples from each fraction
were analysed by TLC (2.7.5) and those containing product were pooled and dried
under vacuum. The dried sample was resuspended in H2O and lyophilised at least
three times using a ALPHA 2-4 LD PLUS Freeze Drier (CHRIST). The sample was
resuspended in 1 mL SolA, and stored at -80 ◦C.
2.7.5 Visualisation of Lipid fractions
Fractions were analysed by thin layer chromatography (TLC). 400 µLsamples were
resuspended in 50 µL Sol A, 25 µL was spotted onto a silica 60-coated ALUGRAM
Xtra SIL G plates (Macherey-Nagel) and the bottom ∼2 cm of the plate was
submerged in chloroform/methanol/water/ammonia (88:48:10:1) for ∼2.5 hours
(or until the solvent front was ∼2 cm from the top). The TLC plate was air dried,
stained by exposure to iodine vapour for 20 mins and visualised on a flatbed scanner.
2.7.6 Quantification of Lipid
The Lipid concentration was determined by acid hydrolysis of the phosphate moiety
and detection using a phosphate release assay (Webb 1992).
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Two 50 µL samples of Lipid II and 50 µL SolA (as a negative
control) were dried down using nitrogen gas and resuspended in 50
µL of 50 mM HEPES, 10 mM MgCl2, 30 mM KCl and 1.5 % (w/v)
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). 50
µL of 1M hydrochloric acid (HCl) was added to one Lipid II sample and the SolA
negative control and the samples were boiled at 100 ◦C for 30 mins. 1 M sodium
hydroxide (NaOH) was added to adjust the boiled samples to pH 7.6.
A 200 µL phosphate release assay (Figure 2.1) comprising 50 mM HEPES, 10 mM
MgCl2 (pH 7.6), 1 unit purine nucleoside phosphorylase (PNP), 1 unit IPP and 200
µM 7-methyl-6-thioguanosine (MESG) (Berry and Associates) were initiated with
10 µL Lipid II sample and the absorbance at 360 nm was monitored using a Varian
Cary 100 spectrophotometer at 37 ◦C. Reactions were conducted in triplicate, and
both the non-hydrolysed Lipid II control and the SolA control used to calculate the
Lipid II concentration using the following equation:
The ∆ extinction coefficient at 360 nm generated by phosphorolysis of MESG was
10,000 M-1.cm-1, per molar phosphate (Webb, 1992). Lipid II concentrations were
calculated based on the release of 2 mols of phosphate per mol of Lipid.
2.7.7 Lipid identity confirmation
All Lipid mass spectrometry (MS) was conducted by Adrian Lloyd, Anita
Catherwood or Julie Tod. Spectra analysis was conducted with assistance from
Adrian Lloyd.
The identity of the product was confirmed by negative ion nanospray time of flight
(TOF) MS using a Waters SYNAPT G2-Si quadrupole-TOF instrument operating in
resolution mode equipped with a nanospray source. The instrument was calibrated
with sodium iodide (NaI) clusters over a 200-2500 m/z range, with an error of less
than 1 ppm. Lipid sample was dried, resuspended at a final concentration of 1-5 mM,
in 70 % (v/v) methanol and 30 % (v/v) 25 mM ammonium acetate and introduced
61
Figure 2.1: Phosphate release assay. PPi produced by the acid hydrolysis of Lipid II is
converted to Pi by IPP. PNP catalyses the conversion of Pi and methylthioguanosine to
ribose-1-phosphate and methylthioguanine, which absorbs at 360 nm.
into the instrument using a Waters thin wall nanoflow capillary. Data was collected
for ∼10 mins at a capillary voltage of 2.0 kV, cone voltage of 100 V and source offset
of 41 V. MassLynxTMsoftware (Version 4.1) was used to analyse the data.
Collision induced fragmentation of Lipid species of the desired m/z was performed
in the trap cell of the mass spectrometer. Argon flow was set at 2 ml.min-1 and data
was acquired for collision energies of 0, 15, 30, 45, 60, 75 and 90 electronvolts (eV).
2.8 tRNA substrate preparation
2.8.1 Growth of S. pneumoniae (159) and purification of crude tRNA
S. pneumoniae (159) glycerol stocks were streaked onto Muller-Hinton agar plates
and incubated at 37 ◦C at 5 % CO2 overnight. Cells were harvested into BHI media to
create an inoculum of OD600nm of >1.0 AU. 1 mL of innoculum was added to 1 L BHI
+ 20-50 µg catalase and grown anaerobically at 37 ◦C. The culture at OD600nm was
monitored at regular intervals using a Jenway 6306 UV-visable spectrophotometer.
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Immediately prior to reaching stationary growth phase, cultures were harvested, by
centrifugation at 10,000 xg for 20 mins. Pellets were resuspended in 20 mM Tris, 2
mM Magnesium acetate (Mg(CH3COO)2) (pH 7.4) and incubated at 37 ◦C, shaking
at 130 rpm for 1 hour. tRNA was isolated as detailed by Zubay (1962) and von
Ehrenstein (1967).
2.8.2 Production of single species of S. pneumoniae tRNAAla, tRNASer
and tRNAThr
The sequences of each tRNAAla, tRNASer and tRNAThr gene from S. pneumoniae R6
were identified (Chan and Lowe, 2009). Sequences of different isoacceptors were
synthesised and cloned into pIDTSMART-Kan by IDT. A T7 promotor sequence at
the 5’ end and a BstNI cleavage site at the 3’ end (to provide a CCA terminus for run
off transcription) were incorporated into the gene. Forward and Reverse primers
were also synthesised by IDT. The tRNA gene sequences and primers are detailed
in Table 2.6.
PCR mixes comprising 1 x Q5 Master Mix, 1.25 µM Forward Primer, 1.25 µM Reverse
Primer, 40 ng plasmid were used to amplify the tRNA genes using the SureCycler
8800 thermocycler (Agilent Technologies) Touchdown PCR programme. Details
of PCR conditions are detailed in Table 2.7. PCR products were analysed on a 2
% (w/v) agarose gel, purified using Monarch R© PCR and DNA clean up kit and
quantified (Section 2.8.3).
To reveal the 3’ CCA motif, 1 U of BstNI per µg of tRNA was incubated at 60 ◦C for
1 hour, as per the manufacturer’s protocol. Samples were purified using Monarch R©






































































































Table 2.6: tRNA gene sequences to be cloned into pIDTSMART-Kan vectors by IDT. All
tRNA isoacceptors will be referred to as per the gene name. The gene sequence (black),
additional 5’ sequence containing a T7 promotor (red) and the additional 3’ sequence
containing a BstNI cleavage site (blue) are shown. The anticodon for the specific isoacceptor,
and forward and reverse primers are detailed.
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Component Temperature (◦C) Time (min:sec)
Initial Denaturation 98 00:30
Max Annealing Temp
• tRNAAla4 - 65
• tRNASer1 - 58
• tRNASer2/3 - 55
• tRNAThr1 - 58
• tRNAThr2 - 65
Min Annealing Temp
• tRNAAla4 - 60
• tRNASer1/2/3 - 50
• tRNAThr1 - 50
• tRNAThr2 - 60
00:30
Elongation Temp 72 00:05
Cycle (x35)
Table 2.7: Touchdown PCR conditions for amplification tRNA genes from
pIDTSMART-Kan constructs
In vitro transcription was conducted using TranscriptAid T7 High Yield Transcription
Kit (Thermo), as per the manufacturers recommendations. Products were quantified
(Section 2.8.3 and analysed for purity Section 2.8.4).
2.8.3 Quantification of tRNA
A280nm of a 1 µL sample was determined using an IMPLEN NanoPhotometer R©. The






Where ε is extinction coefficient, predicted using Oligo Extinction Coefficient
Calculator.
(https://www.scripps.edu/researchservices/old/corefac/biopolymercalc2.html).
2.8.4 Visualisation of tRNA samples
7 M urea polyacrylamide gel electrophoresis (7M urea PAGE) was used to analyse
tRNA purity. Gels were cast using a Mini-PROTEAN R© Tetra handcast system
(BioRad), the gel was poured, a comb inserted and was allowed to set. The gel
comprised 90 mM Tris base, 90 mM boric acid, 10 mM EDTA (adjusted to pH 8.0
with HCl), 7 M urea, 40 % (v/v) AccuGel
TM29:1 (National Diagnostics), 0.06 % (w/v)
APS and 0.006 % (v/v) TEMED.
For analysis of gels, loading was standardised to 20 µg crude tRNA and 5 µg in
vitro transcribed tRNA, 10 µg Low Molecular Weight DNA Ladder (NEB) was
used. Samples were prepared in loading buffer comprising 1 M urea, 90 mM Tris
base, 90 mM boric acid, 10 mM EDTA (adjusted to pH 8.0 with HCl), 0.1 % (w/v)
bromophenol blue and 0.1 % (w/v) xylene cyanol.
Gels were assembled in a Mini-PROTEAN R© Tetra Cell, samples loaded to each well
and gels run at 120 V for 3 hours in 90 mM Tris base, 90 mM boric acid, 10 mM
EDTA (adjusted to pH 8.0 with HCl).
Gels were stained for 15 mins using 0.4 % (w/v) Toludine Blue in 50 % (v/v)
methanol and 10 % (v/v) acetic acid. Gels were de-stained overnight in 50 %
(v/v) Methanol and 10 % (v/v) acetic acid, rehydrated in dH2O and imaged using
ImageQuant LAS 4000 instrument (GE Healthcare).
2.9 Aminoacyl-tRNA synthetase spectrophotometric assays
All assays were conducted using a Cary 100 Bio UV-Visable Spectrophotometer
(Agilent) with Cary WinUV Software (Version 4.20). Kinetic analysis was conducted
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using Prism 7 (Version 7.0c).
2.9.1 Amino acid activation by aminoacyl-tRNA synthetases
Amino acid activation assay
A 200 µL 5’-adenylyl-β,γ-imidodiphosphate (ADPNP) reaction (Figure 2.2)
comprising 50 mM HEPES, 10 mM MgCl2 (pH 7.6), 1 mM DTT, 10 mM D-Glucose, 50
mM KCl, 0.15 mM NADP+, 0.34 U Hexokinase (Roche), 0.17 U glucose-6-phosphate
dehydrogenase (Roche), 0.5 mM ADPNP, 0.108 mM inorganic pyrophosphate (PPi)
and appropriate concentration of aaRS was prepared. The reaction was initiated
by addition of varying concentrations of amino acid. Absorbance at 340 nm was
measured at 37 ◦C using a Cary 100 Bio UV-Visable Spectrophotometer (Agilent)
with Cary WinUV Software (Version 4.20). The initial (steady state) change in
velocity was converted to turnover number related to substrate concentration and
plotted using Prism 7 (Version 7.0c).
Specific assay conditions
0.8 µM AlaRS and 0.05-20 mM L-Ala or 20-200 mM L-Ser, was used to measure the
rate of amino acid activation by alanyl-tRNA Synthetase (AlaRS). 4.08 µM ThrRS
and 0.5-20 mM L-Thr was used to measure the rate of amino acid activation by
threonyl-tRNA synthetase (ThrRS).
2.9.2 Pre- and post-transfer editing of aminoacyl-tRNA synthetases
Pre and post-transfer editing assay
A pre- and post-transfer editing assay (Figure 2.3) comprised 50 mM HEPES, 10 mM
MgCl2 (pH 7.6), 1 mM DTT, 50 mM KCl, 1 mM ATP, 2 mM phophoenolpyruvate
(PEP) (MP Biomedicals), 0.3 mM reduced nicotinamide adenine dinucleotide
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Figure 2.2: ADPNP assay for measuring enzymatic activity. ADPNP is an ATP
analogue which is consumed during the formation of an aminoacyl-adenylate. The
aminoacyl-adenylate is cleaved by PPi to form ATP. Hexokinase* then utilises the ATP
and phosphorylates D-Glucose to form Glucose-6-phosphate. Glucose-6-phosphate
dehydrogenase then converts Glucose-6-phosphate to 6-phosphogluconate by the reduction
of NADP+ to NADPH. The production of NADPH is measured as an increase in absorbance
at 340 nm. *Hexokinase is able to completely discriminate between ATP and ADPNP.
(NADH), 60-120 U myokinase, 1.2-2.0 U pyruvate kinase/1.8-2.8 U lactate
dehydrogenase (PK/LDH), and an appropriate concentration of non-congnate
amino acid. The pre-transfer reaction was initiated by addition of aaRS, and the
post-transfer reaction subsequently initiated by addition of E. coli crude tRNA.
Absorbance at 340 nm was measured using a Cary 100 UV-Vis Spectrophotometer
at 37 ◦C. The pre-transfer editing rate was subtracted from the rate obtained on
addition of tRNA to yield the post-transfer editing rate. Editing rates were plotted
against [H2O2] or time, defending upon the experimental design.
Effect of H2O2 concentration on editing of aminoacyl-tRNA synthetases
The effect of H2O2 on pre- and post-transfer editing rates of AlaRS and ThrRS was
established by addition of varying concentrations of H2O2 to the reaction prior to
initiation.
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Figure 2.3: Schematic of spectrophotometric pre- and post-transfer editing assay. In the
presence of amino acid but not tRNA, the ATP is consumed in the formation of aminoacyl
adenylate, the rate observed is due to Pre-transfer editing. Upon addition of the tRNA
aa-tRNA is formed, this is then edited by the synthetase releasing AMP, which is converted
to adenosine 5’diphosphate (ADP) by myokinase and ATP by pyrivate kinase using PEP
as a phosphoryl donor. The resulting pyruvate is then converted to lactate by lactate
dehydrogenase (LDH) converting NADH into NAD+, producing a fall in the absorbance at
340 nm.
In the case of AlaRS, reactions contained 200 mM L-Serine (or 200 mM L-Ala for
control) and 0 - 75 mM H2O2. Pre-transfer editing was initiated by the addition of
0.3 µM AlaRS and post-transfer editing was initated by addition of 0.66 mg.mL-1 E.
coli crude tRNA. In the case of ThrRS reactions contained 50 mM L-Ser (or 50 mM
L-Thr for control) and 0 - 50 mM H2O2. Pre-transfer editing was initiated by the
addition of 10 µM ThrRS and post-transfer editing was initiated by addition of 1.9
mg.mL-1 E. coli crude tRNA.
To provide a negative control, the post-transfer editing rate of the aaRS in the
presence of the non-cognate amino acid was established in the absence of H2O2.
Finally, the effect of H2O2 on the coupled system was characterized, to ensure that
the measurements were a direct result of the effect of H2O2 on the aaRS.
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Effect of incubation time on pre- and post-transfer editing of aminoacyl-tRNA
synthetases
The effect of time on pre- and post-transfer editing was investigated by incubation
of AlaRS of ThrRS with a fixed concentration of H2O2 for varying lengths of time at
room temperature. At specific time points, samples of the aaRS was taken and used
to initiate the reaction (as above).
For AlaRS, pre-transfer editing reactions were initiated with 0.3 µM pre-treated
AlaRS after 0-30 mins incubation with 50 mM H2O2. Post-transfer editing reactions
were initiated with 0.76 mg.mL-1 E. coli crude tRNA. Negative controls were
conducted at 0 and 30 min time points.
For ThrRS, pre-transfer editing reactions were initiated with 10 µM pre-treated
ThrRS after 0-40 mins incubation with 20 mM H2O2. Post-transfer editing reactions
were initiated with 0.76 mg.mL-1 E. coil crude tRNA. Negative controls were
conducted at 0 and 40 min time points.
To provide a negative control, aaRS was incubated in the absence of H2O2, samples
were taken at time points and assayed.
Since the reaction master mix contained DTT, a reducing agent, the effect of omitting
DTT from the reaction mixture was also determined. aaRS was incubated with H2O2
for 10 mins, and post-transfer editing was assayed in the presence and absence of
DTT.
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2.10 Investigating aminoacyl-tRNA synthetase oxidation by
mass spectrometry
2.10.1 Intact protein mass spectrometry
AlaRS and ThrRS were treated with 10,000 x molar ratio H2O2 or 200 x molar ratio
of H2O2 for 30 mins and 40 mins respectively. AlaRS and ThrRS were purified in
HPLC grade H2O using a PD-10 column (pre-equilibrated as per manufacturers
protocol) and analysed by positive ion nanospray TOF MS using a Waters SYNAPT
G2-Si quadrupole-TOF instrument with a nanospray source. The instrument was
calibrated using 2 µg.µl-1 NaI and the sample prepared in 50 % (v/v) methanol and
0.1 % formic acid (FA) was introduced via a nanospray needle at a capillary voltage
of 2 kV. Analysis was conducted using MassLynxTMsoftware (Version 4.1 SCN957).
Mock spectra were generated to assess the quality of data and the MaxEnt function
was used to determine the molecular mass of components present in the sample.
2.10.2 Peptide-based mass spectrometry
AlaRS and ThrRS were treated with 10,000 x molar ratio H2O2 or 200 x molar ratio of
H2O2 for 30 mins and 40 mins respectively. AlaRS and ThrRS were buffer exchanged
into 50 mM HEPES, 100 mM NaCl, 1 mM MgCl2 (pH 7.0), 1 µM pepstatin, 1 µM
leupeptin and 50 % (v/v) glycerol, to remove the H2O2. SDS-PAGE of samples was
conducted and gel bands at the appropriate molecular weight were cut out and diced
into 2 mm x 2 mm cubes using a scalpel. The gel was de-stained completely using 50
mM ammonium bicarbonate with 50 % ethanol, and dehydrated using 100 % ethanol
for 5 mins. Gel pieces were incubated with 10 mM Tris(2-carboxyethyl)phosphine
(TCEP) and 40 mM chloroacetamide (CCA) for 5 mins at 70 ◦C, and subsequently
washed in 50 % ethanol and 50 mM ammonium bicarbonate. Gel was dehydrated
for 5 mins in 100 % ethanol and treated with 2.5 ng.µl-1 trypsin (diluted in 50 mM
ammonium bicarbonate) at 37 ◦C overnight. Sample was sonicated (in a waterbath)
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in 25 % acetonitrile, 5 % formic acid 3 times for 10 mins each. Liquid was retained
and pooled, dried down using a speed vac and resuspended to a final volume of 50
µL in 2 % acetonitrile and 0.1 % trifluoroacetic acid.
Tandem mass spectrometry of samples was conducted by the Proteomics Research
Technology Platform (University of Warwick).
Analysis was conducted using Scaffold (Version 4.8.1).
2.11 MurM assays
2.11.1 Mass spectrometry MurM activity assay
This MurM assay is coupled to aminoacyl-tRNA synthetase activity and Lipid
product was detected by mass spectrometry. Reactions contained 50 mM HEPES,
10 mM MgCl2, 30 mM KCl, 1.5 % CHAPS (w/v) (pH 7.6), 5 mM ATP, 2 mM DTT,
500 µM Lipid II (lys)-5P, 3 µM AlaRS, 10 mM L-Ala or L-Ser and 1.5 mg.mL-1
S. pneumoniae (159) tRNA either with or without 1.5 µM gMurM159. Reactions
were incubated at 37 ◦C for 1 hour, purified (using stock ammonium bicarbonate
concentrations of 50, 100 mM and 1 M for elution) and freeze dried as per Section
2.7.4. The sample was resuspended in 70 % (v/v) methanol and 30 % (v/v) 25
mM ammonium acetate. The identity of the product was confirmed by negative
ion nanospray TOF MS using a Waters SYNAPT G2-Si mass spectrometer. The
instrument was calibrated with NaI clusters and the sample was introduced via
a nanospray needle at a capillary voltage of 2.0 kV. The expected exact mass of
Lipid II(Lys)-Ala/Ser and iGln Lipid II(Lys)-Ala/Ser were 1946.10/1962.09 and
1945.11/1961.11 respectively.
Collision induced dissociation (CID) in combination with positive ion tandem MS
(MS/MS) was conducted using the Waters SYNAPT G2-Si mass spectrometer to
determine the amino acid sequence and therefore exact location of amino acid
addition to the peptide stem of Lipid II(Lys).
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2.12 Radioactive assays
The experimental set ups were initially tested with readily available crude E.
coli tRNA and subsequently repeated with the appropriate S. pneumoniae tRNA.
[3H]L-Ala (Moravek), [3H]L-Ser (Moravek) and [3H]L-Thr (ARC Inc) were all
prepared to stock concentrations of 0.6 mM. When experiments were repeated
with multiple radioactive amino acids, the amino acid is referred to as [3H]-aa.
Samples were spotted onto 1 cm x 1 cm Whatman cellulose chromatography papers
3MM. Radioactivity was followed by scintilltion counting using a Tri-Carb 2800TR
Liquid Scintillation Analyzer.
2.12.1 Radioactive tRNA-aminoacylation activity assay
Reactions containing 30 mM HEPES, 15 mM MgCl2, 25 mM KCl, 5 mM DTT, 2 mM
ATP (pH 7.5), 5 mM DTT, 73 µg crude OR 0.3 µM pure tRNA, 7 µg IPP and 0.1 mM
[3H]-aa were initiated with 3 µM aaRS and incubated at 37 ◦C. At time = 1, 5, 10, 20,
30, 60 and 90 minutes 10 µL was spotted onto Whattman paper and immediately
submerged in 10 % (w/v) trichloroacetic acid (TCA). Papers were washed 3 x 15
mins in 10 % (w/v) TCA and 1 x 15 mins in 100 % ethanol, then left to air dry.
To obtain a total count (TC) of radioactivity, 5 µL of a 1/10 dilution was spotted
onto paper but not submerged in 10 % (w/v) TCA. All papers were added to 5 mL
scintillant and counted.
2.12.2 Radioactive preparative charging assay
To test the purification procedure, and to generate charged tRNA for a trial MurM
activity assay, a preparative charging experiment with AlaRS and cognate amino
acid [3H] L-Ala was conducted using E. coli tRNA.
Reactions containing 30 mM HEPES, 15 mM MgCl2, 25 mM KCl, 5 mM DTT, 2 mM
ATP (pH 7.5), 330 µg crude E. colitRNA, 0.045 mM [3H] L-Ala, 5 mM DTT were
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incubated at 37 ◦C for 10 minutes. 6 µM AlaRS was added to initiate the reaction,
mixed and incubated for 1 hour. 20 µL was spotted onto Whatmann paper and
submerged in 10 % (w/v) TCA. Total count (TC) of radioactivity was measured
by spotting 5 µL of a 1/10 dilution onto Whattman paper. 20 µL 3 M sodium
acetate (pH 5.0) was added to the sample. 205 µL phenol was added, sample was
vortexed and centrifuged at 13,000 xg for 3 mins. Aqueous phase was retained
and 520 µL ice cold ethanol was added. Sample was incubated at -20 ◦C for 15
minutes to precipitate tRNA. tRNA was pelleted by centrifugation at 13,000 xg
for 3 mins, supernatant was discarded and pellet was dried in a dessicator. Pellet
was resuspended in 50 µL 3 mM sodium acetate (pH 5.0), 2 µL was spotted onto
Whattman paper and submerged in 10 % (w/v) TCA. Papers were washed 3 x 15
mins in 10 % (w/v) TCA and 1 x 15 mins in 100 % ethanol, then left to air dry. All
papers were added to 5 mL scintillant and counted. tRNA was stored at -80 ◦C.
2.12.3 Radiolabelled MurM activity assay
During these experiments, aminoacyl-tRNA were kept on ice to minimise
deacylation.
A trial MurM activity assay was conducted using E. coli [3H]alanyl-tRNAAla
prepared in Section 2.12.2 experiment. 0.15 mM Lipid II(Lys) or iGln Lipid II(Lys)
was dried down and resuspended in 150 µL 50 mM HEPES, 10 mM MgCl2, 30 mM
KCl, 1.5 % (w/v) CHAPS (pH 7.6). Reactions comprising 50 mM HEPES, 10 mM
MgCl2, 30 mM KCl, 1.5 % (w/v) CHAPS (pH 7.6), 2 mM DTT, 1 mM L-Ala, 0.005
mg/ml gMurM159 were initiated with 2.5 µM and 1.94 µM E. coli [3H]alanyl-tRNAAla
for reactions containing Lipid II(Lys) and iGln Lipid II(Lys) respectively. Reactions
were incubated at 37 ◦C for 1 hour. 1 x incubation volume of ice cold pyridinium
acetate was added and sample was vortexed. 2 x incubation volume of N-butanol
was added, sample was vortexed and centrifuged at 13,000 xg for 3 mins in a chilled
centrifuge. The top phase was removed and added to 2 x incubation volume of H2O
, sample was vortexed and centrifuged at 13,000 xg for 3 mins. The top phase was
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added directly to scintillation vials and counted.
Negative controls were conducted with reactions in the absence of MurM, in the
presence of RNase and in the absence of Lipid II(Lys).
2.13 Computational modelling of MurM
2.13.1 Homology modelling of MurM
S. pneumoniae gMurM159, S. aureus FemX, S. aureus FemA (PDB ID: 1LRZ) and W.
viridescens FemX (PDB ID: 3GKR) were aligned using EMBOSS Needle CLUSTAL
(Madeira et al., 2019) and sequence identity and similarity determined.
The structure of S. aureus FemX (unpublished work from Roper group) was used
as the template for homology modelling due to its high relatedness with MurM.
FemX and MurM sequences were aligned and using MODELLER (Eswar et al., 2006;
Martı́-Renom et al., 2000; Šali and Blundell, 1993; Fiser et al., 2000) an initial test
model was generated to verify the validity of the template and the alignment. We
evaluated this model by computing its energy profile using the high-resolution
version of the Discrete Optimized Protein Energy (DOPE-HR) (Shen and Sali, 2006),
smoothed via window averaging with size 15 residues. The profiles of template
and model were compared (Appendix 7.8), refinement was conducted in the region
between Lys230 and Pro299. Thus, we proceeded to create 64 different models,
refining their secondary structure using the slowest annealing protocol available
in Modeller. The loop regions of each of the 64 base models were refined 16
independent times also using a very slow annealing procedure. Subsequently,
we evaluated and ranked each of the resulting 1024 models using DOPE-HR as well
as the Statistically Optimized Atomic Potentials (SOAP) (Dong et al., 2013). The
10 best scoring models for each score were selected and eliminated based on the
number of physical constraint violations present.
The final model of MurM (MurM159) was aligned with the previous MurM
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model (Fiser et al., 2003) or W. viridescens Femx homologues (Fonvielle et al., 2013;
Biarrotte-Sorin et al., 2004) for visualisation and analysis in PyMOL (Version 2.1.0).
All sequences, except S. pneumoniae MurMPn16 and S. pneumoniae
MurM159 (Appendix 7.3), were obtained from the GenBank database
(https://www.ncbi.nlm.nih.gov/genbank/). Pairwise sequence alignments were
generated using Jalview (Version 2.10.5) (Waterhouse et al., 2009). Ramachandran
plots were generated using MolProbity (Chen et al., 2010; Lovell et al., 2003).
2.13.2 Molecular docking of truncated Lipid II(Lys) to MurM
Since the Lipid II(Lys) was too large for use in molecular docking, the hydrocarbon
tail was shortened to create a smaller substrate (referred to as truncated Lipid II(Lys).
The truncated Lipid II(Lys) was drawn in ChemDraw Professional (Version 17.1)
and converted to a pdb file using Avogadro (Version 1.2.0). To prepare the ligand file
for docking, the protonation state in H2O at pH 7.4 was computed. Subsequently
the equilibrium geometry minimizing the potential energy was computed using the
GAFF force field (Wang et al., 2004) from within the Avogadro2 software (Hanwell
et al., 2012). Molecular docking was conducted using AutoDock Vina (Trott and
Olson, 2010) and pdbqt files were generated (from the pdb files of receptor model
and ligands) using AutoDock Tools (Morris et al., 2009). Initially the location of
the binding site was verified by providing the algorithm with a search space that
included the whole protein, requesting the 10 best positions. The top 10 poses
were all within the same pocket on the molecular surface of the protein, very
strongly implying that the pocket is indeed the binding site. Docking was then
repeated, restricting the search space to the binding pocket to obtain the final docked
conformation.
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2.13.3 Molecular dynamics of MurM interactions with the membrane
Molecular dynamics (MD) simulations of MurM with the membrane were conducted
in collaboration with Prof. Syma Khalid (University of Southampton). Simulations
and initial analysis were conducted by Jonathan Shearer (PhD student - University
of Southampton).
Coarse-grained simulations
All coarse-grained simulations were carried out with the GROMACS package
(Version 2018) and the Martini (Version 2.2) forcefield (Abraham et al., 2015; de Jong
et al., 2012).
Initial protein coordinates from the MurM homology model were used to generate
a coarse-grained model using the Martini script. The protein was coarse grained to
the ElNeDyn model with an elastic network strength and cutoff of 500 kJmol-1nm-2,
respectively.
The Lipid II(Lys) model for inclusion in the membrane was parameterised using a
United atom model (Gromos 53a6) generated by the Automated topology builder
(ATB) web-interface. Following this the coarse-grained mapping was decided
iteratively and the bonded terms fitted with PyCGTOOl (Graham et al., 2017).
Simulations were conducted with three different membrane systems. System 1
contained 75 % phosphatidylethanolamine (PE) and 25 % phosphatidylglycerol
(PhG), system 2 contained 72 % PE, 16 % PG and 12 % cardiolipin (CL) and
system 3 contained 72 % PE, 12 % PG and 16 % cardiolipin (CL). The membrane
systems of ∼16x16x11.5 nm were generated with the Martini-maker module
of the CHAMRMM-GUI web interface (Jo et al., 2017). Na2+ ions were then
added to neutralise each system and equilibration was conducted using the usual
CHARMM-GUI protocol. The temperature of all simulations was 313 K and was
controlled with a stochastic velocity rescale thermostat with a coupling constant
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of 1.0 ps. The CHARMM GUI protocol involved initial steepest descent energy
minimisations, followed by a series of NPT equilibrations with 5, 10, 15 and 15
fs timesteps for a cumulative total of around 20 ns. During this procedure the
Berendsen barostat was employed with a coupling constant of 4.0 ps (Berendsen
et al., 1984). Following equilibration ∼1 % of Lipid II(Lys) (10 in total) was added
to each membrane. Minimisations and a 10 ns equilibration were conducted and
then followed by a 2 production run to ensure sufficient mixing of all the lipid
components. Note that all production runs were carried out using a 10 fs timestep
and a Parrinello-Rahman semi-isotropic barostat with a 12 ps coupling constant
(Parrinello and Rahman, 1981). The Lennard-Jones potential was cutoff using the
Potential shift Verlet scheme at long ranges. The reaction field method was used
for electrostatics calculations, with dielectric constants of 15 and infinity for charge
screening in the short- and long-range regimes, respectively. The short-range cutoff
for both non-bonded and electrostatic interactions was 1.2 nm. The size of the
system was increased to ∼32 nm in dimension perpendicular to the membrane
normal and the MurM was added in a random orientation around 8 nm above each
membrane. Addition of H2O and 0.15 M NaCl was added to provide biologically
relevant salt concentrations. Around 10 % of dH2O molecules were changed to
antifreeze particles if systems froze during simulation. After an initial steepest
descent minimisation and 1 ns equilibration, in which the protein backbone was
restrained with 1000 kJmol-1.nm-2 harmonic restraints, production runs were carried
out with 6 repeats per system.
All-atom simulations
All atomistic simulations were conducted using the CHARMM36m 2018 forcefield
(Huang et al., 2017). The Lipid II(Lys) model used here was used in previous studies
(Witzke et al., 2016). Equilibration steps were for increasing timesteps of 1 and 2 fs
were conducted with a berendsen thermostat and barostat with coupling constants
of 1.0 and 5.0 ps, respectively. During production runs a timestep of 2 fs was used
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and the pressure (1 atm) regulated with a semi-isotropic Parrinello-Rahman barostat
with a coupling constant of 5.0 ps. The Lennard-Jones potential was cutoff with the
Force-switch modifier from 1.0 to 1.2 nm. The short range cutoff for the electrostatic
interaction was also 1.2 and the Particle mesh Ewald (PME) algorithm was used
for the long-range regime. For each membrane system two distinct orientations for
MurM relative to the membrane were chosen. These systems were then backmapped
to the all-atoms model as previously described. After the reverse transformation
was carried out, each system was cropped in the z dimension to a height of 16.5 nm,
to remove the now unnecessary H2O molecules. Each system was minimised and
equilibrated for a total of 1 ns, while the backbone of the protein was restrained
with 1000 kJmol-1.nm-2 harmonic restraints. 2 production runs were carried out for
each system for 300 ns.
2.13.4 Analysis of all-atom simulations
Analysis was carried out over the final 150 ns of each simulation, unless stated
otherwise. All simulations were visualised using Visual Molecular Dynamics
(VMD) or PyMOL (Version 2.2.0). Hydrogen bonding analysis was performed
with the VMD hydrogen bonding extension. Other analysis tools were written with
a combination of GROMACS tools and in house scripts that utilised the python
module MDAnalysis (Gowers et al., 2016). The depletion/enrichment (D-E) indices
were determined by first counting the number of lipids with a center of geometry
within 1.4 nm of the protein and then comparing this number to the number expected
in the bulk of the membrane, using the procedure described by Corradi et al. (2018).
The depletion/enrichment index was obtained by dividing the lipid composition
in the 1.4 nm shell around the protein by the bulk membrane composition. Thus a
D-E index >1 indicates enrichment, while a D-E index <1 indicates depletion. The
D-E index was determined for the last 150 ns of each simulation in 50 ns blocks for
both repeats. This gave 5 D-E index values for each lipid, from which the average
and standard deviation was calculated. The enrichment maps were generated by
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first determining the 2D density map of the membrane using the GROMACS tool
densmap. Following this the enrichment was determined using the procedure
described by Corradi et al. (2018).
2.13.5 Flexibility simulation and homo-/hetero-dimerisation of MurM
Pdb2movie (Jimenez-Roldan et al., 2012; Römer et al., 2016) was used to rapidly
identify the potential movements and flexibility of the whole protein, by combining
three software packages; ELNEMO, FIRST and FRODA. Default parameters were
used with the following modifications; number of conformers, 5000; energy cutoff
value, 1.0 and Modes 7, 8, 9 and 10.
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Chapter 3
Effect of H2O2 on aminoacyl-tRNA
synthetases
The authors would like to acknowledge the contribution of the WPH Proteomics
Research Technology Platform (RTP), Gibbet Hill Road, University of Warwick, UK,
for the peptide based mass spectrometric analysis of proteins.
3.1 Introduction
S. pneumoniae is a facultative anaerobe, in aerobic conditions pyruvate oxidase
(SpxB) converts pyruvate into acetyl phosphate, which can be converted to acetate
to generate an additional 2 molecules of ATP per molecule of glucose. However,
this additional ATP comes at a cost; H2O2 is produced as a toxic biproduct of SpxB.
Intriguingly, despite producing high levels of endogenous H2O2 S. pneumoniae does
not possess the global regulators (OxyR or PerR), or either of the H2O2 scavenging
enzymes (catalase and NADH peroxidase) that are present in many other species
(Pericone et al., 2003). Very little is known about how S. pneumoniae protects itself
against oxidative stress caused by H2O2, but studies indicated that SpxB activity
itself confers a protective effect (Pericone et al., 2003).
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The effects of oxidative stress on translation and cell viability have been well
documented and high levels of H2O2 are known to increase mis-aminoacylation
and translational error in other organisms (Bullwinkle et al., 2014; Costa et al.,
2007; Ling and Söll, 2010). Ling and Söll (2010) showed previously that hydrogen
peroxide oxidised cysteine 182 of E. coli ThrRS, resulting in a reduction of editing
activity and an increase in seryl-tRNAThr production. Both ThrRS and AlaRS are
prone to mis-activation of serine and therefore posses pre- and post-transfer editing
mechanisms to minimise mis-aminoacylation of tRNAThr and tRNAAla with L-Ser.
Additionally, serine is incorporated to the first position of an indirect dipeptide
cross-link in S. pneumoniae PG by MurM and unpublished data (Dr Adrian Lloyd)
indicates that MurM has a preference for mis-aminoacylated tRNA. As such the
focus of this chapter is to understand the effects of H2O2 on amino-acid activation,
pre-transfer and post-transfer editing of ThrRS and AlaRS in S. pneumoniae.
In contrast to the work of Ling and Söll (2010), this chapter utilised a novel
post-transfer editing assay developed by Dr Adrian Lloyd (unpublished) (Figure
2.3). Previous investigations by Ling and Söll (2010) relied on a radiolabelled
ATP consumption end point assay (hereon in referred to as the end point assay).
The end point assay measures the overall amount of editing by monitoring ATP
consumption, ATP is consumed to produce an aa-AMP which is subsequently
converted to aa-tRNA. It works on the premise that where editing is occurring
and aa-AMP or aa-tRNA are hydrolysed back to aa and tRNA, multiple rounds
of aminoacylation and hence ATP hydrolysis can occur per molecule of tRNA,
whilst in the absence of editing (e.g. in the presence of a cognate amino acid) only
one round of ATP consumption will occur per molecule of tRNA. It is therefore
possible to follow the combined pre- and post-transfer editing activities of the aaRS
using the end point assay. Since this is an end point assay, only the final ATP
consumption after a specific time period is measured. In contrast, the assay used
in this chapter is a novel continuous spectrophotometric assay, which generates a
background rate in the absence of tRNA (pre-transfer editing rate) and a subsequent
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rate following the addition of the tRNA (combination of pre- and post-transfer
editing). This assay works by following the production of AMP which occurs
during the hydrolysis of aa-AMP (pre-transfer editing), or transfer of the aminoacyl
moiety from the adenylate to the tRNA where the aa-tRNA is hydrolysed releasing
AMP (post-transfer editing). The production of AMP is coupled by myokinase,
PK and LDH, to the conversion of NADH to NAD+ which can be monitored by a
loss in absorbance at 340 nm (Figure 2.3). This assay provides continuous data for
kinetic analysis and also permits the distinction between pre-transfer editing and
post-transfer editing mechanisms.
3.2 Aims
This chapter demonstrates the purification of S. pneumoniae AlaRS, SerRS and ThrRS.
The catalytic efficiency of cognate and non-cognate amino acid activation by AlaRS
and ThrRS was investigated. In addition the effect of H2O2 on amino acid activation,
pre-transfer and post-transfer editing activities of S. pneumoniae AlaRS and ThrRS
was determined and the site of oxidation investigated using mass-spectrometry.
3.3 Purification of aminoacyl-tRNA synthetases
AlaRS, SerRS and ThrRS were overexpressed, purified and quantified as per Section
2.5. Figure 3.1 a), b) and c) respectively, shows the purity of these proteins at each
stage of the purification procedure.
For AlaRS a significant increase in purity was achieved by IMAC and a small
increase in purity was achieved during the second, anion exchange chromatography
step. SEC as an alternative or additional chromatography step, did not increase
purity of the protein sample and so was eliminated to reduce the length of the
purification procedure. A strong band corresponding to the expected mass of AlaRS
at ∼97 kDa, was observed by SDS-PAGE. In addition there were a small number of
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weaker bands which may represent contaminating proteins or products of AlaRS
proteolysis (Figure 3.1a). The final purity of AlaRS, post anion exchange, was
estimated to be >60 % using ImageJ (Version 1.51).
For SerRS a significant increase in purity was achieved by IMAC and SEC
purification steps. A strong band corresponding to the expected mass of SerRS
at ∼50 kDa was observed by SDS-PAGE, the final purity of SerRS was estimated to
be ∼90 % using ImageJ (Version 1.51).
For ThrRS a significant increase in purity was achieved during both the IMAC and
SEC steps. The final MonoQ chromatography step did not further enhance the
sample’s purity. A strong band corresponding to the expected mass of ThrRS at ∼75
kDa was observed, there are also some additional weaker bands at ∼55 kDa which
may be contaminating proteins or degradation products. The final purity of ThrRS
was estimated to be >75 % using ImageJ (Version 1.51).
Figure 3.1: 12 % SDS-PAGE showing protein purification summary. a) Summary gel for
the purification of AlaRS. Lane 1 - AmershamTM protein marker, Lane 2 - 10 µg 50,000 xg
supernatant, Lane 3 - 10 µg pooled IMAC fractions, Lane 4 - 10 µg pooled anion exchange
fractions. b) Summary gel for the purification of SerRS. Lane 1 - AmershamTM protein
Marker, Lane 2 - 10 µg 50,000 xg supernatant, Lane 3 - 10 µg pooled IMAC fractions, Lane
4 - 10 µg pooled SEC fractions. c) Summary gel for the purification of ThrRS. Lane 1 -
AmershamTM protein marker, Lane 2 - 10 µg 50,000 xg supernatant, Lane 3 - 10 µg pooled
IMAC fractions, Lane 4 - 10 µg pooled SEC fractions, Lane 5 - 10 µg pooled anion exchange
fractions.
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3.4 Effect of H2O2 on amino acid activation
The first step of aminoacylation is activation of the amino acid by the aaRS. This
is a condensation reaction between amino acid and ATP forming an aaRS bound
aa-AMP. The consumption of ADPNP and concomitant pyrophosphate-dependent
turnover of aa-AMP to form ATP is monitored using a coupled reaction which
measures the production of NADPH and an associated increase in absorbance at
340 nm (see Figure 2.2).
3.4.1 Michaelis-Menten kinetics of amino acid activation by AlaRS with
L-alanine and L-serine
Figure 3.2 shows the Michealis-Menten kinetics of S. pneumoniae AlaRS amino acid
activation with cognate and non-cognate amino acids (L-Ala and L-Ser respectively).
AlaRS has a catalytic efficiency (kcatApp/kmApp) of 73.4 min-1.mM-1 with L-Ala,
however it is also capable of incorrectly activating L-Ser with a much lower
kcatApp/kmApp of 0.15 min-1.mM-1. Despite AlaRS having a selectivity for L-Ala
over L-Ser of 489, it is clearly capable of mis-activation with L-Ser at a rate greater
than that consistent with the error frequency of translation. This demonstrates the
importance of both pre- and post-transfer editing mechanisms.
3.4.2 Michaelis-Menten kinetics of amino acid activation by ThrRS with
L-threonine
Figure 3.3 shows the catalytic efficiency of ThrRS with L-Thr, which was determined
to be 1.49 mM-1.min-1 is ∼ 50-fold lower than that of AlaRS. This reduced catalytic
efficiency is due to a combination of comparatively low kcatApp, indicating low
turnover, and high kmApp, suggesting low binding affinity, for S. pneumoniae
ThrRS. In order to determine if an alternate ATP analogue such as adenosine
5’-(β-γ-methylene) triphosphate (ADPCP) was a better substrate for ThrRS the assay
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Figure 3.2: Michaelis-Menten kinetics of AlaRS. A plot of the reaction velocity (V0) as a
function of a) cognate amino acid (L-Ala) concentration and b) non-cognate amino acid
(L-Ser) concentration. Apparent kcat, km, and kcat/km are presented. R2 = 0.96 and 0.94 for
a) and b) respectively. Mean and standard deviation were plotted from triplicate data sets.
GraphPad Prism (Version 7.0c) was used for data analysis and figure preparation.
was repeated (Figure 3.3 b)). Whilst, ADPCP did improve the turnover of ThrRS
by 2.5-fold, only a very small change in binding affinity for L-Thr was observed.
The kcatApp/kmApp of ThrRS with L-Thr, was determined to be 4.49 min-1.mM-1 and,
even with this improved catalytic activity it was still not possible to obtain kinetic
data for mis-activation of ThrRS with L-Ser.
3.4.3 Amino acid activation assay limitations
The purpose of this assay was to demonstrate that AlaRS and ThrRS can mis-activate
with serine. This was only possible for AlaRS since the kinetics of ThrRS were
so poor that it was not possible to monitor mis-activation of serine using this
assay. Traditionally, amino acid activation studies have been conducted using
the pyrophosphate exchange assay (Francklyn et al.), however in this study a
coupled spectrophotometric assay, referred to as the ADPNP assay, was employed
(Figure 2.2). The pyrophosphate exchange assay measures the incorporation of
pyrophosphate into ATP through the intermediacy of the enzyme.AMP-AA complex
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Figure 3.3: Michaelis-Menten kinetics of ThrRS. A plot of the reaction velocity (V0) as a
function of cognate amino acid (L-Thr) concentration. a) Assay using ADPNP as the ATP
analogue. Data collected in triplicate with average and standard deviation plotted. R2
= 0.96. b) Assay using ADPCP as the ATP analogue. Data collected in singlicate. R2 =
0.94. Apparent Kcat, Km, and catalytic efficiency Kcat/Km are presented. GraphPad Prism
(Version 7.0c) was used for data analysis and figure preparation.
(Francklyn et al.). As with all experimental procedures both assays have their
advantages and disadvantages, the ADPNP assay eliminates the necessity to work
with radiolabelled compounds and is a continuous assay, but utilises an ATP
analogue (ADPNP or ADPCP) as substrate, whilst the pyrophosphate exchange
assay uses the natural ATP substrate but requires radiolabelled pyrophosphate and
is a non-continuous assay. Amino acid activation of L-Thr by E. coli ThrRS, using
the [32P]-pyrophosphatase assay, was reported to be 8400 min-1.mM-1 (>5000-fold
higher than reported here) Ling and Söll (2010). The reduced catalytic activity of
AlaRS and ThrRS reported here may indicate that aaRS’s have a particularly high
selectivity for ATP over analogues, and so the pyrophosphatase assay may be more
suitable for characterising the kinetic parameters of these enzymes.
3.4.4 Effect of H2O2 on amino acid activation
ADPNP assays for AlaRS and ThrRS were conducted at a saturating concentration of
cognate and non-cognate amino acid (as determined previously), and the effect of 50
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mM H2O2 on amino acid activation was measured. Unless otherwise stated data was
collected in triplicate (n=3) and analysed using a paired t-test or a one-way analysis
of variance (ANOVA) (for multiple comparisons) with a 95 % confidence interval
(p≤0.05). H2O2 had no statistically significant effect on amino acid activation of
cognate or non-cognate amino acids by AlaRS or ThrRS (Figure 3.4). Furthermore,
this demonstrates that H2O2 had no impact on the enzymatic coupling system.
Figure 3.4: Effect of H2O2 on aminoacylation activity of AlaRS and ThrRS. a) Initial
velocity of AlaRS amino acid activation with L-Ala or L-Ser in the presence and absence of
50 mM H2O2. b) Initial velocity of ThrRS amino acid activation with L-Thr in the presence
and absence of 50 mM H2O2. Mean and standard deviation were plotted from triplicate data
sets. NS = not statistically significant as determined by a paired t-test or one-way ANOVA.
GraphPad Prism (Version 7.0c) was used for data analysis and figure preparation.
Amino acid activation of L-Ala by AlaRS was not statistically different (p>0.05)
between reactions containing 0 mM H2O2 (31.57 ± 1.568 min-1) and 50 mM H2O2
(28.62 ± 1.475 min-1). Amino acid activation of L-Ser by AlaRS was not statistically
different (p>0.05) between reactions containing 0 mM H2O2 (16.43 ± 1.171 min-1)
and 50 mM H2O2 (16.81 ± 0.7082 min-1). Amino acid activation of L-Thr by ThrRS
was not statistically different (p>0.05) between reactions containing 0 mM H2O2
(28.58 ± 1.298 min-1) and 50 mM H2O2 (26.09 ± 0.6438 min-1).
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3.5 Effect of H2O2 on pre- and post-transfer editing of
AlaRS and ThrRS
Figures 3.5 and 3.6 show the full data sets of pre- and post-transfer editing rates
plotted against H2O2 concentration for AlaRS and ThrRS respectively. In addition
a bar chart corresponding to each data set summarises the results by comparing
data at both the lowest and highest concentrations of H2O2. For both AlaRS and
ThrRS increasing H2O2 concentrations positively correlated with loss of post-transfer
editing activity but had no effect on pre-transfer editing activity. AlaRS and ThrRS
in the presence of cognate amino acids (L-Ala and L-Thr respectively) were used as
negative controls, to show the absence of pre- or post-transfer editing activity.
0.5 µM AlaRS required∼75 mM H2O2 (150,000 x molar concentration) to reduce the
rate of post-transfer editing to background, whilst 10 µM ThrRS required∼17.5 mM
(1750 x molar concentration) to achieve background post-transfer editing activity.
ThrRS is therefore ∼85 x more sensitive to H2O2 than AlaRS.
The novel editing assay was used to investigate the effects of H2O2 on pre- and
post-transfer editing of AlaRS. Unless otherwise stated data was collected in
triplicate (n=3) and analysed using a paired t-test or a one-way ANOVA (for multiple
comparisons) with a 95 % confidence interval (p≤0.05).
3.5.1 Effect of H2O2 on pre- transfer editing in AlaRS
Figure 3.5a and 3.5b show that pre-transfer editing of AlaRS occurs with L-Ser but
not L-Ala (negative control), and that H2O2 has no effect on pre-transfer editing.
There is no statistically significant difference (p>0.05) in pre-transfer editing rate of
AlaRS with L-Ala between reactions containing 0 mM (0.0024 ± 0.0029 min-1) and
75 mM (0.0024 ± 0.00014 min-1, n=2) H2O2. At 0 mM H2O2 the rate of pre-transfer
editing of AlaRS with L-Ala (0.0024 ± 0.0029 min-1) was statistically significantly
lower than with L-Ser (0.063 ± 0.0062 min-1) (p=0.0015). This demonstrates that, as
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Figure 3.5: Effect of H2O2 on pre-transfer and post-transfer editing rates of AlaRS. 0.5
µM AlaRS with 200 mM L-Ala or 200 mM L-Ser were used in these spectrophotometric
assays to obtain suitable rates of reaction. a) The rate of pre-transfer editing of L-Ser (or
L-Ala as a negative control) by AlaRS at varying concentrations of H2O2. b) Bar chart
showing pre-transfer editing rates of AlaRS at 0 and 75 mM H2O2 with both L-Ser and
L-Ala (negative control). c) The rate of post-transfer editing of L-Ser (or L-Ala as a negative
control) by AlaRS at varying concentrations of H2O2. d) Bar chart showing post-transfer
editing rates of AlaRS at 0 and 75 mM H2O2 with both L-Ser and L-Ala (negative control).
Mean and standard deviation were plotted from triplicate data sets. NS = not statistically
significant, S = statistically significant, as determined by a paired t-test or one-way ANOVA.
GraphPad Prism (Version 7.0c) was used for data analysis and figure preparation.
expected the cognate amino acid (L-Ala) undergoes very little pre-transfer editing
when compared to non-cognate amino acid (L-Ser), and that H2O2 has no impact on
the negative control.
In addition there was no statistically significant difference (p>0.05) in pre-transfer
editing rate of AlaRS with L-Ser between reactions containing 0 mM (0.063 ± 0.0062
min-1) and 75 mM (0.070 ± 0.0041 min-1) H2O2. This demonstrates that increasing
concentrations of H2O2 has no effect on the pre-transfer editing activity of AlaRS,
and demonstrates that H2O2 had no impact on the enzymatic coupling system.
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3.5.2 Effect of H2O2 on post-transfer editing in AlaRS
Figure 3.5c and 3.5d show that increasing concentrations of H2O2 positively
correlated with the reduction in post-transfer editing activity of AlaRS. Post-transfer
editing of AlaRS occured with L-Ser but not L-Ala (negative control) and high
enough concentrations of H2O2 completely abolished post-transfer editing of AlaRS,
reducing rates to those of the negative control.
There is no statistically significant difference (p>0.05) in post-transfer editing rate of
AlaRS with L-Ala between reactions containing 0 mM (0.00095 ± 0.0012 min-1) and
75 mM (0.015 ± 0.000084 min-1, n=2) H2O2. Additionally at 0 mM H2O2 there was a
statistically significant difference between the rate of post-transfer editing by AlaRS
with L-Ala (0.00095 ± 0.0012 min-1) and L-Ser (0.19 ± 0.0060 min-1) (p<0.0001).
This shows that as expected the cognate amino acid (L-Ala) undergoes very little
post-transfer editing when compared to the non-cognate amino acid (L-Ser). The
presence of H2O2 has no impact on the negative control.
The rate of post-transfer editing of AlaRS with L-Ser was statistically significantly
higher at 0 mM H2O2 (0.19 ± 0.0060 min-1) than with 75 mM H2O2 (0.017 ± 0.0064
min-1) (p<0.0001). In addition there was no statistically significant difference
between AlaRS with L-Ser at 75 mM (0.017 ± 0.0064 min-1) and AlaRS with L-Ala at
75 mM (0.015± 0.0085 min-1) (p>0.05) demonstrating that increasing concentrations
of H2O2 reduces the post-transfer editing rate to that of the negative control.
3.5.3 Effect of H2O2 on pre- transfer editing in ThrRS
Figure 3.6a and 3.6b show that pre-transfer editing of ThrRS occurred with L-Ser
but not L-Thr (negative control), and that H2O2 has no effect on pre-transfer editing.
There was no statistically significant difference (p>0.05) in pre-transfer editing rate
of ThrRS with L-Thr between reactions containing 0 mM (0.010 ± 0.014 min-1) and
50 mM (0.0.019 ± 0.014 min-1, n=2) H2O2. In addition, there was no statistically
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Figure 3.6: Effect of H2O2 on pre-transfer and post-transfer editing rates of ThrRS. 10
µM ThrRS with 50 mM L-Thr or 50 mM L-Ser was used in these spectrophotometric assays
to obtain suitable rates of reaction. a) The rate of pre-transfer editing of L-Ser (or L-Thr
as a negative control) by ThrRS at varying concentrations of H2O2. b) Bar chart showing
pre-transfer editing rates of ThrRS at 0 and 50 mM H2O2 with both L-Ser and L-Thr (negative
control). c) The rate of post-transfer editing of L-Ser (or L-Thr as a negative control) by
ThrRS at varying concentrations of H2O2. d) Bar chart showing post-transfer editing rates
of ThrRS at 0 and 50 mM H2O2 with both L-Ser and L-Thr (negative control). Mean and
standard deviation were plotted from triplicate data sets. NS = not statistically significant, S
= statistically significant, as determined by a paired t-test or one-way ANOVA. GraphPad
Prism (Version 7.0c) was used for data analysis and figure preparation.
significant difference (p>0.05) between the rate of pre-transfer editing of ThrRS
with L-Thr (0.010 ± 0.014 min-1) at 0 mM H2O2 and ThrRS with L-Ser (0.024 ± 0.015
min-1) . Taken together these results demonstrate that the rate of pre-transfer editing
activity of ThrRS is the same in the presence of cognate and non-cognate amino
acids, and that H2O2 has no impact on the negative control.
In addition, there was no statistically significant difference (p>0.05) in pre-transfer
editing rate of ThrRS with L-Ser between reactions containing 0 mM (0.024 ±
0.015 min-1) H2O2 and 50 mM (0.059 ± 0.041 min-1) H2O2. This demonstrates that
increasing concentrations of H2O2 has no effect on the pre-transfer editing activity
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of ThrRS, and demonstrates that H2O2 had no impact on the enzymatic coupling
system.
3.5.4 Effect of H2O2 on post-transfer editing in ThrRS
Figure 3.6c and 3.6d show that increasing concentrations of H2O2 positively
correlated with the reduction in post-transfer editing activity of ThrRS. Post-transfer
editing of ThrRS occurs with L-Ser but not L-Thr (negative control) and high enough
concentrations of H2O2 completely abolish post-transfer editing of ThrRS, reducing
rates to those of the negative control.
There was no statistically significant difference (p>0.05) in post-transfer editing
rate of ThrRS with L-Thr between reactions containing 0 mM (0.035 ± 0.0013 min-1)
and 50 mM (0.033 ± 0.0012 min-1, n=2) H2O2. Additionally at 0 mM H2O2 there
was a statistically significant difference between the rate of post-transfer editing by
ThrRS with L-Thr (0.035 ± 0.0013 min-1) and L-Ser (0.081 ± 0.0093 min-1) (p=0.0004).
This shows that as expected the cognate amino acid (L-Thr) undergoes very little
post-transfer editing when compared to the non-cognate amino acid (L-Ser), and
that the presence of H2O2 had no impact on the negative control.
The rate of post-transfer editing of ThrRS with L-Ser was statistically significantly
higher at 0 mM H2O2 (0.081 ± 0.0093 min-1) than with 50 mM H2O2 (0.018 ±
0.0091 min-1) (p<0.0001). In addition there was no statistically significant difference
between ThrRS with L-Ser at 50 mM (0.018 ± 0.0091 min-1) and ThrRS with L-Thr
at 50 mM (0.033 ± 0.0012 min-1, n=2) (p>0.05) demonstrating that increasing
concentrations of H2O2 reduced the post-transfer editing rate to that of the negative
control.
93
3.6 Effect of aaRS and H2O2 incubation time on
post-transfer editing of L-Ser by AlaRS and ThrRS
The observation that increasing concentrations of H2O2 positively correlated with
loss of post-transfer editing of aaRSs gave rise to two additional questions; was this
directly due to oxidation of the aaRS by H2O2 alone and, if so, was this oxidation
reaction a time dependent process. In order to investigate these, aaRS was incubated
with H2O2 and at various time points the post-transfer editing activity was assayed
as before. Since the oxidation of aaRS by H2O2 is a bimolecular reaction, the rate of
this reaction will be dependant upon the relative concentration of both reactants. The
molar ratio of aaRS:H2O2 from previous experiments (Section 3.5) which generated
little/no reduction in post-transfer editing was used in these assays. The molar
ratios of aaRS:H2O2 were 1:10,000 and 1:200 (equivalent to 5 mM H2O2 and 2 mM)
for AlaRS and ThrRS respectively.
Figure 3.7 and 3.8 show that compared to 0 mM H2O2 control, incubation time has no
effect on pre-transfer editing of serine. However, loss of post-transfer editing activity
of mis-serylated tRNAAla or tRNAThr was positively correlated with incubation time
in both AlaRS and ThrRS. Incubation of aaRS at room temperature without H2O2
was used as a negative control at the first and last time point, no effect on pre- or
post-transfer editing was observed.
Unless otherwise stated data was collected in triplicate (n=3) and analysed using
a paired t-test or a one-way ANOVA (for multiple comparisons) with a 95 %
confidence interval (p≤0.05).
3.6.1 Effect of incubation time on pre- and post-transfer editing activity
of AlaRS with L-Ser
At a fixed concentration of H2O2, the length of incubation time of AlaRS with H2O2
was shown to positively correlate to the loss of post-transfer editing. No effect on
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pre-transfer editing activity of AlaRS was observed with varying incubation times.
Figure 3.7a shows that there was no difference in the rate of pre-transfer editing
with respect to increased incubation time of AlaRS with 5 mM H2O2. In addition the
negative controls demonstrated that incubation in the absence of H2O2 had no effect
on pre-transfer editing of AlaRS; there was no statistically significant difference in
the rate of pre-transfer editing of AlaRS between an incubation period of 0 mins
(0.036 ± 0.0093 min-1) and 30 mins (0.045 ± 0.018 min-1) with H2O2. Additionally,
there was no difference between pre-transfer editing of AlaRS with L-Ser after
0 mins incubation with (0.036 ± 0.0093 min-1) or without (0.022 ± 0.0053 min-1)
H2O2. These results suggest that neither H2O2 or incubation time affect the rate of
pre-transfer editing activity of AlaRS.
Figure 3.7: Effect of pre-incubation time for AlaRS and H2O2 on pre- and post-transfer
editing activity of L-Ser. a) 30 minute time-course showing pre-transfer editing of AlaRS
following incubation with H2O2. b) 30 minute time-course showing post-transfer editing of
ThrRS following incubation with H2O2. The final concentration of AlaRS and H2O2 in the
assay was 0.5 µM and 5 mM respectively. Incubation of AlaRS with 0 mM H2O2 was used
as a negative control. Mean and standard deviation were plotted from triplicate data sets.
GraphPad Prism (Version 7.0c) was used for data analysis and figure preparation.
Figure 3.7b shows that increasing incubation time of AlaRS with a fixed
concentration of H2O2 positively correlated with a loss of post-transfer editing
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activity. In the presence of H2O2 there was a statistically significant different
reduction in post-transfer editing of AlaRS with L-Ser, between an incubation
time of 0 mins (0.12 ± 0.010 min-1) and 30 mins (0.015 ± 0.0055 min-1) (p<0.0001 ).
In contrast the negative control showed that there was no statistically significant
difference (p>0.05) between the rate of post-transfer editing of AlaRS after an
incubation time of 0 mins (0.036 ± 0.0093 min-1) or 30 mins (0.045 ± 0.018 min-1) in
the absence of H2O2. These results demonstrate that the length of incubation time
of AlaRS with H2O2 affects the editing activity of AlaRS with L-Ser. The negative
control showed that there was no difference in post-transfer editing activity of AlaRS
in the absence of H2O2, indicating that the presence of H2O2 does not have any
adverse effect on other components of the assay (e.g. tRNA or enzymes from the
coupling reaction).
3.6.2 Effect of incubation time on pre- and post-transfer editing activity
of ThrRS with L-Ser
At a fixed concentration of H2O2, the length of incubation time of ThrRS with H2O2
was shown to positively correlate to the loss of post-transfer editing. No effect on
pre-transfer editing activity of AlaRS was observed with varying incubation times.
Figure 3.8a shows that there was no difference in the rate of pre-transfer editing
with respect to increased incubation time of ThrRS with 2 mM H2O2. In addition the
negative controls demonstrated that incubation in the absence of H2O2 had no effect
on pre-transfer editing of ThrRS. There was no statistically significant difference
(p>0.05) on the rate of pre-transfer editing of ThrRS between an incubation period
of 0 mins (0.041 ± 0.0034 min-1) and 40 mins (0.034 ± 0.0030 min-1) with H2O2.
Additionally, there was no statistically significant difference (p>0.05) between
pre-transfer editing of ThrRS after 0 mins incubation with (0.041 ± 0.0034 min-1)
or without (0.038 ± 0.012 min-1) H2O2. These results suggest that neither H2O2 or
incubation time affect the rate of pre-transfer editing activity of ThrRS.
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Figure 3.8b shows that increasing incubation time of ThrRS with a fixed
concentration of H2O2 positively correlated with a loss of post-transfer editing
activity. In the presence of H2O2 there was a statistically significant different
reduction in post-transfer editing activity of ThrRS, between an incubation time of 0
mins (0.18 ± 0.032 min-1) and 40 mins (0.049 ± 0.011 min-1) (p=0.0003). In contrast,
the negative control showed that there was no statistically significant difference
(p>0.05) between the rate of post-transfer editing of ThrRS after an incubation time
of 0 mins (0.18 ± 0.014 min-1) or 40 mins (0.14 ± 0.023 min-1) in the absence of H2O2.
These results demonstrate that the length of incubation time of ThrRS with H2O2
affects the editing activity of ThrRS with L-Ser. The negative control showed that
there was no difference in post-transfer editing activity of ThrRS in the absence of
H2O2, indicating that the presence of H2O2 does not have any adverse effect on
other components of the assay (e.g. tRNA or enzymes from the coupling reaction).
Figure 3.8: Effect of pre-incubation time for ThrRS and H2O2 on pre- and post-transfer
editing activity of L-Ser. a) 40 minute time-course showing pre-transfer editing of ThrRS
following incubation with H2O2. b) 40 minute time-course showing post-transfer editing of
ThrRS following incubation with H2O2. The final concentrations of ThrRS and H2O2 in the
assay were 10 µM and 2 mM respectively. Incubation of ThrRS with 0 mM H2O2 was used
as a negative control. Mean and standard deviation were plotted from triplicate data sets.
GraphPad Prism (Version 7.0c) was used for data analysis and figure preparation.
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3.6.3 Additional experimental controls
In order to determine if the presence of DTT in the reaction mix was diminishing the
observed effects of H2O2 on post-transfer editing rates, control experiments were
conducted in the absence of DTT at incubation times of 10 mins for aaRSs (Figure
3.9a and b, for AlaRS and ThrRS respectively).
Unless otherwise stated data was collected in triplicate (n=3) and analysed using
a paired t-test or a one-way ANOVA (for multiple comparisons) with a 95 %
confidence interval (p≤0.05).
There was no statistically significant difference (p>0.05) between assays conducted
in the presence (0.13 ± 0.015) or absence of DTT (0.15 ± 0.018) when post-transfer
editing of AlaRS with L-Ser was monitored following a 10 min incubation with
0 mM H2O2. Similarly, there was no statistically significant difference (p>0.05)
between assays conducted in the presence (0.030 ± 0.0036) or absence of DTT (0.035
± 0.0079) when post-transfer editing of AlaRS with L-Ser was monitored following
a 10 min incubation with 5 mM H2O2.
There was no statistically significant difference (p>0.05) between assays conducted
in the presence (0.13 ± 0.015) or absence of DTT (0.15 ± 0.020) when post-transfer
editing of ThrRS with L-Ser was monitored following a 10 min incubation with
0 mM H2O2. Similarly, there was no statistically significant difference (p>0.05)
between assays conducted in the presence (0.10 ± 0.0034) or absence of DTT (0.11 ±
0.0043) when post-transfer editing of ThrRS with L-Ser was monitored following a
10 min incubation with 2 mM H2O2.
These results demonstrate that the presence of DTT in the assay mixture does not
affect the post-transfer editing rate of either AlaRS or ThrRS.
In addition, to ensure that the measured effects of H2O2 were directly due to
modified post-transfer editing activity, the effect of H2O2 on the coupled reaction
was measured (Figure 3.9c and d). In this assay the rate limiting step is the
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post-transfer editing mechanism and so the rate of the coupled system (comprising
myokinase, PK and LDH) must be much faster. The coupled reaction was initiated
by addition of AMP and can be seen to reach completion in < 30 s, this is unaffected
by the addition of 50 mM H2O2. However, whilst this has no affect on the initial rate
of reaction measured, interestingly the overall absorbance change of the reaction
decreases in the presence of H2O2. This experiment shows that the rate of the
coupled reactions are so rapid, even in the presence of H2O2, that any effect H2O2
may have on these enzymes would be negligible in this assay.
Figure 3.9: Effect of H2O2 controls. Effect of presence of DTT in master mix on Post-transfer
editing of a) AlaRS and b) ThrRS, following 0 min and 10 min incubation with 50 mM H2O2.
Spectrophotometric data of the coupled reactions occurring in real-time as detected by
changes in absorbance at 340 nm c) in the absence of H2O2 d) in the presence of 50 mM
H2O2. NS = not statistically significant, as determined by a paired t-test or one-way ANOVA.
GraphPad Prism (Version 7.0c) was used for data analysis and figure preparation.
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3.7 An alternate ThrRS construct
In addition to the low catalytic efficiency of ThrRS compared to AlaRS observed in
the amino acid activation assay, the post-transfer editing assay required a 20-fold
higher concentration of ThrRS than AlaRS in order to obtain a measurable editing
rate. The ThrRS used by Ling and Söll (2010) and Wu et al. (2014) contained
an N-terminal 6-His tag whilst the S. pneumoniae ThrRS used here possessed a
C-terminal 6-His tag. If the C-terminal end of S. pneumoniae ThrRS is important
for activity, the location of the 6-His tag may explain the marked reduction in
catalytic efficiency of this enzyme. The pET22::ThrRS(spr1472) construct does not
have a cleavage site present for removal of the C-terminal 6-His tag, and so in
order to understand the importance of the C-terminus for activity, ThrRS was
cloned into pET28(a) to engineer an N-terminally tagged construct (ThrRS(N-term)).
ThrRS(N-term) was overexpressed, purified and quantified as outlined in Section
2.5.
For ThrRS(N-term) a significant increase in purity was achieved by IMAC and very
little additional purity was achieved during the second chromatography step using
SEC. The final purity of ThrRS(N-term) was estimated to be ∼ 63 % using ImageJ
(Version 1.51).
ThrRS(N-term) was re-assayed using both the ADPNP amino acid activation assay,
and the post-transfer editing assay. The activity of ThrRS(N-term) remained low and
no significant improvement was achieved in either assay, therefore all subsequent
assays were conducted with the C-terminally tagged ThrRS for consistency. This
result suggests that the presence of a C-terminal his-tag does not explain the low
activity of ThrRS when compared to AlaRS.
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Figure 3.10: 12 % SDS-PAGE showing ThrRS protein purification summary. a) Summary
gel for the purification of N-terminally tagged ThrRS. Lane 1 - Amersham Protein Marker,
Lane 2 - 10 µg 50,000 x g supernatant, Lane 3 - 10 µg pooled IMAC fractions, Lane 4 - 10
µg pooled SEC fractions.
3.8 Mass Spectrometry to identify the modification made to
ThrRS and AlaRS by H2O2
This section aims to demonstrate that AlaRS and ThrRS undergo stable oxidative
modifications when treated with H2O2 and secondly to characterise which residues
are modified (and to what oxidation state) in the conditions previously shown to
abolish post-transfer editing activity. Cysteine and methionine both contain sulphur
and so are the most likely amino acids to undergo oxidation (Ahmad et al., 2017).
Each residue can form multiple oxidation states (Table 3.1); cysteine residues can be
oxidised upto 3 times creating sulphenic, sulphinic and sulphonic acids respectively,
whilst methionine residues can exist in one of two oxidation states; methionine
sulphoxide or methionine sulphone. The molecular weight of oxygen is 15.9949 Da,
therefore it was anticipated that intact protein mass spectrometry would identify
shifts in protein mass occurring as multiples of 15.9949 Da. S. pneumoniae AlaRS
contains a single cysteine residue, whilst ThrRS contains two cysteine residues
which are suitable targets for oxidation by H2O2 (Appendix 7.3).
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Name Structure ∆Mass (Da)
Cysteine sulphenic acid +15.9949
Cysteine sulphinic acid +31.9899
Cysteine sulphonic acid +47.9848
Methionine sulphoxide +15.9949
Methionine sulphone +31.9899
Table 3.1: Oxidation states of cysteine and methionine residues. Adapted from Jeong et al.
(2011).
3.8.1 Intact protein mass spectrometry
Based on the loss of post-transfer editing activity, evident from previous experiments
(Section 3.6, AlaRS and ThrRS were incubated with H2O2 in a ratio of 1:10,000 and
1:200 (or water as a negative control) for 30 mins and 40 mins respectively. 50 µl
samples containing 5-10 pmols purified protein in 50 % (v/v) methanol + 0.1 %
(v/v) formic acid were analysed by electrospray mass spectrometry.
Figure 3.11a, 3.12a, 3.13a and 3.14a show molecular ions in the m/z range of 600-3000
for AlaRS (without H2O2), AlaRS (with H2O2), ThrRS (without H2O2) and ThrRS
(with H2O2) respectively.
Following interpretation of the m/z spectra by the Maximum Entropy algorithm,
a number of major species were identified around the expected molecular mass




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































species clustered at ∼97 kDa however in ThrRS two major clusters, ∼75 and ∼77
kDa were present. The presence of multiple clusters and species within each cluster
may be explained by post-translational modifications (e.g. acylation, alkylation or
phosphorylation) or loss of amino acids at the C- or N-terminus of the protein. In
addition, in electrospray mass spectrometry, metal ion adducts are also common and
so can generate modified species that are not found at the expected molecular mass.
For example in Figure 3.11c, the peak with mass 97,459.20 Da may be attributed to
AlaRS which has lost the N-terminal methionine and is sodiated (expected mass
of 97,457.9 Da). Therefore, due to the complex nature of the protein samples this
analysis did not aim to assign species to all major peaks but instead identify any
shift between untreated AlaRS/ThrRS and the corresponding H2O2 treated samples
a which indicates oxidation.
Figure 3.15 and 3.16 show that in both AlaRS and ThrRS respectively, mass spectra
shifts to a higher molecular mass after treatment with H2O2, indicating that there is
a stable modification occurring. The increase in mass is more apparent in AlaRS, an
overall shift of ∼100 Da can be observed whereas in ThrRS the overall shift is less
apparent ∼50 Da, this observation indicates that under these conditions AlaRS is
more highly oxidised than ThrRS.
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Figure 3.15: Intact protein mass spectrometry of AlaRS with and without hydrogen
peroxide treatment.
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Figure 3.16: Intact protein mass spectrometry of ThrRS with and without hydrogen
peroxide treatment.
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3.8.2 Peptide-based mass spectrometry
AlaRS and ThrRS were incubated with H2O2 in a ratio of 1:10,000 and 1:200 (or
water as a negative control), buffer exchanged to remove H2O2 and prepared
for SDS-PAGE in a non-reducing loading buffer. Bands at a molecular weight
corresponding to that of AlaRS and ThrRS were excised (Figure 3.17) and
digested with trypsin for peptide-based mass spectrometry conducted by the WPH
Proteomics RTP (University of Warwick).
Figure 3.17: 12 % SDS-PAGE of AlaRS and ThrRS samples for peptide based mass
spectrometry. Lane 1 - Amersham Protein Marker, Lane 2 - 15 µg AlaRS, Lane 3 - 15
µg AlaRS (H2O2 treated), Lane 4 - 15 µg ThrRS, Lane 5 - 15 µg ThrRS (H2O2 treated). Red
boxes indicate bands which were excised for tryptic digest and mass spec analysis.
The mass of peptides corresponding to those containing modified residues,
mono-oxidised (sulpenic acid), di-oxidised (sulphinic) and tri-oxidised (sulphonic
acid) or unmodified residues, were identified.
For AlaRS, good sequence coverage was obtained; 74 % for the control sample and 77
% for the H2O2 treated sample. In each AlaRS sample up to 19 residues (methionine,
tryptophan and cysteine) were found to be sites of potential modifications (Figure
3.18). Unexpectedly, Cys669 was tri-oxidised to sulphonic acid in both the control
and treated AlaRS samples (Appendix 7.4). Sequence coverage was also good
in ThrRS; 87 % for the control sample and 85 % for the H2O2 treated sample.
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Each ThrRS sample contained 26 residues (methionine, tryptophan and cysteine)
which contained modifications (Figure 3.19. Both Cys181 and Cys336 residues were
tri-oxidised to sulphonic acid in the control and treated ThrRS samples (Appendix
7.4). In both AlaRS and ThrRS, all other modifiable residues were found as
un-oxidised, mono-oxidised or di-oxidised forms. Most residues with the potential
for modifications, were identified in multiple states, which indicates that the
protein sample is heterogenous and many possible combinations of modifications
exist within the sample. It is not possible to deconvolute between these different
combinations to better understand the samples heterogeneity.
Figure 3.18: Sequence coverage and modified residues of AlaRS. a) AlaRS control sample,
b) AlaRS H2O2 treated sample. Sequence coverage (yellow) and modified residues (green)
are displayed. Results analysed in Scaffold (Version 4.8.1).
The high levels of oxidation and the presence of tri-oxidised cysteines in control
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Figure 3.19: Sequence coverage and modified residues of ThrRS. a) ThrRS control sample,
b) ThrRS H2O2 treated sample. Sequence coverage (yellow) and modified residues (green)
are displayed. Results analysed in Scaffold (Version 4.8.1).
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samples may have occurred as a result of sample preparation. Both SDS-PAGE and
tryptic digest preparation occurs in an oxidative environment and it is common for
methionine residues to show oxidation with peptide-based mass spectrometry. In
order to prevent the reducing agent from reversing the oxidation from the H2O2
incubation, initial samples were prepared for SDS-PAGE in the absence of a reducing
agent. Due to the large amount of oxidation observed, subsequent samples were
prepared with reducing agent, however this did not appear to have any effect on
the level or extent of oxidation in AlaRS or ThrRS.
3.9 Discussion
This chapter demonstrates that S. pneumoniae AlaRS and ThrRS are both capable of
activating non-cognate amino acids leading to aminoacylation of tRNA with L-Ser.
The presence of pre- and post-transfer editing mechanisms of AlaRS and ThrRS aim
to minimise the impact of mischarging events, however, this research demonstrates
that in vitro H2O2 can affect the ability of AlaRS and ThrRS to undertake post-transfer
editing activity. H2O2 has been shown to have no effect on amino acid activation or
pre-transfer editing activity but markedly reduces the rate of post-transfer editing
in a concentration and time dependent manner. Intact protein mass spectrometry
experiments have identified an increase in molecular mass of AlaRS and ThrRS
species following incubation with H2O2 indicating that stable modifications to the
proteins have occurred.
In addition, whilst both the amino acid activation and post-transfer editing activity
of ThrRS was significantly lower than that of AlaRS, there was no increase in activity
when the 6-His tag was transferred from the C-terminus to the N-terminus. Cleavage
of the 6-His tag may improve ThrRS activity in future experiments.
Initially the background rate for the ADPNP amino acid activation assay (Figure
2.2) was intended to be obtained in the presence of the aaRS and absence of amino
acid. However, it was observed that the initial rate of reaction was not consistent
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or reproducible under seemingly identical conditions. The variation in initial rate
was due to the variation in time between addition of the aaRS to the assay mix and
the recording of spectrophotometric data. It was hypothesised that the aaRS’s were
therefore contaminated with trace amounts of IPP, a ubiquitous and highly active
enzyme. To test this, the amino acid was added to the assay master mix and the
first reaction was initiated by the addition of aaRS instead. Identical rates could
be achieved if the reaction was initiated with either the aaRS or PPi, but not amino
acid, which confirmed that if aaRS was incubated with the PPi, contaminating IPP
would break down the PPi thereby affecting the initial velocity upon true initiation
of the reaction.
Fluoride has previously been shown to inhibit IPP (Josse, 1966; Tono and Kornberg,
1967) and so 50 mM potassium fluoride (KF) was added to the assay mix, however
this completely abolished ThrRS activity. It was therefore decided that for these
experiments, the amino acid would be included in the assay master mix and the
reaction would be initiated by the addition of the aaRS.
The amino acid activation assays were intended to test activity of the aaRS
enzymes before progressing to further experiments. Whilst both AlaRS and ThrRS
demonstrated activity in the ADPNP assay, the catalytic efficiencies of both proteins
was low. The activity of ThrRS was ∼ 20 x lower than that of AlaRS and >5000 x
less active than was reported for E. coli ThrRS (Ling and Söll, 2010; Ling et al., 2012).
These previous studies used a pyrophosphate exchange assay, which measures
radioactivity transferred from pyrophosphate to ATP during amino acid activation.
In contrast, experiments in this chapter utilised an alternate spectrophotometric
assay to measure amino acid activation. Since the spectrophotometric assay
uses an ATP analogue (ADPNP) it is possible that the greatly reduced kinetic
constants were due to an inability of ThrRS to utilise this alternative substrate. The
assay was repeated using another ATP homologue (ADPCP) which improved the
observed amino acid activation rate only slightly. In addition to low amino acid
activation activity, the concentration of ThrRS required to achieve an observable
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and measurable rate of post-transfer editing was ∼20 x the concentration required
for AlaRS to achieve a similar rate.
The requirement of zinc ions for ThrRS activity has been documented previously
(Nureki et al., 1993), but neither addition of zinc chloride (ZnCl2) to the assay mixture
or the purification protocol resulted in an improvement in enzymatic activity of
ThrRS. It was identified that previous experiments with E. coli ThrRS were conducted
with an N-terminal 6-His tagged protein (Ling and Söll, 2010), whilst in contrast the
construct used in these experiments was a C-terminal 6-His tagged protein. This
observation raised questions regarding the impact of the tag and importance of the
C-terminus on ThrRS activity. However, ThrRS(N-term) showed no improvement
in catalytic efficiency in either amino acid activation or post-transfer editing assays.
The effect of H2O2 on initial rates of pre- and post-transfer editing activities of AlaRS
and ThrRS were demonstrated using a novel post-transfer editing assay developed
by Dr Adrian Lloyd. In contrast to the assay used by (Ling and Söll, 2010), which
was a radiolabelled end point assay measuring the production of mis-aminoacylated
tRNA species, this assay is a continuous spectrophotometric assay, measuring the
rate of pre- and post-transfer editing reactions by coupling the production of AMP
during post-transfer editing to the oxidation of NADH to NAD+ by myokinase, PK
and LDH (Section 2.9.2).
The result from the post-transfer editing assays taken together show that oxidation
of AlaRS and ThrRS is both a concentration and time dependent process in vitro. If
AlaRS or ThrRS are in close proximity to significant amounts of H2O2 for extended
periods of time in S. pneumoniae, oxidation and hence loss of post-transfer editing
activity would likely occur in vivo. It is important to note that the concentrations
of aaRS and H2O2 used in these assays were concentrations necessary to obtain
accurately measurable rates of reaction and are not necessarily biologically relevant.
The concentration of H2O2 and the effect of H2O2 on aaRS in vivo is likely to be
more complex and the relative local concentrations of aaRS and H2O2 would be
important.
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A 35,000 x molar concentration of H2O2 is required to reduce the post-transfer
editing rate of AlaRS by ∼50 %, whilst only 1,500 x molar concentration of H2O2
is required to reduce the post-transfer editing of ThrRS by ∼50 %. These values
are in line with those previously reported by (Ling and Söll, 2010), whereby a
significant reduction in total editing activity of 1.5 µM ThrRS was achieved with 4
mM H2O2 which is a 2,666 x molar concentration, and the lowest concentration of
H2O2 reported to induce mis-aminoacylation of 2.3 µM ThrRS, was 200 µM or 86 x
molar concentration.
H2O2 was found to have no effect on pre-transfer editing of AlaRS or ThrRS. As
expected, the rate of pre-transfer editing of AlaRS was found to be higher for
non-cognate amino acid when compared to the cognate amino acid. However,
no significant difference in pre-transfer editing of ThrRS was observed between
non-cognate amino acid and cognate amino acid. This may be explained due to the
overall lower level of pre-transfer editing, and inherently larger error with ThrRS.
It is important to note that for all the post-transfer editing assays, since the reaction
was initiated with amino acid and subsequently tRNA, aaRS (either with or without
H2O2) was, in all cases added to the master mix prior to initiating and measuring
the reaction. The time between the addition of aaRS to the master mix and the
recording of data is referred to as zero, but is the minimum amount of time required
for addition to and mixing with master mix, time for the spectrophotometer to be
zeroed and time taken to obtain a suitable background rate. This duration is ∼40
seconds. Background rates were obtained for 1 minute prior to the addition of
amino acid and 30 seconds following addition of amino acid prior to addition of
tRNA. As such each recording has 2 - 2.5 mins of additional time for which aaRS
and H2O2 were always incubated. This time was as consistent as possible and since
data was obtained in triplicate any variation incurred from this has been accounted
for in the measured error.
Intact protein mass spectrometry indicated that there was an increase in molecular
mass of both AlaRS and ThrRS following treatment with H2O2. The quality of
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this data was relatively poor and so increasing the protein concentration may have
been beneficial. However, significant protein losses were incurred when a desalting
column or centrifugal concentrator were used to remove the H2O2; as such protein
concentration was the limiting factor. Additionally, as an alternative to direct
injection, it may have been beneficial to use LC-MS (e.g. a C4 column). In E. coli
ThrRS Cys182 and the equivalent Cysteine (Cys666) in AlaRS have been identified
as essential for editing of misacylated amino acids (Ling and Söll, 2010; Beebe et al.,
2003). Since the editing domain of S. pneumoniae AlaRS contains the only cysteine
residue (Cys669) in the protein, it was proposed that this residue is oxidised by
H2O2 in a similar manner to that in E. coli ThrRS (Cys182) which resulted in loss of
editing activity Ling and Söll (2010).
Peptide-based mass spectrometry was used in order to overcome the issues
encountered with intact protein mass spectrometry. It was hoped that peptide-based
mass spectrometry would identify oxidation of C669 and C181 of AlaRS and ThrRS
respectively, and any additional residues which are oxidised upon exposure to
H2O2.
However, analysis of protein modifications by mass spectrometry can be difficult,
and a number of factors must be considered. Firstly, the mass shift in the peptide
molecular weight, which in the case of oxidation is relatively small but can range
from +16 Da to +48 Da and the stability of the modification are important. Secondly,
the overall abundance of the modified peptide, and the effect of the modification on
the peptides ionization efficiency are also factors to consider (Parker et al., 2010).
Good coverage of both AlaRS and ThrRS was obtained, but many residues were
highly oxidised in both the treated and untreated samples. This high level of
oxidation may indicate that the loss of post-transfer editing activity is related to
the proportion of protein oxidised at specific sites in the protein, rather than the
absolute presence or absence of oxidation. Alternatively, the sample preparation,
comprising SDS-PAGE, gel extraction and tryptic digest, which all occur in an
oxidative environment, may have resulted in high levels of oxidation in these
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proteins. Given that AlaRS and ThrRS samples are highly pure, the amount of
oxidation occurring during sample preparation could be minimised by eliminating
gel-extraction and preparing samples in solution for future mass spectrometric
experiments.
Given that sequence coverage for both AlaRS and ThrRS is high, and that the
residues of interest (cysteines) were successfully detected, this experiment acts as
a proof of concept. With some optimisation, peptide-based mass spectrometry
would be the preferred method for identification of specific sites which are modified
and responsible for the loss of post-transfer editing activity of AlaRS and ThrRS.
However, in order to thoroughly investigate these modifications a quantitative
experimental design and more complex analysis is required. Since the intensity
of the peak is unique to each peptide, comparison of the same peptide in its
un-modified and modified form can be difficult and, in addition to > triplicate
runs the samples must be prepared and analysed at the same time, with equal
loading of each sample. The ratio between modified and un-modified peptide
can then be calculated for a specific sample, and this ratio can be compared to the
equivalent ratio from another sample. This could provide information on whether
the level of particular modifications varied between control and treated samples.
In addition to peptide-based mass spectrometry the relationship between loss of
post-transfer editing and the oxidation of cysteine residues could be investigated
using a 5,5-dithio-bis-(2-nitrobenzoic acid (DTNB) assay. Performing a DTNB assay
after incubation of aaRS with H2O2 for different lengths of time, or at different H2O2
concentrations could determine if oxidation of cysteines occurred proportionally to
the reduction in post-transfer editing activity.
3.10 Future Work
Specific modifications which are responsible for the loss of post-transfer editing
activity observed in in vitro editing assays should be determined using quantitative
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mass spectrometry experiments. Oxidation of Cys669 of AlaRS and Cys181 of ThrRS
could also be investigated using a DTNB assay.
The work conducted here could also be extended to additional aaRSs. Ten aaRS
families are capable of misactivating non-cognate amino acids, and therefore possess
editing activities in order to maintain translational fidelity (Perona and Gruic-Sovulj,
2013). The effect of H2O2 on editing activities in aaRSs such as LysRS, which
is known to misacylate tRNALys with both alanine and serine (Shepherd and
Ibba, 2014), and ProRS which has been shown to misacylate tRNAPro with alanine
(Beuning and Musier-Forsyth, 2000) should also be investigated.
Additionally, the wider effects and consequences of H2O2 on misacylation of tRNA
in vivo should be considered. The SpxB gene encodes a protein which, under aerobic
conditions, converts pyruvate to acetyl phosphate, producing H2O2 as a metabolic
bi-product (Spellerberg et al., 1996). SpxB and MurM are both non-essential
genes and so ∆SpxB mutants and ∆MurM mutants could be used to investigate
the interplay between H2O2 and the PG in vivo (Regev-Yochay et al., 2007). S.
pneumoniae is a facultative anaerobe, therefore, the generation of H2O2 will depend
on environmental O2 concentrations. It is possible that aerobic growth creates the
requirement for support by factors such as MurM to maintain the fidelity of protein
synthesis; whilst anaerobic growth or growth without SpxB relaxes this necessity. If
misacylated tRNAs, occurring as a response to increased H2O2 levels, are directed
into PG synthesis by MurM, then it would be expected that the composition of
the PG would alter in ∆SpxB or ∆MurM mutants. S. pneumoniae (159) shows a
natural bias towards incorporation of alanine at the first position of the dipeptide
bridge in PG. Therefore it would be expected that in S. pneumoniae (159) in the
absence of SpxB and in the presence of MurM there would be higher proportions of
alanine in the PG, and that in the presence of SpxB or exongenously added H2O2
the incorporation of serine into the the dipeptide bridge of PG would increase.
Similarly, modulation of indirect cross-linking might also be apparent in wild type
pneumococal peptidoglycan in cells grown aerobically compared to those grown
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anaerobically. AlaRS or ThrRS editing site mutants, whereby the Cys669 and C181
respectively, have been mutated to serine would likely be lethal, but transformation
with donor DNA containing this aaRS editing mutant may result in increased
incorporation of serine into the dipeptide bridge. The composition of the PG layer
can be investigated by mass spectrometry as described by Garcia-Bustos and Tomasz
(1990).
In vivo the loss of post-transfer editing by synthetases in S. pneumoniae grown in
aerobic conditions would result in a reduction in the fidelity of protein synthesis
and ultimately cell death. Therefore, in the next chapter we investigate a proposed
mechanism in which MurM acts to restore the fidelity of protein synthesis by




MurM kinetics and substrate
specificity
The optimisation of iGln Lipid II synthesis was conducted in collaboration with
Catherine Rowland (School of Life Sciences, University of Warwick). Next
Generation Sequencing (NGS) of S. pneumoniae (159) and S. pneumoniae (Pn16)
was conducted at Micropathology Ltd with Daniel Hand providing experimental
guidance and analysis, and John Moat (Antimicrobial Screening Facility, Warwick)
for CAT2 training and MIC determination.
4.1 Introduction
MurM is an aminoacyl-tRNA-dependent ligase which is responsible for the addition
of L-Ala or L-Ser to the third position lysine of the Lipid II(Lys) (Filipe et al.,
2000a). MurM belongs to the MurMN operon, where MurN encodes the protein
responsible for the subsequent addition of a second amino acid, an invariable
L-Ala, to that appended by MurM. MurM and MurN together generate a dipeptide
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branched precursor required for the formation of indirect cross-links in the PG of
S. pneumoniae. The MurM gene is required but not sufficient for the generation
of high-level penicillin resistance. Deletion of the MurM gene has been shown to
significantly reduce the β-lactam MIC of a strain, restoring susceptibility to resistant
strains (Filipe et al., 2001a). Therefore, MurM serves as a potential target for the
development of novel antimicrobials, which could restore sensitivity to penicillin to
otherwise resistant strains.
Whilst the proportion of cross-links in the PG varies very little between susceptible
and resistant strains of S. pneumoniae, the level of indirect cross-linking between
branched substrates, strongly correlates with resistance (Garcia-Bustos and Tomasz,
1990). This suggests that the ability of S. pneumoniae to generate indirect cross-links
is closely related to the resistance of a strain. It was therefore proposed that
remodelling of the PBP active site, which results in a reduced affinity for penicillin
(and hence penicillin resistance) may also alter the substrate specificity, resulting in
use of an alternate (branched) substrate (Garcia-Bustos and Tomasz, 1990). MurM
is a highly mosaic gene, with many different MurM alleles. Whilst there is no
particular MurM sequence required for resistance in S. pneumoniae, MurM alleles
from a number of resistant strains contain a highly divergent sequence which differs
in length and exact location, and is completely absent from susceptible strains (Filipe
et al., 2000b). This indicates that acquisition of this sequence is linked to the presence
of resistance.
Studies by Lloyd et al. (2008) demonstrated that the catalytic activity of MurM was
directly linked the observed proportion of branched muropeptide present in the
pneumococcal cell wall of resistant and susceptible strains S. pneumoniae (159) and
S. pneumoniae (Pn16) respectively. The bias towards incorporation of L-Ser or L-Ala
at the first position of the indirect dipeptide cross-link in the pneumococcal cell wall
was not linked to the strains susceptibility, but was instead dictated by the specific
MurM allele present. A 30 amino acid sequence from residue 244 to 274 was found
to determine the specificity for L-Ala or L-Ser, with residue 260 being particularly
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important. MurM alleles containing a lysine or threonine at position 260 were found
to more commonly incorporate L-Ala or L-Ser respectively, into the pneumococcal
cell wall (Filipe et al., 2001b). Additionally, in vitro the amino acid selectivity of
MurM was determined by the MurM allele and not due to strain specific differences
in the tRNA pool (Lloyd et al., 2008).
MurM alleles from S. pneumoniae (Pn16), S. pneumoniae (159) and S. pneumoniae
(R6), which show differential bias towards amino acid incorporation to the PG in
vivo, all showed a preference for mis-aminoacylated seryl-tRNAAla, compared to
correctly-aminoacylated alanyl-tRNAAla or seryl-tRNASer (Shepherd, 2011). This
observation indicated that use of mis-aminoacylated tRNA substrates is of greater
importance than the amino acid being incorporated. S. pneumoniae generates
high levels of H2O2 as a biproduct of aerobic metabolism, and lacks many of the
canonical ROS response mechanisms. As shown previously in Chapter 3, exposure
of aaRSs to H2O2 results in a reduction in post-transfer editing and an increase
in mis-aminoacylated tRNA. It was therefore proposed that MurM preferentially
utilises amino acids from mis-aminoacylated tRNA species, encorporating them
into the PG, in order to eliminate them from the cellular tRNA pool and thereby
maintaining the fidelity of protein synthesis.
In addition, previous work on MurM demonstrating the selectivity of MurM
for individual ’pure’ substrates, was conducted using the tRNASer3 isoacceptor.
However, there are three isoacceptors for tRNASer, which possess sequence
differences at 51-63 bp which was shown previously to confer stability with EF-Tu
(Sanderson and Uhlenbeck, 2007). We therefore questioned whether MurM utilises
all isoacceptors equally, and aimed to characterise this before proceeding with
experiments to understand MurM’s preferences towards mis-aminoacylated tRNA’s.
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4.2 Aims
This chapter allowed preparation for a myriad of MurM experiments which will
permit investigation of MurM substrate preference and kinetics. MurM from two
strains (S. pneumoniae (159) and S. pneumoniae (Pn16)) was successfully sequenced,
over-expressed and purified. Significant quantities of possible MurM substrates;
Lipid II(Lys), iGln Lipid II(Lys), S. pneumoniae (159) tRNA and in vitro transcribed
tRNA isoacceptors were (where necessary synthesised and) purified. Initial tests
and protocol optimisation were conducted to ensure that enzymes and substrates
were suitable for the proposed experiments. This preparative work will greatly
assist future experiments which will investigate the ability of MurM to utilise
mis-aminoacylated tRNAs and identify any difference in tRNA isoacceptor usage by
MurM. In addition the Lipid II substrate for MurM will be determined, identifying
where, with respect to MurM, amidation of the Lipid II precursor by MurT/GatD
occurs.
4.3 Cloning, expression and purification of MurM from S.
pneumoniae (159) and S. pneumoniae (Pn16)
4.3.1 Expression of MurM159 and MurMPn16
Both MurM159 and MurMPn16 have been cloned and expressed previously as per
published methods (Lloyd et al., 2008; Shepherd, 2011).
Constructs pET21b::MurMPn16(1) and pET21b::MurM159(1) created by Lloyd et al.
(2008) were used to transform E. coli C41(DE3)/pRIL cells. The proteins were
expressed for 4 hours in accordance with the published protocol (Lloyd et al., 2008).
Despite no obvious signs of over-expression of MurM for either construct (Figure
4.1), the sample was progressed to purification due to reports of low levels of
expression for MurM previously.
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Figure 4.1: 12 % SDS-PAGE showing 4 hour expression of MurM a) MurMPn16(1) and b)
MurM159(1). Lane 1 - Amersham protein marker, Lane 2 - T=0, Lane 3 - T=1, Lane 4 - T=2,
Lane 5 = T=3, Lane 6 - T=4. T = expression time (h).
In contrast to the numerous purification steps used by Lloyd et al. (2008), Shepherd
(2011) had previously demonstrated that MurM could be purified in a one-step
IMAC purification. Therefore purification of MurM159(1) using this method
was attempted. Figure 4.2 shows that following IMAC, MurM159(1) contained
a significant number of impurities and would require additional purification steps.
Figure 4.2: 12 % SDS-PAGE showing IMAC purification of MurM159(1). Lane 1 -
Amersham protein ladder, Lane 2 - 10 µg protein from 10,000 xg supernatant, Lane 3 -
10 µg protein from column load, Lane 4 - 10 µg protein from column flow through, Lane 5
= 10 µg protein from column wash, Lane 6 to 9 - 20 µl of elution fractions.
The purification was therefore repeated in accordance with the protocol published
by Lloyd et al. (2008). Figure 4.3 shows the fractions from the final IMAC purification
step of this protocol. Using ProtParam the molecular weight of MurM159(1)
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(containing a 6-His tag) was predicted to be 48,500 kDa. A strong band at ∼45 kDa,
can be identified in the elution fractions, however, despite the improvement in purity
compared to the one-step IMAC, there are still a large number of contaminating
bands. The high levels of impurities were thought to be attributed to the low
expression levels. Therefore optimising the expression level was deemed to be the
most prudent way forward.
Figure 4.3: 12 % SDS-PAGE showing final chromatography step (SEC) during
purification of MurM159(1). Lane 1 - Amersham protein ladder, Lane 2 - 5 µg protein
from column load, Lane 3 - 16 µl flow through, Lane 4 - 16 µl column wash, Lane 5 = 16 µl
first elution fraction, Lanes 6 to 10 - 5 µg protein from elution fractions.
Constructs containing a TEV-cleavable 6-His tag (pET21b::MurM159(2) and
pET21b::MurMPn16(2)) were created by Shepherd (2011). Since the presence of
a cleavable 6-His tag may prove useful in downstream experiments, and these
constructs had been located, they were used from hereon in.
MurMPn16 was previously found to express slightly better than MurM159 and so was
the preferred choice for small scale expression trials in E. coli C41(DE3)/pRIL.
The effect of temperature and IPTG concentration on MurM expression were
investigated. Figures 4.4, 4.5 and 4.6 show both the insoluble (IS) and soluble
(S) fraction of samples taken over 12 hours from expressions at 25 ◦C, 15 ◦C and 11
◦C respectively. A band of ∼45 kDa, which was not present at the 0 hour time point
(T=0), can be seen at 2 hours (T=2) but it was difficult to determine whether or not a
significant increase in expression was achieved over the time course.
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Figure 4.4: 12 % SDS-PAGE showing a trial expression of MurMPn16(2) at 25 ◦C over 12
hours. a) Expression induced by addition of 0.5 mM IPTG b) Expression induced by addition
of 0.1 mM IPTG. 2 µg protein loaded per lane. T = time (hours), M = Marker (Amersham
protein ladder), S = soluble fraction, IS = insoluble fraction. Gels were visualised by silver
staining.
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Figure 4.5: 12 % SDS-PAGE showing a trial expression of MurMPn16(2) at 15 ◦C over 12
hours. a) Expression induced by addition of 0.5 mM IPTG b) Expression induced by addition
of 0.1 mM IPTG. 2 µg protein loaded per lane. T = time (hours), M = Marker (Amersham
protein ladder), S = soluble fraction, IS = insoluble fraction. Gels were visualised by silver
staining.
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Figure 4.6: 12 % SDS-PAGE showing a trial expression of MurMPn16(2) at 11 ◦C over 12
hours. a) Expression induced by addition of 0.5 mM IPTG b) Expression induced by addition
of 0.1 mM IPTG. 2 µg protein loaded per lane. T = time (hours), M = Marker (Amersham
protein ladder), S = soluble fraction, IS = insoluble fraction. Gels were visualised by silver
staining.
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Conditions used in Figure 4.4 a) (25 ◦C and 0.5 mM IPTG) were used in a large
scale expression for 4 hours. Samples at different time points were used to check
expression levels by western blot (Figure 4.7).
The western blots showed the presence of the 6-His tag confirming that this protein
was MurM. As previously reported, expression levels appeared to be higher in
MurMPn16(2) compared to MurM159(2). In addition, MurM is found in both the
soluble and insoluble fractions, with a slightly higher proportion found in the
insoluble sample.
Following an improved yield of MurM, MurM159(2) was purified in accordance with
Lloyd et al. (2008) methods. Figure 4.8 shows SDS-PAGE analysis of fractions eluting
from the final IMAC purification step. It is clear that whilst MurM159(2) is present at
the expected molecular weight of∼45 kDa a large number of contaminating proteins
at both higher and molecular weights can be observed. Strong contaminating bands
are present at a molecular weight of 30 kDa and 20 kDa.
Expression in LB generated a slight increase in yield of MurM and so was used
in a subsequent large scale expression, cells were incubated at 37 ◦C for 2.5 hours
and subsequently left for a further 12.5 hours at 25 ◦C. Cultures were disrupted
using a cell disrupter and MurMPn16(2) was purified by IMAC, reverse IMAC
(following TEV cleavage) and SEC (Figure 4.9). Whilst the band corresponding to
the molecular weight of MurMPn16(2) was dominant, there were significant bands
at both higher and lower molecular weights indicating contaminating proteins.
A further hydrophobic interaction chromatography (HIC) purification step was
applied to half the sample was shown to have no effect on the purity of this sample.
The protein concentration was determined and the total yield was 19.3 mg, however,
when tested in the mass spectrometry MurM activity assay this protein was found
to be inactive.
Due to the ongoing issues with with low levels of expression, and the inability to

















































































































































































Figure 4.8: 12 % SDS-PAGE showing final chromatography step (IMAC) during
purification of MurM159(2). Lane 1 - Amersham protein marker, Lane 2 - 20 µl column
load, Lane 3 - 20 µl flow through, Lane 4 - 20 µl column wash, Lane 5 to 10 = 20 µl of
elution fractions.
Figure 4.9: 12 % SDS-PAGE showing final chromatography step (SEC) during
purification of MurMPn16. Lane 1: Amersham Marker, Lane 2 - 10 µl Sample Load, Lane 3
to 10 - 5 µl of elution fractions
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it was deemed prudent to cease from using the constructs provided and to re-clone
the MurM genes.
4.3.2 Cloning, expression and purification of MurM from S. pneumoniae
(159) and S. pneumoniae (Pn16)
MurM from S. pneumoniae (159) and S. pneumoniae (Pn16) were to be codon optimised
and re-cloned, these new constructs would then undergo expression trials and
purification; protocols would be based on previously published methods but
optimised where necessary.
Gibson cloning of pET22b::MurMPn16 and pET22b::MurM159
The sequence of MurMPn16 and MurM159 (Lloyd et al., 2008) were codon optimised
and synthesised by IDT as g-blocks (referred to as gMurMPn16 and gMurM159 from
hereon in).
Successful amplification of gMurMPn16, gMurM159 and pET22b are shown in Figure
4.10.
Figure 4.10: 1 % agarose gel of gMurMPn16 and gMurM159 and linearised pET22b Lane 1:
1 kb DNA Ladder, Lane 2 - 50 µl MurMPn16, Lane 3 - 50 µl pET22b for MurMPn16, Lane 4 -
50 µl gMurM159, Lane 5 - 50 µl pET22b for gMurMPn16
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Following Gibson assembly and transformation into NEB-5α cells, 12 colonies were
picked for each of pET22::gMurMPn16 and pET22b::gMurM159. Following a colony
PCR, 3 of the 12 colonies generated a band on a 1 % (w/v) agarose gel at ∼1
kb (corresponding to MurM). Plasmid was purified from these colonies and the
presence of gMurMPn16 or gMurM159 into the pET22b vector was confirmed by
sequence analysis.
4.3.3 Expression of gMurM159 and gMurMPn16
Small scale expression trials to compare expression of gMurMPn16 and gMurM159 in
E. coli BL21*R, C41(DE3) and C43(DE3) in both LB and AI media were conducted.
Figure 4.11 shows a strong band corresponding to the expected molecular weight of
gMurM159 in the insoluble fraction of BL21*R cells grown in LB media. There was
little difference between 4 hour and overnight expression in LB, however expression
in AIM was significantly lower. Smaller bands, indicating lower expression levels
could also be observed in C41(DE3) cells but bands in C43(DE3) looked similar to
those in the negative control.
Figure 4.12 shows a large band corresponding to the expected molecular weight
of gMurMPn16 in the insoluble fraction of BL21*R cells grown in both LB and
AIM. Significantly lower levels of overexpression of gMurMPn16 were achieved
in C41(DE3) and C43(DE3) cells in both LB and AIM media.
Based on the trial expressions, the best conditions for over-expression of both
gMurMPn16 and gMurM159 were E. coli BL21*R, induced with IPTG for a 4 hour
expression at 25 ◦C. gMurM159 was transformed into BL21*R and expressed on a
large scale (6 L LB) at the optimised conditions. gMurM159 was purified as per
(Lloyd et al., 2008) and a strong band at ∼45 kDa, corresponding to the molecular
weight of gMurM159, can be observed throughout. A significant increase in purity
was achieved between SEC and IMAC (Figure 4.13). The final purity of gMurM159
was estimated to be >60 % using ImageJ (Version 1.51) and the total yield was 40
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Figure 4.11: 12 % SDS-PAGE analysis of expression trial of gMurM159 in BL21*R,
C41(DE3) and C43(DE3) in both LB media and AIM. 1a) BL21*R in LB media, 1b) BL21*R
in AIM, 2a) C41(DE3) in LB media, 2b) C41(DE3) in AIM, 3a) C43(DE3) in LB media, 3b)
C43(DE3) in AIM. M = Amersham protein ladder, S = Soluble fraction, IS = Insoluble fraction
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Figure 4.12: 12 % SDS-PAGE analysis of expression trial of gMurMPn16 in BL21*R,
C41(DE3) and C43(DE3) in both LB media and AIM. 1a) BL21*R in LB media, 1b) BL21*R
in AIM, 2a) C41(DE3) in LB media, 2b) C41(DE3) in AIM, 3a) C43(DE3) in LB media, 3b)
C43(DE3) in AIM. M = Amersham protein ladder, S = Soluble fraction, IS = Insoluble fraction
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mg.
Figure 4.13: 12 % SDS-PAGE showing gMurM159 protein purification summary Lane 1 -
Amersham protein marker, Lane 2 - 20 µg protein from crude extract, Lane 3 - 20 µg protein
from 10,000 xg pellet, Lane 4 - 20 µg protein from 100,000 xg supernatant, Lane 5 - 20 µg
protein from ammonium sulphate cut at 25 %, Lane 6 - 20 µg protein from ammonium
sulphate cut at 50 %, Lane 7 - 20 µg protein from SEC , Lane 8 - 20 µg protein from IMAC.
4.4 Characterising S. pneumoniae (159) and S. pneumoniae
(Pn16)
A discrepancy of two amino acids, at position 134 and 135, between the gMurMPn16
sequence and the pET21(b)::MurMPn16 sequence was identified. The original
pET21(b)::MurMPn16 clone, from which all previous work was conducted contained
LQ at position 134 and 135, however the published sequence for MurMPn16 (Lloyd
et al., 2008) contained the amino acids MR at the corresponding positions. Since the
gMurMPn16 and gMurM159 had been synthesised based on the published sequences,
it was deemed important to establish the correct sequence in order to ensure that
the work conducted in this chapter is in line with previous experiments. In order to
confirm that this was not a point mutation that had been accidentally introduced
into pET21(b)::MurMPn16, the original S. pneumoniae (159) and S. pneumoniae (Pn16)
strains were located and sequenced. Locating the original strains was problematic
and introduced new questions, as such it could not be confirmed that the strains that
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were obtained were the exact S. pneumoniae (159) and S. pneumoniae (Pn16) stocks
required. Since the MIC’s of these strains had previously been characterised and
documented, and due to the characteristically high resistance of S. pneumoniae (159)
to penicillin, the strains’ MICs were first determined in an attempt to confirm their
identity.
4.4.1 Susceptibility testing
Figure 4.14: Oxacillin Disk Susceptibility Testing. Resistance of a) S. pneumoniae (Pn16)
and b) S. pneumoniae (159) determined in line with the Clinical Laboratory Standards Institute
(CLSI).
Initial attempts at classifying S. pneumoniae (Pn16) and S. pneumoniae (159) using
oxacillin disk diffusion technique clearly highlighted the difference in susceptibility
between the two strains (Figure 4.14). S. pneumoniae (Pn16) showed a zone of
inhibition of∼20 mm, whilst S. pneumoniae (159) did not show any zone of inhibition.
Therefore according to EUCAST zone diameter breakpoints, S. pneumoniae (Pn16)
and S. pneumoniae (159) are classified as susceptible and resistant strains respectively.
Figure 4.15 shows that MICs were determined to be 0.03 ng.µl-1 and 32 ng.µl-1 for S.
pneumoniae (Pn16) and S. pneumoniae (159) respectively when using PenG E-strip
method. The MIC of the positive control (ATCC Staphylococcus aureus 29213) was
determined to be 0.25 ng.µl-1 .
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Figure 4.15: PenG E-strip MIC Determination. The MIC of a) S. pneumoniae (Pn16) and
b) S. pneumoniae (159) was determined using PenG E-strips c) ATCC Staphylococcus aureus
29213 was used as a positive control.
The E-strip and broth dilution techniques identified the MIC to be 32 ng.µl-1 and
16 ng.µl-1 respectively for S. pneumoniae (159) whilst for S. pneumoniae (Pn16) the
MIC was determined to be 0.03 ng.µl-1 for both methods. The MIC for the positive
control (ATCC Staphylococcus aureus 29213) was determined to be 0.25 ng.µl-1 and
0.2 ng.µl-1 by E-strip and Broth Dilution respectively. The control MICs are in the
middle of the EUCAST guidelines, as such the confidence in these results is high.
The MICs obtained are similar to those determined previously using E-Test and
agar dilution with benzylpenicillin (Barcus et al., 1995). Despite the small variations
in estimation of the MIC of S. pneumoniae (159) all MICs result in the classification
of S. pneumoniae (159) as resistant and S. pneumoniae (Pn16) as sensitive according
to EUCAST (EUCAST). The MICs obtained corroborated previous data and were
therefore taken to be the S. pneumoniae (159) and S. pneumoniae (Pn16) strains that
were required.
4.4.2 Next generation sequencing
Due to the discrepancy between the published sequence and previous constructs
sequences for it was decided that both S. pneumoniae (159) and S. pneumoniae (Pn16)
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strains MurM proteins should be re-sequenced, in order to establish the correct
sequence for future studies.
Next generation sequencing (NGS) of the S. pneumoniae (159) and S. pneumoniae
(Pn16) genomes was deemed preferable to PCR of the MurM gene alone. NGS would
generate a reliable MurM sequence as well as a full genome sequence for both strains,
which may be benificial for making comparisons between these two strains. The
NGS was conducted in collaboration with Catherine Rowland at Micropathology
Ltd. with the guidance and supervision of Dr Daniel Hand.
De-novo assembly provided the full genome sequence of S. pneumoniae (Pn16) and
S. pneumoniae (159). MurM from de novo assembled S. pneumoniae (159) and S.
pneumoniae (Pn16) was aligned with the previously published MurM sequences
(Figure 4.16). The NGS and de novo alignment confirms that the published sequence
of MurM159 is correct, however MurMPn16 is incorrect at amino acid position 134
and 135. The correct amino acid sequence at these positions is LQ, and is the
protein sequence that has been used in all previous experiments. The MurM
pET22b::gMurMPn16 therefore contains the two incorrect amino acids (MR) at these
positions.
4.4.3 Site directed mutagenesis of gMurMPn16
The importance of the amino acids as position 134 and 135 on the MurM structure
and activity is not known. Whilst the mutation at position 134 is conservative, at
position 135 the mutation is non-conservative (a charged residue is mutated to a
polar residue). Therefore it was decided that these positions of gMurMPn16 would
be mutated from MR to LQ to keep experiments in line with all previous work.
GATC sequencing of gMurMPn16 in the pET22(b)::gMurMPn16 construct confirmed
that the site directed mutagenesis had been successful. Position 134 and 135 in
the amino acid sequence had been mutated from MR to LQ. From hereon in the
mutated gMurMPn16 will be referred to as gMurMPn16(1). Given that both gMurM159
140
Figure 4.16: Sequence alignments of MurM from de novo assembled a) S. pneumoniae
(Pn16) and b) S. pneumoniae (159) with previously published MurM sequences. Residues
coloured according to % identity using Jalview (Version 2.10.5).
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(containing LQ at position 134 and 135) and gMurMPn16 (containing MR at position
134 and 135) both showed optimal over-expression in the same conditions, the trial
expression was not repeated with gMurMPn16(1) and the previously established
expression conditions were used.
4.5 Lipid II(Lys) and iGln Lipid II(Lys) synthesis
In order to identify the true substrate of MurM both Lipid II(Lys) and iGln Lipid
II(Lys) were synthesised. Synthesis and purification procedures for all Lipid II(Lys)
or iGln Lipid II(Lys) substrates are outlined in Section 2.5-2.7. Structures and details
such as molecular weights of intermediate and final compounds are shown in
Appendix 7.5.
4.5.1 Synthesis of UDP-MurNAc-5P and iGln UDP-MurNAc-5P
Expression and Purification of Mur ligases A-F
Mur ligases A-F were expressed and purified by IMAC, the final purity of the Mur
ligases was >75 % Figure 4.17.
Figure 4.17: 12 % SDS-PAGE showing final purity of Mur ligases A-F. Lane 1 - Amersham
protein marker, Lane 2 - 20 µg MurA, Lane 3 - 20 µg MurB, Lane 4 - 20 µgMurC, Lane 5 -
20 µg MurD, Lane 6 - 20 µg MurE, Lane 7 - 20 µg MurF.
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UDP-MurNAc-5P and iGln UDP-MurNAc-5P synthesis
Both UDP-MurNAc-5P and iGln UDP-MurNAc-5P were synthesised and purified to
a purity of >97 % (Figure 4.18). UDP-MurNAc-5P and iGln UDP-MurNAc-5P eluted
at a conductivity of 25.62 mS/cm and 13.51 mS/cm as expected. The successful
synthesis of UDP-MurNAc-5P and iGln UDP-MurNAc-5P were confirmed by
negative ion mass spectrometry (Figures 4.19 and 4.20).
4.5.2 Optimisation of iGln Lipid II(Lys) synthesis
Due to previously low yields of iGln Lipid II(Lys), optimisation of the synthesis and
purification of iGln Lipid II(Lys) was pursued.
Lipid II(Lys) synthesis was used as a starting point for iGln Lipid II(Lys)
synthesis. The effects of doubling the iGln UDP-MurNAc-5P concentration,
incubation overnight (compared to the standard 3 hour incubation) and
addition of moenomycin were investigated. Figure 4.21 indicates that doubling
UDP-MurNAc-5P concentration to 4 mM and incubation at 37 ◦C overnight,
increased iGln Lipid II(Lys) yields. However, incubation with moenomycin had no
effect, suggesting that there was no significant loss of iGln Lipid II(Lys) product
arising from TG activity of M. flavus PBPs. It was noted that Lanes 5 and 8 ran
differently to all other lanes, however the cause of this remains uncertain (Figure
4.21).
A time course of incubation over 13.5 hours was conducted to ensure that iGln Lipid
II(Lys) was harvested at the optimal time. Figure 4.22 shows that whilst there is a
steady increase in yield over the first 6 hours, there is no further increase after this
time point. However, since there was no decrease in product when the syntheses
were incubated for up to 13.5 hours, overnight syntheses were used for both Lipid
II(Lys) and iGln Lipid II(Lys) for convenience.
The iGln Lipid II(Lys) purification was based upon that of Lipid II(Lys), whereby
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Figure 4.18: Chromatograms from MonoQ Purity Test of a) UDP-MurNAc-5P and b) iGln
UDP-MurNAc-5P. Absorbance at 254 nm (Red) and absorbance at 280 nm (Blue) recorded.























































































































































































































































































Figure 4.21: TLC of iGln Lipid II(Lys) synthesis optimisation. Standard incubation (Lane
5) were modified with variations on length of incubation (3 hours vs overnight), addition of
moenomycin or 2 x concentration of iGln UDP-MurNAc-5P as indicated by the table.
Figure 4.22: TLC of iGln Lipid II(Lys) time course. Lane 1 and 11 - Undecaprenyl
pyrophosphate, Lane 2 and 12 - Lipid II(Lys) , Lanes 3 to 10 - hourly samples at T = 0
- 7 hours, Lanes 13 to 18 - hourly samples at T = 8 - 12 hours, Lane 18 - sample at T = 13.5
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the product was eluted in 2:3:1 chloroform:methanol:ammonium bicarbonate when
the stock concentration of ammonium bicarbonate was between 250 mM and 1 M.
Since iGln Lipid II(Lys) is less negatively charged than Lipid II(Lys) it was found to
bind the DEAE sephacryl more weakly, resulting in elution at lower concentrations
of ammonium bicarbonate (i.e. <100 mM). Since the undecaprenyl-pyrophosphate
also elutes between 50 mM and 100 mM, additional washes with small increments of
ammonium bicarbonate were used to improved the purity of iGln Lipid II(Lys). The
additional washes resulted in the separation of the undeccaprenyl-pyrophosphate
and the iGln Lipid II(Lys) with them eluting at 50 - 75 mM and 80 - 100 mM
respectively. TLC of final Lipid II(Lys) and iGln Lipid II(Lys) elutions are shown in
Figure 4.23. The final yield of Lipid II(Lys) and iGln Lipid II(Lys) were 4 mg and 0.1
mg respectively.
Negative ion electrospray mass spectrometry was used to confirm the presence of
Lipid II(Lys) (Figure 4.24) and iGln Lipid II(Lys) (Figure 4.25) following synthesis
and purification. Some additional high intensity peaks which do not correspond
to the m/z of Lipid II or iGln Lipid II are present and may be due to ammonium
or sodium ion adducts, or solvent contamination. However it is important to note
that the intensity of the peak does not necessarily reflect the abundance of that
compound in the sample. Furthermore, this data is consistent with Lloyd et al. (2008)
which confirmed the presence of Lipid II by fragmentation.
4.6 Preparation of pure in vitro transcribed tRNA
isoacceptors and S. pneumoniae (159) crude tRNA
Sanderson and Uhlenbeck (2007) demonstrated that the presence of a G in either
of the 51-63 bp position of tRNA conferred stability with EF-Tu. tRNASer2 has a
G at position 51 whilst tRNASer1 and tRNASer3 do not have a G at this position.
In S. pneumoniae D39, the codons which base pair with the anticodon of tRNASer1,
tRNASer2 and tRNASer3 appear in 0.5, 0.81 and 1.45 % of the total genome. The
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Figure 4.23: TLC of Lipid II(Lys) and iGln-Lipid II(Lys) purifications. a) Standard
Purification of Lipid II(Lys) b) Optimised purification of iGln Lipid II(Lys).
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Figure 4.24: Negative ion ES-MS of Lipid II(Lys) a) Full spectra with m/z range 0 -2000, b)
Enlarged spectra showing the series corresponding to(m-1)/1 (1874.05) c) Enlarged spectra
showing the series corresponding to (m-2)/2 (936.52)
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Figure 4.25: Negative ion ES-MS of iGln Lipid II(Lys) a) Full spectra with m/z range 0
-2000, b) Enlarged spectra showing the series corresponding to (m-1)/1 (1873.07) c) Enlarged
spectra showing the series corresponding to (m-2)/2 (936.03)
151
availability of different tRNA isoacceptors for non-translational functions would
depend upon a number of factors including tRNA isoacceptor expression levels,
affinity for tRNA by aaRS, stability of interaction with EF-Tu and also codon usage
within the organism (and therefore requirement in protein synthesis). In the absence
of H2O2 MurM continues to synthesise branched PG, and so likely obtains cognately
charged tRNAs which are surplus to protein synthesis. It is therefore possible that
MurM may demonstrate bias towards specific isoacceptors. As such characterising
kinetics of MurM with different isoacceptors would be useful for experiments going
forward.
4.6.1 Alignment of tRNA isoacceptors
Isoacceptors of tRNAAla, tRNASer and tRNAThr from S. pneumoniae R6 were aligned
using GtRNAdb (Figure 4.26) (Chan and Lowe, 2009). This indicated that whilst
tRNAAla has only one isoacceptor, tRNASer has three isoacceptors and tRNAThr
has two isoacceptors. The tRNA isoacceptors present in the genome are able to
supply all codons with amino acid, even in the absence of an exact codon-anticodon
match, due to the presence of the wobble position. Further analysis of the
tRNASer(GGA), tRNASer(GCU) and tRNASer(UGA) isoacceptors identified that base
pairs at positions 51:63 are U-C, C-U and G-C respectively, whilst tRNAThr(GGT)
and tRNASer(TGT) have base pairs C-G and G-T respectively. This suggests that
tRNASer(GGA) and tRNASer(GCU) are less EF-Tu stable than tRNASer(UGA) and so
may be good candidates as high affinity MurM substrates.
tRNASer(GGA), tRNASer(GCU), tRNASer(UGA), tRNAThr(GGU) and tRNAThr(UGU)
from hereon in will be referred to as tRNASer1, tRNASer2, tRNASer3, tRNAThr1 and
tRNAThr2 respectively.
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Figure 4.26: tRNA gene alignments showing isoacceptors present in the S. pneumoniae
(R6) genome. a) tRNAAla, b) tRNASer and c) tRNAThr. Alignments conducted using
GtRNAdb.
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4.6.2 Purification of tRNA
S. pneumoniae (159) was grown for extraction of crude tRNA. Initially growth was
conducted in the presence of whole blood and the cell yield was high. However, the
whole blood would contain tRNA, which would cross-contaminate the S. pneumoniae
(159) tRNA and so instead S. pneumoniae (159) was grown in the presence of purified
bovine catalase (to a lower cell density). In vitro transcribed tRNA isoacceptors were
purified as detailed in Section 2.8.
Both crude tRNA preparation and in vitro transcribed tRNAs can be seen in Figure
4.27. S. pneumoniae crude tRNA possesses a similar electrophoretic profile to E. coli
crude tRNA, with a high density of bands corresponding to ∼75-100 bp. All bands
of purified tRNA appear to run higher than the DNA marker of a corresponding
size, this may be due to the tertiary structure present in tRNA. The pure in vitro
transcribed tRNAs form single strong bands with few contaminants, however the
isoacceptors did not follow the expected size based pattern on the gel (tRNAAla4
is 76 bp, tRNASer1 and tRNASer2 are 91 bp, tRNASer3 is 93 bp and tRNAThr1 and
tRNAThr2 are 76 bp). In addition, the band of tRNAThr2 shows smearing rather
than a single band, smearing was observed in all in vitro transcription reactions for
tRNAThr2 and was not effected by heating of tRNA samples prior to electrophoresis.
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Figure 4.27: Purified tRNA summary gel. Lane 1 - NEB Low Molecular Weight DNA
ladder, Lane 2 - 10 µg E. coli crude tRNA, Lane 3 - 10 µg S. pneumoniae (159) crude tRNA,
Lane 4 - 5 µg pure tRNAAla, Lane 5 - 5 µg pure tRNASer1, Lane 6 - 5 µg pure tRNASer2,
Lane 7 - 5 µg pure tRNASer3, Lane 8 - 5 µg pure tRNAThr1, Lane 9 - 5 µg pure tRNAThr2. 7
M urea 12 % polyacrylamide gel.
4.7 Mass spectrometry MurM activity assays
4.7.1 Mass spectrometry of MurM assays
Mass spectrometry was used previously to demonstrate the addition of L-Ala or
L-Ser to the third position lysine of the Lipid II(Lys) by MurM159 (Lloyd et al., 2008).
These experiments were repeated with Lipid II(Lys) in order to confirm the activity
of gMurM159, and branching of the Lipid II(Lys) with both L-Ala and L-Ser. Products
from reactions were identified by mass spectrometry.
Table 4.1 shows a summary of reactions conducted, the doubly charged expected
mass (if the reaction was positive) and the observed mass from each sample.
The activity of gMurM159 was confirmed by identification of an ion, with an m/z of
972.03 which corresponds to doubly charged species of Lipid II(Lys)-Ala in reaction
1. Reaction 2 is the negative control, the ion was absent from this spectra, instead
an ion with an m/z of 936.52 which corresponds to a doubly charged unmodified
Lipid II(Lys) was present (Figure 4.28). Reaction 3 indicated that in contrast to
findings published by Lloyd et al. (2008) gMurM159 cannot append L-Ser, charged by
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SerRS onto tRNASer, onto the Lipid II(Lys). Reactions 4-8 investigated the ability of
gMurM159 to utilise mis-acylated tRNAs (seryl-tRNAAla or seryl-tRNAThr). Despite
previous observations these results suggest that under these conditions gMurM159
is unable to append L-Ser to Lipid II(Lys) from mis-aminoacylated tRNAs. The
activity of SerRS was confirmed using a radiolabelled assay (Section 4.8) which
Reaction
No.




1 AlaRS, L-Ala, Lipid
II(Lys), gMurM159
972.042 972.029
2 AlaRS, L-Ala, Lipid II
(Lys)
936.522 936.524
3 SerRS, L-Ser, Lipid
II(Lys), gMurM159
980.037 936.52

















Table 4.1: Summary of results from gMurM159 activity assays. Negative ion mass
spectrometry of Lipid II purified from gMurM159 activity assays. Reaction components,
predicted and observed mass of doubly charged species are presented. The expected (m-2)/2
values for Lipid II(Lys), Lipid II(Lys)-Ala and Lipid II(Lys)-Ser were 936.52, 972.04 and
980.04 respectively.
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eliminated SerRS activity as a possible issue in these assays. The ability of MurM
to utilise seryl-tRNASer and mis-acylated tRNAs can also be investigated using the
radiolabelled MurM activity assay.
4.7.2 Tandem mass spectrometry characterising the Lipid II(Lys) product
Collision Induced Dissociation (CID) combined with positive ion tandem mass
spectrometry (MS/MS) of the singly charged molecular ion of Lipid II(Lys)-Ala
(1947.1/1), was used to confirm the exact location of the apparent addition of L-Ala
to Lipid II(Lys) by gMurM159 in reaction 1 (Table 4.1).
Figure 4.29 shows the annotated CID positive ion MS/MS spectra at Collision
Energy of 75 kV, fragment ions were singly charged. Table 4.3 shows that peak 28
has a mass of an additional 71.0004 when compared to peak 27. The additional
mass of 71.0004 corresponds to the exact mass expected by the condensation of
alanine with the ε-amino group of the third position stem peptide lysine. The
mass of peak 27 in the negative control (-gMurM159) corresponds to the predicted
mass of GlcNAcMurNAc-AEKAA. This result indicates that the addition of a single
L-Ala occurred in the test sample (+gMurM159) but not in the negative control
(-gMurM159).
Peaks 6 and 7 have observed m/z values corresponding to KAAA and EKAA or
AEKA respectively and can be observed in the +gMurM159 sample but are absent
from the -gMurM159 spectra, instead peaks 4 and 5 were observed at m/z values
corresponding to the linear fragments (without an additional L-Ala appended to
the third position lysine). The masses of peaks 6 and 7 are consistent with the




































































































































































































































































































































































































































1 MurNAc (minus H2O) 240.0872
2 EK 258.1454
3 KAA 289.1876
4 EKA or AEK or EKA 329.1825
5 AKAA 360.2247
6 EKAA or AEKA 400.2196
7 Lactyl AEK 401.2036
8 EKAA 418.2302
9 Lactyl AEKA (minus H2O) or Lactyl AEKA
(minus H2O)
454.2302
10 Lactyl AEKA or Lactyl AEKA 472.2407
11 EKAAA or AEKAA 489.2673
12 Lactyl AEKAA or Lactyl AEKAA (minus H2O) 543.2778
13 Lactyl AEKAA 561.2884
14 Lactyl AEKAAA (minus H2O) 614.31497
15 Lactyl AEKAAA 632.3255
16 MurNAc AEKA (minus H2O) 639.2990
17 MurNAc AEKA 657.3096
18 MurNAc AEKAA (minus H2O) 710.3361
19 MurNAc AEKAA (minus H2O) or AEKAA 728.3467
20 MurNAc AEKAA 746.3572
21 MurNAc AEKAAA (minus H2O) 799.3838
22 MurNAc AEKAAA 817.3944
23 GlcNAcMurNAc AEKA (minus H2O) 842.3784
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24 GlcNAcMurNAc AEKA or GlcNAcMurNAc
AEKA
860.3889
25 GlcNAcMurNAc AEKAA or GlcNAcMurNAc
AEKAA (minus H2O)
931.4260
26 GlcNAcMurNAc AEKAA 949.4366
27 GlcNAcMurNAc AEKAAA 1020.4737
Table 4.3: Fragments assigned to peaks in Figure 4.29. Peak number, the assigned possible
fragments and the associated expected m/z. All amino acids are shown sequentially, those
not in bold are part of the main pentapeptide chain, whilst any amino acid shown in bold
font, is appended to the ε-amino group of the third position lysine of the 5P stem. Note:
single letter code for amino acids used in this table.
4.8 Preparation for radiolabelled MurM activity assays
Radioactive assays which follow the transfer of [3H]aa from [3H]aa-tRNAaa to Lipid
II(Lys) have previously been used to monitor the activity of MurM (Lloyd et al.,
2008; Shepherd, 2011).
Radioactive MurM activity assays with both Lipid II(Lys) and iGln Lipid
II(Lys) as well as different tRNA isoacceptors will provide information on the
substrate specificity of MurM. MurM kinetics with correctly acylated tRNA
and mis-aminoacylated tRNA could also be investigated using this assay.
Answering these questions will help elucidate any link between MurM and
protein synthesis, especially under oxidative stress where H2O2 levels are high
and mis-aminoacylation of tRNA increases.
Initially the ability of AlaRS, SerRS and ThrRS to aminoacylate cognate S. pneumoniae
tRNAs, creating substrates for MurM was demonstrated.
The transfer of free [3H]aa to tRNA by aaRS was followed over 90 mins by
precipitation of tRNA in 10 % TCA (w/v) and scintillation counting was used
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to measure [3H]aa-tRNAaa. A negative control (-tRNA), at corresponding time
points, and an absolute background (scintillant only) reading were deducted from
the measured counts per minute (cpm) for every sample. Figure 4.30 shows that
AlaRS, SerRS and ThrRS are capable of charging S. pneumoniae (159) crude tRNA
with [3H]aa. The extent of acylation varies between AlaRS, SerRS and ThrRS and
likely reflects the total amount of tRNAAla, tRNASer and tRNAThr in the crude tRNA.
In all cases the the vast majority of aminoacylation has occurred in the first minute
with some gradual increase occurring over the remaining 90 minute period.
Figure 4.30: Aminoacylation of S. pneumoniae (159) crude tRNA by AlaRS, SerRS and
ThrRS in the presence of cognate amino acids a) charging of AlaRS in the presence
of L-alanine b) charging of SerRS in the presence of L-serine c) charging of ThrRS in
the presence of L-threonine. The specific activity of [3H]L-alanine, [3H]L-serine and
[3H]L-threonine were calculated to be 128.5 cpm/pmol, 46.8 cpm/pmol and 69.7 cpm/pmol
respectively.
Aminoacylation of the in vitro transcribed tRNAs with their cognate amino acids
were investigated (Figure 4.31). From this, it is clear that the level of aminoacylation
was highest for tRNASer, where all three tRNASer isoacceptors acylated well.
tRNAAla did undergo aminoacylation but the final yield was a lot lower, and for
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tRNAThr isoacceptors very little aminoacylation occurred. The reason for low levels
of aminoacylation with tRNAAla and tRNAThr isoacceptors may indicate an issue
with the in vitro transcribed tRNA, or may more be reflective of the activity of AlaRS
and ThrRS. If the aaRS activity is low, then spontaneous deacylation may be limiting.
It would therefore be useful to repeat this experiment with higher concentrations of
AlaRS and ThrRS.
Since S. pneumoniae (159) tRNA is limited and E. coli tRNA is readily available from
Sigma Aldrich, both preparative charging and MurM assays were conducted with
E. coli crude tRNA as a preliminary test. These assays were to ensure that the assay
set up was appropriate, to gain a better idea of aminoacylated tRNA yields, and to
establish appropriate working concentrations/ cpm readings for MurM assays.
Preparative charging of 0.38 mg.mL-1 E. coli tRNA was conducted with AlaRS and
[3H]L-alanine, the sample was incubated at 37 ◦C for 1 hour. The final yield of
[3H]alanyl-tRNAAla was 50 µl of 10 µM. The losses incurred during purification of
the [3H]alanyl-tRNAAla were ∼25 %.
An end-point radioactive MurM assay was used to test; the functionality of the
assay, the [3H]alanyl-tRNAAla from the previous preparative charging experiment,
and to compare the ability of MurM to use Lipid II(Lys) iGln Lipid II(Lys) as
substrates. Table ?? shows the cpm for each test reaction and all the negative
controls. The cpm were well within an easily detectable range and were considerably
higher than readings from all the negative controls. This demonstrated that tRNA
from preparative charging provided a suitable substrate, that gMurM159 was active
and that the radioactive MurM assay worked as expected. In addition this assay
demonstrated that gMurM159 was capable of utilising both Lipid II(Lys) and iGln
Lipid II(Lys) substrates. However, it does not provide any information regarding the
rates of each reaction; kinetic experiments would be required in order to determine





































































































































































































































































































































Complete reaction 2213 1796
-gMurM159 206 162
+RNase 259 197
-Lipid II(Lys) 176 127
Table 4.4: Summary of end-point MurM radioactivity assay results. gMurM159 and three
negative controls; -gMurM159, +RNase and -Lipid II(Lys) were incubated in a radioactivity
assay at 37 ◦C for 1 hour. *Raw cpm data has been normalised to the second data set based
on total radioactivity.
4.9 Discussion and conclusions
This chapter demonstrates significant progress in preparation for a thorough
investigation into substrate specificity of gMurM159. Initially, since S. pneumoniae
(159) has a higher proportion of L-alanine in the dipeptide cross bridge and S.
pneumoniae (Pn16) has a higher proportion of L-serine, it was intended that both
gMurM159 and gMurMPn16 would be investigated and compared. However, due
to time constraints and the delays due to difficulties outlined in this chapter, only
gMurM159 was expressed, purified and tested.
Throughout this chapter, challenges in expression of gMurM159 and gMurMPn16
have been overcome. The sequences of gMurM159 and gMurMPn16 have been
confirmed and full genome sequencing of S. pneumoniae (159) and S. pneumoniae
(Pn16) has been conducted. Both MurM substrates (Lipid II(Lys) and tRNA) and
variants thereof have been synthesised and purified for downstream experiments.
Preliminary experiments have confirmed gMurM159 activity and ability of aaRSs to
generate aminoacylated tRNA.
The synthesis and purification of iGln Lipid II(Lys) was optimised, however the yield
still remained low (∼40-fold lower than Lipid II(Lys) ). Radioactive MurM end-point
assays indicated that both Lipid II(Lys) and iGln Lipid II(Lys) are substrates for
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MurM, however, further kinetic analysis is required.
In vitro transcription and purification of isoacceptors of tRNAAla, tRNASer and
tRNAThr was conducted. tRNAAla is 76 bp, tRNASer1 tRNASer2 are 91 bp, tRNASer3
is 93 bp and tRNAThr1 tRNAThr2 are 76 bp, however the migration on 7 M urea 12
%-PAGE did not reflect these values. The isoacceptors template DNA did follow
the correct size pattern on a 3 % agarose gel, indicating that the apparent incorrect
masses may be due to residual tertiary structure of different isoacceptors. However,
it is also important to consider that these differences in expected size may indicate
premature termination of tRNA during in vitro transcription which would cause
issues in downstream experiments due to the loss of the 3’ CCA, which is required
for charging of tRNA by the aaRSs. As such it would be useful to confirm the identity
of the tRNA products by mass spectrometry (Huang et al., 2010). Heterogeneity of
length or tertiary structure may also explain the smearing of tRNAThr2 in a 7 M urea
12 %-PAGE.
In contrast to Lloyd et al. (2008) gMurM159 was only able to append L-Ala and not
L-Ser onto Lipid II(Lys). One such explanation for this observation may be the
experimental design and the kinetics of the enzymes involved. The total amount
of tRNA used in these reactions was ∼7-fold lower than was used by Lloyd et al.
(2008). Since in S. pneumoniae the total isoacceptors for tRNAAla are ∼2.5-fold more
abundant than tRNASer isoacceptors (Lloyd et al., 2008), even in the presence of a
7-fold reduction in total tRNA, AlaRS may have been able to turnover tRNAAla at
a rate suitable to provide substrate for gMurM159. In contrast, for SerRS, the low
concentration of tRNASer may have resulted in a rate of aminoacylation slower than
that of deacylation. If the rate of deacylation was too rapid for gMurM159 to complete
with there would have been no seryl-tRNASer substrate available for gMurM159.
Therefore, reactions with SerRS should be repeated with a higher concentration
of total tRNA. Similarly, all reactions exploring mis-aminoacylation (Figure 4.1
reactions 6-10) should be repeated at a higher concentration of aaRS, tRNA and
L-Ser, since the rate of mis-aminoacylation would be significantly slower than
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cognate aminoacylation. The MurM assays therefore do not conclusively show that
gMurM159 is unable to utilise tRNASer as a substrate, but instead indicates that the
experiments need to be repeated with more appropriate substrate concentrations
and considerations to the kinetic parameters of each reaction. The radiolabelled
MurM activity assays can be used to investigate the ability of MurM to utilise
purified charged tRNA substrates directly, without the coupling of aaRS and MurM
activity.
4.10 Future experiments
The future work for this chapter consists of large scale expression and purification
of gMurMPn16, confirmation of activity and use in final kinetic experiments.
The identity of in vitro transcribed tRNAs may be confirmed by mass spectrometry
as per Huang et al. (2010).
Mass spectrometric MurM activity assays will be optimised in order to demonstrate
the addition of L-serine to Lipid II(Lys) by MurM from tRNAs charged with both
cognate and non-cognate amino acids. In addition these assays will be used to
demonstrate the addition of L-Ala and L-Ser to iGln Lipid II(Lys) by MurM from
tRNAs charged with both cognate and non-cognate amino acids.
A number of sequential experiments will be required in order to investigate the
hypothesis that MurM preferentially utilises mis-aminoacylated tRNAs in order
to maintain the fidelity of protein synthesis. S. pneumoniae crude tRNA and in
vitro transcribed tRNAs will be aminoacylated or mis-aminoacylated using the
appropriate synthetase and conditions. These acylated tRNAs will then provide
substrate for MurM assays. The kinetic parameters of MurM with Lipid II(Lys) and
iGln Lipid II(Lys) will be investigated. Whilst maintaining a constant concentration
of Lipid II(Lys) the effect of varying crude tRNA concentration will be investigated.
These experiments will aim to establish the substrate specificity of MurM for crude
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extract containing alanyl-tRNAAla, seryl-tRNASer, seryl-tRNAAla and seryl-tRNAThr.
Subsequently different isoacceptors of tRNASer and tRNAThr as substrates for
gMurM159 and gMurMPn16 will be investigated.
In addition, since other synthetases such as ProRS and LysRS are known to
mis-aminoacylate tRNA with L-Ala and L-Ser (Beuning and Musier-Forsyth, 2000;
Shepherd and Ibba, 2014), it would be prudent to investigate whether MurM also





The work in the chapter was conducted in collaboration with Dr. Charo I. del Genio
(School of Life Sciences, University of Warwick) for homology modeling, Prof. Rudo
Roemer (Department of Physics, University of Warwick) for flexibility simulations
and Prof. Syma Khalid (School of Chemistry, University of Southampton) for
protein-membrane interaction simulations.
5.1 Introduction
Insight from protein structure is commonly used to assist structure-based drug
design, elucidation of enzyme mechanisms and specificity of protein-ligand
interactions. Additionally, structural knowledge can aid experimental design
and focus future research, for example providing target residues for rational site
directed mutagenesis (Smyth and Martin, 2000). The main experimental techniques
to determine the structure of proteins, and protein:protein complexes, both in
the presence and absence of ligands are X-ray crystallography, Nuclear Magnetic
Resonance (NMR) and Electron Microscopy (EM).
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X-ray crystallography is a widely used, powerful technique which can be used to
help answer complex biological questions. Potential dynamic movements within
the protein may be inferred or sometimes modelled in the presence of multiple
different structures of the same protein (Acharya and Lloyd, 2005). Furthermore,
crystal structures represent time and space averages of all molecules present within
the crystal lattice, therefore, conformational variations between these can provide
information about the flexibility of a region, which may or may not be important
for function (Acharya and Lloyd, 2005). X-ray crystallography does however have
its own limitations since crystallography only provides a snap-shot of a protein
in a particular conformation; proteins are dynamic structures and the presence of
substrates, co-factors or other proteins may dramatically alter their conformation.
Furthermore, some structures occur as a direct consequence of the protein being in
a crystalline state, and so it is important to consider the biological relevance of any
structure (Acharya and Lloyd, 2005). Collection of X-ray crystallography data at
ambient temperature causes radiation damage such that complete diffraction data
sets must be collected from multiple crystals, as such it is common to cryogenically
freeze crystals and collect data at liquid nitrogen temperature. However, it has been
shown that cryogenic freezing can remodel conformational distributions of more
than 35 % of side chains, eliminate packing defects necessary for functional motion
and hinder identification of sites with the potential to allosterically modulate protein
function. Therefore, cryogenically frozen and room-temperature data collection
may be used in tandem to reveal motions crucial for catalysis, ligand binding and
allosteric regulation which would otherwise be lost (Fraser et al., 2011; Fischer et al.,
2015). Importantly, however, data collection at room temperature results in radiation
damage such that complete diffraction data sets must be obtained from multiple
crystals.
With the advancement of DNA sequencing techniques it is evident that it will not
be possible to obtain structural information on all proteins of interest using the
current experimental methods (Schwede, 2013). However, homology modelling, a
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computational technique also known as comparative modelling can ”be applied
with reasonable accuracy to ten times more protein sequences than the number
of experimentally determined protein structures” (Sanchez and Šali, 1997). In the
absence of experimental 3D protein structures, homology models can direct and
focus future experiments and assist analysis of existing experimental data.
Homology modelling consists of four steps: identification of related proteins with
experimentally determined structures; sequence alignment of these and the target
to identify a ’template’ structure; build a model of the target protein based upon
the structure; and sequence alignment of the template and finally evaluation of the
model (Sanchez and Šali, 1997). A huge number of different software packages are
available for the homology modelling of proteins, including The SWISS-MODEL
workspace (Arnold et al., 2006), SegMod (Levitt, 1992) and MODELLER (Eswar et al.,
2006). These examples represent three different methods used to build the model
of the target protein; rigid-body assembly, modelling by segment matching and
modelling by satisfaction of spatial restraints respectively (Sanchez and Šali, 1997).
As a result of slightly different methods, the quality and accuracy of the models can
vary significantly between different software/servers, however Schwede et al. (2009)
acknowledge that even lower resolution models are useful for focused experimental
design (e.g site directed mutagenesis) and for supporting experimental structure
determination. Additionally the time taken for the result to be returned can vary
between different software/servers, ranging from hours to weeks. Ultimately,
however, the higher the sequence identity between template and target, the better
the quality of the model.
Determining protein flexibility as well as identifying interactions with protein
binding partners, ligands or membranes, can be important in understanding
protein function and elucidating mechanisms of action. However, proteins have a
high number of degrees or freedom, which can be challenging for computational
modelling methods. Molecular Dynamics (MD) is a simulation method for looking
at the physical movement of atoms of molecules within a structure. This type of
171
Figure 5.1: Application ranges for molecular modeling at different resolutions:
quantum, all-atom, coarse-grained, and mesoscale. The plot shows approximate ranges of
time scales and system sizes (lengths). The presented application ranges can be expanded by
merging tools of different resolution into multiscale schemes. Figure sourced from Kmiecik
et al. (2016).
atomistic representation results in most accurate and reliable results, however
it can be time-consuming and computer intensive. Due to the limitations of
available computing power, atomistic simulations can only be conducted for
biological processes occurring in very short (picosecond to nanosecond) time-frames.
Coarse-grained modelling is a method which has gained popularity and provides a
means of circumventing these issues (Hospital et al., 2015). The overall resolution
(granularity) of the model is reduced such that instead of modelling individual
atoms, atoms are grouped together into pseudo-atoms which can then be modelled
as an overall approximation for that group. This lower resolution model with
reduced degrees of freedom permits an increase in simulation times or system size
(Figure 5.1) (Kmiecik et al., 2016).
A number of different programs that simulate protein flexibility and movement,
such as CABS-flex (Jamroz et al., 2013) and pdb2movie (Jimenez-Roldan et al., 2012;
Römer et al., 2016) are also available.
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Proteins rarely act in isolation (Xenarios et al., 2002), often locating and binding
(docking) to specific binding partners in a very precise fashion, despite being in a
dense and crowded environment (Vakser, 2014). Protein dimerisation and formation
of higher order oligomers is very common and facilitates many biological processes
such as enzyme activation or inhibition, allosteric regulation, substrate induced
cooperativity of ligand binding, cell signalling and transport across cell membranes
(Marianayagam et al., 2004). Cytoplasmic proteins, such as aaRSs, are active in homo-
and hetero- dimeric or multimeric forms (Naganuma et al., 2009; Logan et al., 1995;
Mosyak et al., 1995), other proteins such as tryptophan synthetase form heterodimers
with intramolecular tunnels for substrate channelling (Hyde et al., 1988; Wheeldon
et al., 2016). In addition integral membrane proteins FtsL, FtsB and FtsQ which are
involved in cell division have been shown to form complexes in the membrane
(Buddelmeijer and Beckwith, 2004; Glas et al., 2015). Proteins also commonly form
interactions with other macromolecular structures. In the cytoplasm, elongation or
initiations factors, aaRSs and DNA-binding proteins, interact with ribosomal RNA,
tRNA and DNA respectively (Ramakrishnan, 2002; Schmeing et al., 2009; Wang et al.,
2015; Luscombe et al., 2000) whilst many amphitrophic proteins form reversible
interactions with the membrane (Johnson and Cornell, 1999).
Whilst, X-ray crystallography is often considered the most advanced method for
obtaining high resolution structural information of proteins, it is not always possible
to generate high-quality crystals (Acharya and Lloyd, 2005). Other techniques
such as Nuclear Magnetic Resonance (NMR) spectroscopy and Cryo-Electron
Microscopy (EM) are increasingly being used in the field of structural biology to
overcome or circumvent some of the challenges faced by X-ray crystallography,
however, all techniques have their limitations. In the absence of successful
structure determination using experimental techniques, structural modelling and
computational simulations can be useful (Krieger et al., 2003). As such a number
of programs and web-based servers have been developed to facilitate predictions
of protein structure using methods such as homology modelling, threading and ab
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initio structure prediction. This moves beyond simple sequence based prediction of
secondary protein structural characteristics including trans-membrane helices and
signal peptides.
5.2 Aims
The aim of this chapter was to use existing modelling techniques and the newly
solved structure of a homologue protein to generate an improved model of
MurM and identify potential Lipid binding sites. Simulations investigating
protein:protein and protein:membrane interactions were also conducted and the
impact of membrane phospholipids (cardiolipin (CL) and phosphatidylglycerol) on
MurM were characterised, in order to gain a better understanding of the mechanism
of action of this enzyme. The knowledge from these studies could be used to
generate hypotheses, direct future studies and assist experimental design.
5.3 An improved homology model of MurM159
5.3.1 Identification of an improved template for homology modelling
Crystal structures of two functional homologues of MurM have been solved
previously; S. aureus FemA (Benson et al., 2002) and W. viridescens FemX (Fonvielle
et al., 2013; Biarrotte-Sorin et al., 2004). In addition, the structure of S. aureus FemX,
which not only utilises the same Lipid II(Lys) substrate but also appends the first
amino acid of the cross-bridge, has been solved recently in our lab (unpublished).
Pairwise sequence alignment of S. aureus FemA, S. aureus FemX and W. viridescens
FemX with MurM159 indicates that the sequence identity of these homologues to
MurM is low, however, S. aureus FemX showed the highest sequence identity to






S. aureus FemA 21.6 40.3
S. aureus FemX 27.3 44.3
W. viridescens FemX 23.1 37.5
Table 5.1: Sequence identity and sequence similarity between S. pneumoniae (159)
MurM and three homologues. S. pneumoniae MurM sequence was aligned with three
homologues S. aureus FemA, S. aureus FemX and W. viridescens FemX using EMBOSS Needle
(Madeira et al., 2019).
The previous homology model of MurM (Fiser et al., 2003) used S. aureus FemA,
which had a sequence identity of 21.6 %. Whilst S. aureus FemA, similarly to S.
pneumoniae MurM, is an aminoacyl transferase, it is functionally different in three
key ways (Schneider et al.). Firstly, S. aureus FemA is responsible for the invariable
addition of glycine to Lipid II(Lys) whereas MurM is responsible for addition of
either L-Ala or L-Ser (Lloyd et al., 2008). Secondly, FemA is responsible for the
addition of two amino acids in a pentapeptide cross-bridge whilst MurM is only
responsible for the addition of only one amino acid in a dipeptide cross-bridge.
Finally, FemA catalyses the addition of amino acids at positions 2 and 3 of the
pentapeptide cross-bridge, therefore accepting Lipid II(Lys) with a single amino
acid branch as its substrate, whilst in contrast MurM can only append an amino
acid at position 1 of the dipeptide cross-bridge to its substrate Lipid II(Lys) (Lloyd
et al., 2008).
In contrast to FemA, S. aureus FemX, has a higher sequence identity at 27.3 %, and
is a closer functional homologue to MurM159. Whilst S. aureus FemX does utilise a
different tRNA-donor (glycyl-tRNAGly), it is similarly responsible for the addition
of only one amino acid at the first position of the cross-bridge. Lipid II(Lys) is
therefore the substrate for both S. aureus FemX and S. pneumoniae MurM159. The
position at which an aminoacyl transferase inserts amino acids is clearly highly
specific, since FemA and FemB are not able to substitute each others activity in
vivo despite having 37 % sequence homology and both being responsible for the
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addition of two glycines to the pentapeptide cross-bridge, at positions 2 and 3, and
4 and 5 respectively (Schneider et al.; Ehlert et al., 1997). It is likely that differences
in the active sites, generate specificity for the Lipid II(Lys) substrate resulting in the
specific functional characteristics of these aminoacyl-transferases.
S. aureus FemX and S. pneumoniae MurM have a sequence identity which falls into
the ’safe homology modelling zone’, which indicates the likelihood of two proteins
sharing similar structures based upon their percentage sequence identity (Krieger
et al., 2003). In addition FemX has a high functional homology to MurM, therefore
it was decided that S. aureus FemX would be used as a template for homology
modelling of MurM.
5.3.2 MurM159 homology model
Initial MurM modelling was conducted in collaboration with Dr. Charo I. del Genio
(School of Life Sciences, University of Warwick). Figure 5.2 shows the top scoring
model of MurM159, generated using S. aureus FemX as a template. The predicted
structure of MurM corroborates previous structural predictions (Fiser et al., 2003)
in that it consists of a globular domain that comprises two twisted β-sheets cores
surrounded by alpha helices, and a coiled-coil helical domain.
Figure 5.3 (a) and (b) highlight some key structural differences between the existing
MurM model (Fiser et al., 2003) and the new MurM model. There is a loss of
secondary structure at the N-terminus and increase in secondary structure at the
C-terminus in the new model when compared to Fiser’s existing model. Three
previously unstructured regions in the globular domain of the existing model show
secondary structure in the new model and the coiled-coil region (α10 and α11) is
structured symmetrically with a small unstructured region forming a tight bend
at the tip in the new MurM model. The most notable difference when comparing
the two models of MurM is the location of the putative Lipid II(Lys) binding site.
Figure 5.3 (c) and (d) use electrostatic surface visualisation and protein orientation
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Figure 5.2: Cartoon representation of gMurM159 predicted structure. 14 α-helices (red),
12 β-sheet (yellow) and unstructured regions (blue). Best model obtained based on SOAP
and DOPE scores following homology modelling using MODELLER with S. aureus FemX as
a template.
identical to that in (Fiser et al., 2003), in order to make direct comparisons between
the two MurM models.
The location of the predicted peptide binding site in the Fiser et al. (2003) MurM
model was proposed upon identification of a structural relationship between MurM
domain I and the N-myristoyl transferase (NMT) fold. Four key features were used
in support of identification of the predicted binding site such as; the presence of a
Lipid substrate for both MurM and NMT’s, the importance of the C-terminus in
both MurM and NMT’s, the identification of a negatively charged surface patch in
MurM, and the structural location of the most highly conserved region of MurM.
Each of these considerations will be challenged and it is proposed here that the
Lipid II(Lys) binding site of MurM is more similar to that of W. viridescens FemX.
Whilst the substrate of both NMT and MurM are lipid substrates, they are
contextually and structurally very different. The NMT proteins are soluble
cytoplasmic proteins, which contain a deep, narrow pocket which is highly specific

































































































































































































































In contrast, since the undecaprenyl C55 lipid tail of the Lipid II(Lys) substrate
is buried in the membrane, MurM does not interact with this. Instead since
MurM appends L-Ser or L-Ala to the third position lysine of the pentapeptide,
it is the headgroup (MurNAc-5P) which must be available for MurM binding.
The headgroup is oriented such that the pentapeptide chain is in an extended
conformation, perpendicular to the membrane. Since the estimated vertical
dimension is only ∼1.9 nm (Ganchev et al., 2006), the MurM protein must be in
very close proximity to the lipid bilayer. Given the stark contextual difference of the
Lipid substrate for MurM, it seems unlikely that this protein would have a binding
site similar to that of an NMT.
The C-terminus in NMT proteins is important for catalysis (Farazi et al., 2001) whilst
the C-terminus has been shown to be required for MurM activity (Filipe et al., 2001b),
it remains unknown as to whether this is due to structural or functional reasons.
The C-terminus of the Fiser et al. (2003) MurM model was unstructured due to
absence of electron density in the template, however, in the new MurM model the
C-terminus is a short α-helix which ends at the edge of the proposed binding site.
The C-terminus is therefore in the immediate vicinity of the putative Lipid II(Lys)
binding site and as such could play a functional or structural role.
Finally, Fiser et al. (2003) identified 11 residues, between residue 66 and 84, which
were fully conserved between FemA and MurM. Since these 11 residues also
overlapped with the negatively charged surface patch, they were believed to form
a dominant part of the proposed binding site (Fiser et al., 2003). These 11 residues
are not well conserved between S. aureus FemX and the new model of MurM, but
are relatively highly conserved between different strains of S. pneumoniae MurM.
Since the negatively charged surface is still present in the new MurM model, and
is located on the opposite side of the protein to the newly proposed Lipid II(Lys)
binding site, it may instead be important for protein:protein interactions.
Further evidence and characterisation of the newly proposed Lipid II(Lys) binding
site is outlined in this chapter demonstrating that the new MurM model provides a
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more accurate and informative representation of MurM then the previous model.
Figure 5.4 shows a Ramachandran plot of the new MurM model indicating that
91.3 % of all residues are within favoured regions and 97.0 % of all residues are in
allowed regions. The 12 outliers are Leu64, Gly65, Glu123, Ile133, Val139, Asp263,
Thr265, Arg266, Asn297, Asp327, Asn369 and Tyr387. Whilst this model has not
achieved the desired ≤ 0.05% of outliers and ≥ 98% of residues in favoured regions,
a small amount of uncertainty is expected due to the nature of these techniques and
it has been noted that even well established crystal structures do not always achieve
these desired values.
5.3.3 Identifying a possible Lipid II(Lys) binding site
Biarrotte-Sorin et al. (2004) solved the structure of W. viridescens FemX with the
co-crystallised UDP-MurNAc-5P substrate bound which identified 9 residues
making contact with the substrate. Similarly Fonvielle et al. (2013) co-crystallised
and solved the structure of W. viridescens FemX in the presence of a peptidyl-RNA
conjugate and identified 10 residues involved in binding the peptide substrate.
Figure 5.5 shows the differences between the two substrates used. When the W.
viridescens FemX crystals are aligned the substrates overlay well, indicating that
the two structures corroborate the others findings. Since the UDP-MurNAc-5P is
closer structurally to the Lipid II(Lys) substrate of MurM, this was used initially to
investigate the MurM binding site.
W. viridescens Fem X is 340 amino acid residues long compared with MurM which is
403 residues, it lacks the coiled-coil helical domain, and has low sequence homology
with MurM. However despite this, MurM does, with very low catalytic activity,
utilise UDP-MurNAc-5P, the substrate of W. viridescens FemX. Since the root mean
squared deviation (RMSD) of W. viridescens FemX and the new MurM model was
2.355 Å, the structure of W. viridescens FemX with UDP-MurNAc-5P was used to
assist identification of the MurM Lipid II(Lys) binding site.
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Figure 5.4: Ramachandran Plot of MurM159 model. Shows 91.3 % of all residues are
within favoured regions (light blue lines) and 97.0 % of all residues are in allowed regions
(dark blue lines). There are 12 residues that are outliers (pink circles). Plot generated in












































































































































































































































Figure 5.6 shows the model of MurM which has been aligned and overlaid to that of
W. viridescens FemX with the UDP-MurNAc-5P substrate bound. It can be seen that
the UDP-MurNAc-5P fits well into a large cavity in the new MurM model. Since the
UDP-MurNAc-5P is significantly smaller than the Lipid II(Lys) substrate of MurM
(Appendix 7.5) this can only be used as a guide. However, with the pentapeptide
of Lipid II(Lys) bound in a similar orientation to that of the pentapeptide in the
structure of W. viridescens FemX, the prenyl chain of Lipid I(Lys) would protrude
out of the active site and away from the protein into the lipid bilayer.
The following 8 residues; Tyr103, Lys36, Asn38, Trp39, Thr209, Arg211, Tyr215,
Tyr256, were independently identified in both W. viridescens FemX structures to
be involved in substrate binding (Biarrotte-Sorin et al., 2004; Fonvielle et al., 2013).
Amino acid residues with similar properties which are closely related in sequence
location or physical space and orientation were identified as ’corresponding
residues’. The corresponding residues in MurM159 were therefore identified in
MurM as; Phe103, Lys35, Asn/Asp37, Trp38, Thr206, Arg215 and Tyr219. Pairwise
alignment MurM159 from 9 different strains (Figure 5.7) shows the sequence location
and conservation of the equivalent residues in S. pneumoniae.
All residues, except Asn/Asp37 were conserved across all strains investigated.
In both penicillin sensitive strains (Pn16 and R6) the residue was Asn37, whilst
in all resistant strains a Asp37 was present. Residues Phe103, Lys35, Trp38,
Arg215 and Tyr316 in MurM159 were all found to occupy the same location in
space as the corresponding residues in W. viridescens FemX, and are therefore
considered structurally conserved. Overlays of the MurM159 model and bound
UDP-MurNAc-5P from the W. viridescens FemX crystal structure, shows that these
structurally conserved residues are all pointing directly towards the substrate
(Figure 5.8). It is therefore likely that these residues are involved in substrate
binding in MurM similarly to those identified in Wv FemX. Additionally, whilst
position 37 is not conserved between homologues from different species, in all S.
pneumoniae strains investigated position 37 is Asn/Asp and interestingly all resistant
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Figure 5.6: Current MurM model with UDP-MurNAc-5P overlaid. a) Cartoon
representation of MurM with UDP-MurNAc-5P overlaid (cyan) b) surface representation
of MurM with UDP-MurNAc-5P overlaid. UDP-MurNAc-5P can be seen to fit tightly into
the cavity shown, this is the proposed binding site for the Lipid II(Lys) substrate of MurM.
Figure prepared in PyMOL (Version 2.2.0).
184
Figure 5.7: Pairwise sequence alignment of MurM sequences. Black arrows indicate
residues proposed to be involved in substrate binding. Residues coloured according to %
identity using Jalview (Version 2.10.5).
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strains were found to contain Asp at this position. Thr206 was not found to be facing
the substrate binding cavity and was at right angles with the equivalent Thr209 in
W. viridescens FemX and is therefore unlikely to be important for substrate binding
in MurM.
An additional three residues Trp31, Asp149 and Glu366 were identified as having
potential importance in the MurM binding site. All three residues point directly
towards the cavity where the substrate binding is proposed to occur, Trp31 is fully
conserved among all S. pneumoniae strains investigated whilst Asp149 and Glu366
are only partially conserved.
Asp109 was identified by site directed mutagenesis as a possible catalytic residue
in W. viridescens (Hegde and Blanchard, 2003), in MurM the Asp107 is similarly
conserved (Lloyd et al., 2008). Asp107 is structurally conserved, Figure 5.8 shows it
oriented directly towards the substrate, with a distance of 12.5 Å between Asp107
and the epsilon amino group of the third position lysine. The surface structure of the
new MurM model indicates that interaction of Asp107 with lysine may be partially
obstructed by some unstructured regions of the enzyme. It is therefore possible
that during catalysis structural rearrangement may increase the proximity of the
catalytic Asp107 relative to the Lipid II(Lys) substrate. The W. viridescens FemX
with bound UDP-MurNac-5P has been overlaid with MurM in order to assist with
identification of the substrate binding site and important residues. However, the
UDP-MurNac-5P is significantly smaller than Lipid II(Lys) substrate (Appendix 7.5)
of MurM and can therefore only be used as a guide. With Lipid II(Lys) bound in a
similar orientation to the UDP-MurNAc-5P in Figure 5.8, the Lipid chain of Lipid
II(Lys) would protrude out of the active site.
Residues 244-274 of the coiled-coil region have been previously identified as
important for determining the specificity of the amino acid to be incorporated
into the PG (Filipe et al., 2001b). Additionally, the role of the coiled-coil arm for
tRNA binding in T. thermophilus SerRS has been demonstrated (Biou et al., 1994).
It is therefore likely that the coiled-coil arm of MurM also plays a role in tRNA
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Figure 5.8: Potential MurM159 binding site residues. MurM with UDP-MurNac-5P
overlaid, inset close up of proposed binding site with residues F103, K35, W38, R215
and Y316 in green shown to be pointing towards the substrate. Note: single letter code for
amino acids used in this diagram.
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binding. Electrostatic surface visualisation of the new MurM model shows that the
residues surrounding the binding site are primarily positively charged (Figure 5.9),
which indicates that this area of the proteins surface may form direct interactions
with the negatively charged phosphate groups of membrane phospholipids. The
electrostatic surface visualisation also indicated that the negatively charged surface
patch is located on the opposite side of the protein from the proposed Lipid II(Lys)
binding site. Therefore, MurM may form simultaneous interactions with both the
membrane and another protein.
Figure 5.10 shows regions of MurM which were previously identified to be required
for activity; the 50 N-terminal residues (red), 10 C-terminal residues (blue) or
residues 244-274 (green) (Filipe et al., 2001a,b). Deletion of N- or C-terminal residues
of MurM results in unbranched peptidoglycan which indicated that these residues
are important for the branching phenotype. However it is currently unclear as to
whether these residues play a functional role in enzyme activity, are important for
structural integrity or correct protein folding or are important for membrane:protein
or protein:protein interactions. Figure 5.10 illustrates that these regions of MurM
are in close proximity to the proposed Lipid II(Lys) binding site and therefore
may have a functional role. Residues 244-274 were identified as important for
defining the specificity for incorporation of alanine or serine into the cross-bridge by
MurM. Attempts to identify a single residue which determined specificity were only
partially successful, it seems that the presence of a threonine or lysine at position
260 correlates with the incorporation of primarily serine or alanine respectively.
However, the presence of that amino acid residue alone cannot determine specificity,
as such additional residues are required working in tandem (Filipe et al., 2001b). The
importance of the coiled-coil region in determining specificity of aminoacyl-tRNA is
reflected in W. viridescens FemX, which, has no coiled-coil domain and demonstrates
a lower selectivity for aminoacylated- tRNA by its ability to utilise serine, alanine or
even glycine depending upon availability. Given the importance of the coiled-coil


























































































































the tRNA. MurM has previously been compared to SerRS, for which deletion of the
N-terminal coiled-coil domain does not affect amino-acid activation but does reduce
aminoacylation activity (Borel et al., 1994), therefore indicating that it is important
for interaction with tRNA. Furthermore, crystal structures of T. thermophilus SerRS
show that the coiled-coil domain makes contact with both the variable arm and TψC
loop of the seryl-tRNA (Biou et al., 1994). It is possible therefore, that the coiled-coil
region of MurM is similarly necessary for the formation of correct interactions
with the tRNA, and plays an important part in determining the specificity of the
aminoacyl-tRNA substrate.
Figure 5.10: Cartoon representation of MurM159 with regions required for activity.
N-terminal residues (red), C-terminal residues (blue) and residues 244-274 (green) are
required for MurM activity.
5.4 Docking of a truncated Lipid II(Lys) to MurM
Following the identification of a potential substrate binding site in the MurM model,
molecular docking was used to investigate docking of the Lipid II(Lys) substrate to
MurM. However, Lipid II(Lys) is a large molecule and is therefore unsuitable for
molecular docking, in addition the lipid tail would be embedded in the membrane
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and so is not itself part of the MurM substrate. Therefore, truncated Lipid II(Lys)
with a reduced hydrocarbon tail was used for these docking experiments (Appendix
7.13).
Molecular docking of the substrate to MurM was conducted using AutoDock Vina
(Trott and Olson, 2010). In the absence of defining the binding site, providing the
entire protein for potential binding, the substrate docked only at the proposed
binding site. Figure 5.11 shows the conformation of the substrate which minimised
the free energy of the system.
Figure 5.12 shows residues which were identified to form hydrogen bonds between
MurM and the Lipid II(Lys) substrate. Across all MurM sequences studied; Ser36,
Lys35, and Tyr375 are completely conserved and Asp37 and Arg144 exist as
conservative mutations.
Whilst the same pocket of MurM was identified as the binding site, the orientation
of the Lipid II(Lys) substrate was significantly different when compared to the
UDP-MurNAc-5P (overlaid in proposed MurM binding site) (Figure 5.13). Initial
identification of this binding site used the W. viridescens FemX substrate, which,
whilst similar, has a number of differences between MurMs natural substrate. In
comparison to UDP-MurNAc-5P, in Lipid II(Lys) the uridine has been replaced
by a long hydrocarbon chain, which is embedded in the membrane, and there
is an additional GlcNAc group appended to the MurNAc. Therefore it is likely
that binding of the two substrates would be slightly different. In the Lipid II(Lys)
docking, the third position lysine, to which the amino acid will be transferred, is
located near the opening whilst the phosphates to which the lipid tails would be
appended are deeper in the binding pocket.
The diphosphates which connect to the hydrocarbon tail of the Lipid II(Lys) are
located in a channel which is at a 90 ◦ angle to the binding site. In vivo the
hydrocarbon of Lipid II(Lys) would be embedded in the membrane and the
diphosphates would be located at the surface of the membrane. The diphosphates
191
Figure 5.11: Molecular docking prediction of current MurM model with modified Lipid
II(Lys). a) Cartoon representation of MurM with docked modified Lipid II(Lys) (cyan) b)
Surface representation of MurM with docked modified Lipid II(Lys).
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Figure 5.12: Molecular docking predictions of MurM binding site residues. Current
MurM model with docked Lipid II(Lys). Inset: close up of residues predicted to form
hydrogen bonds. Lys35, Ser36, Asp37, Arg144 and Tyr357 (green) are directed towards the
substrate. Note: single letter code for amino acids used in this diagram.
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in the docked substrate are ∼1.5 nm deep in the binding pocket and ∼2.2 nm away
from the exit of the channel, therefore it is unlikely that this orientation is correct
for the membrane bound Lipid II(Lys). Docking the Lipid II(Lys) in the complete
absence of both the lipid tail and the diphosphates may produce results that are
more plausible.
Figure 5.13: Orientation of substrate in the binding site of current MurM model. a)
Surface representation of MurM overlaid with UDP-MurNAc-5P, b) Surface representation
of MurM with molecular docking of truncated Lipid II(Lys). Dashed boxes are used to
demonstrate differences between the two substrates and the relative orientations within the
binding site.
5.5 Atomistic molecular dynamics simulations of
membrane interactions with MurM159
This work was conducted in collaboration with Prof. Syma Khalid and PhD student
Jonothan Shearer (University of Southampton).
MurM is an amphitrophic protein, forming temporary and reversible interactions
with the lipid bilayer, specifically through binding of its substrate Lipid II(Lys).
MD techniques were used to investigate the orientation of MurM docking with the
lipid bilayer and to further identify the Lipid II(Lys) binding site and any direct
interactions between MurM and the membrane associated Lipid II(Lys) (Witzke
et al., 2016). In addition simulations were conducted with membranes containing
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cardiolipin in order to identify the effect of this membrane phospholipid on MurM.
5.5.1 Interactions between and the lipid bilayer
Coarse grain simulations were conducted six times for each of three membrane
systems; system 1, 2 and 3 contained 75:25:0, 72:16:12 and 72:12:16 of PE, PhG
and CL respectively. Interaction with the membrane was observed in < 3 µs and
remained unchanged for the remaining 2 µs. Interaction between MurM and the
membrane occurred in a number of different orientations and the predicted binding
site was found both facing towards and away from the membrane. Additionally, the
Lipid II(Lys) was found inside the proposed binding site in one of the simulations
(Figure 5.14). Since this is a dynamic system, and these simulations cover very short
periods of time, it would not be possible for all interaction scenarios to be identified.
Therefore identifying Lipid II(Lys) binding in the proposed binding site in one of
the 18 simulations is significant and strongly supports this as the location of the
Lipid II(Lys) binding site.
Following backmapping, prevalent hydrogen bonds were identified to be occurring
at Lys35, Lys60 and Arg144. Lys35 and Lys60 are completely conserved, and
Arg144 exists only as conservative mutants across all MurM sequences studied.
Additionally, Lys35 was also proposed to be involved in substrate binding of W.
viridescens FemX (Biarrotte-Sorin et al., 2004). Previous studies suggest that the height
of the Lipid II(Lys) head group is 1.9 nm (Ganchev et al., 2006); the measurement
from the phosphate group at the membrane surface to the terminal carboxyl group
of the D-Ala-D-Ala (at the deepest point of the binding pocket) was ∼1.2 nm. In
addition, comparison of the orientation of UDP-MurNAc-5P substrate (overlaid
in the MurM binding pocket) and Lipid II(Lys) substrate in the MurM binding
pocket, shows that the positioning of the diphosphate, MurNAc and pentapeptide
(and particularly the third position lysine) is strikingly similar (Figure 5.15). Taken
together this strongly supports the identification of the binding pocket and suggests
that the Lipid II(Lys) binds to MurM in this orientation which is similar to that of W.
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Figure 5.14: Interactions between current MurM model and the cell membrane. a) MurM
association with the membrane containing Lipid II(Lys) (cyan), b) Lipid II(Lys) (cyan) in the
binding site of current MurM model (cartoon representation).
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viridescens FemX binding to its substrate.
Figure 5.15: Orientation of Lipid II(Lys) in the binding site of current MurM model. a)
Surface representation of MurM overlaid with UDP-MurNAc-5P, b) Surface representation
of MurM with membrane embedded Lipid II(Lys). The surrounding membrane has been
removed for clarity. Dashed boxes are used to demonstrate differences between the two
substrates and the relative orientations within the binding site.
In each membrane system, two repeats, one with the binding site facing toward the
membrane and one with the binding site facing away from the membrane, were
backmapped to the all-atom model (Appendix 7.10). All-atom simulations indicated
that in general, Lipid II(Lys) clustered around the MurM primarily associating with
the positively charged surfaces.
5.5.2 Interactions of MurM159 with phospholipids
Phospholipids such as CL and PhG are known to be involved in the spatio and
temporal biochemistry of cells. The presence of cardiolipin has been demonstrated
to upregulate the activity of MurG (Lin et al., 2019; Boots et al., 2003) and similarly
the activity of MurM159 in vitro was reported to increase in the presence of CL
and decrease in the presence of PhG (unpublished data - Dr Adrian Lloyd). We
therefore investigated the effects of CL and PhG to the MurM simulations. A
Depletion-Enrichment (D-E index) was used to measure enrichment or depletion of
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specific lipids in the membrane occurring within a 1.1 nm perimeter of the protein.
In the absence of CL (membrane system 1) the D-E index of PE and PhG is is
∼1, indicating that upon MurM binding to the membrane, there is no change in
distribution of PE or PhG throughout the membrane (Appendix 7.9). In the presence
of CL, the D-E index for PE and PhG remains similar or decreases slightly (for PhG);
concomitantly, an increase the D-E index of CL was observed, indicating that CL
moves into the area of membrane making contact with MurM. Figure 5.16 shows
example data of the D-E index and a visual representation of CL enrichment around
MurM, from both membrane systems. CL enrichment occurs in simulations with
different MurM orientations, and also in both membrane systems; CL enrichment is
slightly more pronounced in membrane system 2 (with 12 % CL). These experiments
demonstrate a relationship between phospholipids and MurM; the increase in
activity of MurM in response to CL, and the enrichment of CL around MurM at
the membrane go hand in hand. Given that MurM successfully associates with a
membrane void of CL, it is possible that CL may be recruited to the membrane
location of MurM following its association, in order to regulate its activity. Further
investigation into the specific sites of MurM which interact with CL would be
beneficial.
5.6 MurM159 Flexibility Modelling
Flexibility modelling was conducted in collaboration with Prof. Rudolf Roemer
(University of Warwick) utilising a fast and efficient method for generating
protein flexibility simulations which could provide insight into functionality
(Jimenez-Roldan et al., 2012; Römer et al., 2016).
Determining the flexibility of MurM showed that the coiled-coil helical domain
is highly flexible. Modes 7 and 8 show flexibility of the coiled-coil in the z and x
plane whilst mode 10 shows rotation about the unstructured region that connects it


















































































































































































































































































































































































































has been suggested to be of importance in the recognition of tRNA for human
SerRS (Biou et al., 1994). Given the structural similarities between MurM and
SerRS in combination with the known importance of residues 224-274 in MurM for
determining amino acid specificity, it is possible that the coiled-coil helical arm of
MurM also undergoes conformational changes to facilitate tRNA binding. However,
unlike the SerRS which requires a long variable arm of tRNA to make interactions
with the coiled-coil arm (Biou et al., 1994), it has previously been shown that MurM
can utilise a mini-helix (Lloyd et al., 2008), containing only a acceptor stem and a
TψC stem, meaning that exact formation of tRNA interactions differ between MurM
and SerRS.
Mode 10 identified movements resembling the closing of the binding site in the
globular domain. This may for example, represent a conformational change that
occurs during binding of Lipid II(Lys), or a conformational change that occurs
during catalysis.
5.7 Prediction of protein:protein interactions
Previously bacterial two hybrid assays showed that S. aureus FemA and FemB
both form homo- and hetero-dimers, S. pneumoniae MurN, but not MurM, was
shown to form homodimers and MurM and MurN did not form heterodimers. This
experiment used MurM and MurN as ’prey’ and ’bait’ proteins, each of which
was conjugated to a domain of the Bordetella pertussis CyaA protein. As such, it is
possible that the folding of MurM and MurN was altered by the additional CyaA
domain resulting in aberrantly folded protein, or that the presence of the CyaA
domain itself hindered any possible homo- or hetero-dimerisation of these proteins.
In addition, unlike the positive results, the negative results were not corroborated
using additional methods (Rohrer and Berger-Bchi, 2003). Since interactions were
found to occur between FemA and FemB, and given the observation of a highly




























































































































to predict interactions between MurM and possible binding partners.
PG synthesis in streptococci is localised to the septum and at the equatorial rings,
with proteins such as PBP1a and PBP2x following FtsZ localization to this region
(Scheffers and Pinho, 2005). It is therefore possible that Lipid II(Lys) accumulates
in these regions of the bilayer resulting in localisation of MurM. Given that MurM
provides the substrate for MurN, GatD/MurT also modify the Lipid II(Lys) and
MurJ is required to transport the final lipid through the membrane; it seems unlikely
that MurM would act in isolation. MurM may form dimers or multimers with
other proteins in this region in order to optimise the final stages of branched
PG production. MurM is located in an operon with MurN, which appends the
second amino acid to the dipeptide bridge sequentially to MurM. It is possible that
the two soluble proteins interact and are transported to the membrane together,
or that they dimerise at the membrane in order to channel the Lipid II(Lys)
substrate in a similar manner to the GatD/MurT complex which is responsible
for amidation of the branched (or unbranched) Lipid II(Lys) substrate (Morlot et al.,
2018). Monobranched cross-bridges have been identified in the PG of S. pneumoniae
MurN deletion mutants (Filipe et al., 2000a), which indicates that the activity of
MurM does not require the presence of MurN. However, given that the substrate for
MurN is the product of MurM, it stands to reason that MurMN heterodimerisation
may assist the activity of MurN by bringing it in close proximity to the membrane
and hence its substrate.
Another consideration is that MurM utilises aminoacyl-tRNA as a substrate, MurM
may form heterodimers with aaRSs in the cytoplasm, in order to assist the transfer
of tRNA to MurM. Furthermore, MurM shares some structural similarity with aaRS
(Fiser et al., 2003), some of which have been found to form homodimers (Itoh et al.,
2013; Wang et al., 2015), raising the possibility that they may too form heterodimers
with proteins such as MurM. In SerRS the coiled-coil helix is required for recognition
of the long variable stem of , and tRNA has been shown to span from the coiled-coil
arm to the globular domain of this synthetase Biou et al. (1994). Whilst MurM
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can recognise a tRNA mini-helix as well as full length tRNA (Lloyd et al., 2008),
and the W. viridescens FemX recognises tRNA in the absence of a coiled-coil region,
evidence suggests that the coiled-coil arm of MurM may play an important role in
determining amino acid specificity (Filipe et al., 2001b). It is therefore likely that the
coiled-coil arm of MurM is involved in the binding of tRNA in a similar manner to
SerRS.
Possible sites of MurM interaction for homo- and hetero-dimerisation with MurN
and SerRS were investigated using the ZDOCK server (Pierce et al., 2014). In the
absence of a S. pneumoniae MurN or SerRS, alternative structures or models were
used for these predictions. A homology model of MurN was produced using S.
aureus FemA as a template in I-TASSER (Yang et al., 2015), and the crystal structure
of T. thermophilis SerRS, which has 37 % sequence identity to S. pneumoniae SerRS,
was obtained (Zhang, 2008; Roy et al., 2010; Yang et al., 2015; Biou et al., 1994).
All possible binding modes in the translational and rotational space between two
proteins is investigated. Any identified pose is then ranked using an energy-based
scoring function. The top two predictions for both MurM homodimerisation and
heterodimerisation with MurN and T. thermophilus SerRS are presented in Figure
5.18.
The two models for MurM homodimerisation both indicate that docking of two
MurM proteins would occur at sites, distant from the substrate binding site. This
would allow the MurM protein complex to dock to the membrane as shown
previously. The first model shows symmetrical docking, such that the sites making
contact are the same in both proteins, with regions Ser113-Gln119, Phe379-Pro382
and Ile160-Lys169 being in close proximity. All of these regions are highly conserved
among all S. pneumoniae strains investigated, with only position 115, 117 and 381
possessing non-conservative mutations. Conversely the second model shows a
non-symmetrical binding such that the regions making contact were different
for each protein. Whilst this is possible it is more unusual than symmetrical
homodimerisation (Goodsell and Olson, 2000).
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In the top prediction for heterodimerisation with MurN, the Lipid II(Lys) binding
site of MurM is not obstructed by the docking of MurN, thereby allowing membrane
interaction and substrate binding. Once MurM has appended the first amino acid,
it may undergo a conformational change such as the ’loosening’ of the globular
domain active site (shown in Mode 10 of Figure 5.17), from around the Lipid II(Lys),
allowing dissociation of MurM from both the Lipid II(Lys) and MurN protein. The
MurN would then be perfectly poised for binding to the Lipid II(Lys) substrate
following addition of L-Ala/L-Ser by MurM. The regions of MurM most likely
to form interactions with MurN were identified as Cys111-Gln119, Tyr124-Ile133,
Lys140-Ser142 and Met381-Pro385. These positions are mostly highly conserved,
however conservative and non-conservative mutations occur between strains at
positions 115, 117, 124, 131-133, 140, 381 and 383. In contrast in the second model
for MurMN hetero-dimerisation the Lipid II(Lys) binding site is clearly obstructed
by the docking of MurN. In this orientation the Lipid II(Lys) would need to fit in
the middle of the two proteins in order to gain access to the binding site. Whilst the
second model would be feasible, the first model corresponds with the position of
MurM at the membrane when Lipid II(Lys) is bound.
Despite being known to form dimers, the structure of T. thermophilus SerRS has
been solved in the monomeric state and so was used for these heterodimerisation
studies. Both models of MurM heterodimerisation with SerRS, show the coiled-coil
domains of both proteins coming into close contact with each other, which would
permit the successful transfer of aminoacylated-tRNA from the synthetase to the
MurM. In the first model, the regions of MurM that are in close proximity to the
SerRS are Tyr161-Lys184, Glu378-Met381 and Asn262-Arg266. Whilst Tyr161-Ly184
and Glu378-Met381 are highly conserved (with the exception of positions 175
and 381 which show some variation between strains), Asn252-Arg266 is a highly
variable region. In the second model, the regions of MurM in close proximity to the
SerRS are Ala158-Lys162, His115-Lys121 and Met381. Ala158-Lys162 are completely
conserved and Met381 is highly conserved only showing variation in one strain,
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whilst the His115-Lys121 region is highly variable. The presence of highly variable
sequences predicted to be present at the protein:protein interface indicates that these
interactions may be less likely to occur in vivo.
The region Ile160-Lys184 of MurM was identified as a possible site for
protein:protein interaction in homodimerisation (first and second models) and
heterodimerisation with SerRS (first model). Identification of this region in multiple
simulations, in combination with the high sequence conservation across all MurM
strains investigated, indicates that this region may be a good candidate for forming
important protein:protein interactions. In addition, the region Cys111-Lys121
of MurM was identified as a possible site for protein:protein interaction in
heterodimerisation with both SerRS (second model) and MurN (first model), as
well as MurM (second model). This region contains a number of highly conserved
residues, but also contains a number of residues with high sequence variation.
The conserved residues of these regions provide a useful basis for site directed
mutagenesis experiments to disturb the protein:protein interactions.
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Figure 5.18: MurM homo- and hetero-dimerisation predictions. Prediction number
1 (a) and number 2 (b). TOP BOX: homodimerisation of MurM. MIDDLE BOX:
heterodimerisation of MurM (green) and MurN (cyan). BOTTOM BOX: heterodimerisation
of MurM (green) and SerRS (magenta). Predictions generated using ZDOCK server (Pierce
et al., 2014) and visualised in PyMOL (Version 2.2.0).
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5.8 Discussion
The MurM model presented in this chapter shows a number of improvements
when compared to the previous MurM model (Fiser et al., 2003). The new MurM
model with an overlaid UDP-MurNAc-5P from W. viridescens FemX, resulted in
the identification of the Lipid II(Lys) binding site which was not apparent in
the previous MurM model (Fiser et al., 2003). This proposed binding site was
independently identified in both molecular docking and MD membrane simulations.
The orientation of binding of Lipid II(Lys) to the MurM binding site is most likely
that identified in the MD membrane simulation, which corresponds well with the
orientation of UDP-MurNAc-5P in the W. viridescens FemX homologue. The overall
orientation of MurM with respect to the membrane when the Lipid II(Lys) is bound,
would support the heterodimerisation of MurM with MurN at the membrane. The
proximity to the membrane and the orientation of the coiled-coil domain indicate
that the flexible nature of this region may be restricted upon MurM binding to the
membrane. Furthermore, the binding site is completely occluded by the membrane
and so access to the binding site by the tRNA seems ever more unlikely. In addition,
the composition of phospholipids in the membrane may modulate both association
of MurM to the membrane and its catalytic activity. Taken together these simulations
support the hypothesis that MurM may use a ping-pong mechanism of action. In
the cytoplasm the amino acid would be transferred from the tRNA to the MurM to
create an aminoacylated-MurM. MurM then travels to the membrane, binds Lipid
II(Lys) and appends the amino acid to the Lipid II(Lys) head-group. MurM may
also form protein:protein interactions with a range of cytoplasmic and membrane
proteins in order to channel substrates effectively.
Atomistic MD simulations of MurM with the membrane have provided novel
insight into how and where Lipid II(Lys) interaction with MurM occurs. In addition
these simulations have shown how phospholipids and MurM form interactions
which may modulate membrane association or activity of MurM. In the simulation
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containing no CL, MurM successfully associated with the membrane indicating
that CL is not required for this interaction. However, in simulations containing
CL, the CL was highly enriched in the area of membrane making contact with
MurM, indicating that interactions with MurM are important. It remains unknown
as to whether in vitro MurM recruits CL or whether the CL localises in the
membrane forming a cluster which recruits MurM. It is important to consider
that the membrane of bacteria in vivo is vast and highly dynamic and that these
simulations use a simplistic membrane which does not accurately represent the
membrane composition of S. pneumoniae.
Flexibility modelling indicates that the coiled-coil arm is highly flexible, which
is likely a contributory factor to the previous lack of success when attempting to
crystallise this protein. Stabilising this domain by addition of tRNA may eliminate
these large scale motions and assist the formation of crystals. Smaller scale motions
observed within the globular domain may be indicative of a conformational change
that occurs upon Lipid II(Lys) binding. Whilst these simulations are useful in
identifying regions of space which are permissible to the molecules, it is important
to note that this algorithm provides information of the physical flexibility of this
protein in the absence of water or any other forces acting on it. These predicted
movements therefore represent regions of MurM which show flexibility but may
not necessarily be of biological significance or occur in vivo. Whilst this method is
not as accurate as atomistic modelling such as MD it remains a useful tool due to
the short run time and the good predictive quality. The information garnered from
flexibility studies of MurM can be used to identify distant regions on the protein
that may make contact upon conformational change.
ZDOCK predictions of MurM homo- and hetero-dimerisation identified potential
sites of protein:protein interactions indicating that MurM may not only form
interactions with the membrane but also with other partner proteins. Further work
to identify binding partners of MurM, and better characterise the protein:protein
interface are required.
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In conclusion, Box and Draper (1987) once said ”all models are wrong, but some
are useful”; in this chapter, modelling and simulation has proved to be highly
useful. In the absence of a MurM crystal structure, modelling and simulation has
provided insight into not only the structure of the MurM protein itself, but also the
possible movements of this protein and potential interactions it may make with
the membrane and other proteins. When taken together this information provides
additional insight into MurM’s mechanism of action which will help direct and
focus future experimental research.
5.9 Future work
Docking experiments in the absence of the hydrocarbon lipid tail and diphosphates,
should be conducted in order to identify the substrate orientation and important
residues involved in binding of Lipid II(Lys). Subsequently, MD using the Nudged
Elastic Band (NEB) method may be used in order to identify the low energy
transition pathway of substrate binding to MurM.
Residues of importance could be confirmed experimentally by single and
combinatorial mutations of residues in the MurM binding site, which were proposed
to be important for Lipid II(Lys) binding. In order to establish residues important for
binding, the dissociation constant (kd) of Lipid II(Lys) and MurM could be compared
for MurM mutants using microscale thermophoresis (MST). In addition, the effects
of different mutations of the catalytic activity of MurM could be investigated using
a MurM assay. Since the MurM residue at position 37 is a conserved Asn, in all
penicillin sensitive strains evaluated, and a conserved D, in all penicillin resistant
strains evaluated, reciprocal mutation of this residue may be informative for both
effect on the catalytic efficiency of MurM in vitro and any effect on penicillin
resistance, or alterations in the PG composition in vivo.
Further simulation and analysis of MurM at the membrane may identify additional
residues directly involved in MurM:cardiolipin interactions. The effect of mutating
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these residues may be investigated experimentally using the MurM assay in the
presence of cardiolipin.
Possible MurM interactions with other proteins present at the membrane, such
as MurJ or MurT/GatD should also be predicted using ZDOCK. Experimental
investigation of MurM/MurN heterodimerisation has previously been hindered by
difficulty in expressing and purifying MurN. Previous work suggests that MurN
co-purifies with the Maltose Binding Protein (MBP) affinity tag, and cannot be
separated, supporting the idea that MurN may form protein:protein interactions.
The presence of this MBP-tag may however interfere with the in vitro experimental
techniques proposed, and so, since MurM and MurN exist in an operon, it may
be beneficial to overexpress them together in pET28a rather than individually.
Native-PAGE, pull-down assays, analytical ultracentrifugation (AUC) or in vivo or
in vitro cross-linking experiments may confirm dimerisation between the suggested
proteins. Carbene labelling is a technique that may be exploited to experimentally
confirm the Lipid II(Lys) binding site (but not substrate orientation) and confirm
other possible protein:protein interactions. Subsequent biomolecular interaction
techniques such as isothermal calorimetry (ITC), surface plasmon resonance (SPR) or
MST could be used to establish binding kinetics. The radiolabelled MurM assay may
be utilised to explore binding kinetics of MurM with the Lipid II(Lys) substrate. If
MurM has a ping-pong mechanism of action then Lineweaver-Burk plots at varying
Lipid II(Lys) concentrations would occur as parallel lines.
Following experimental identification of MurM homo- or hetero-dimerisation,
site-directed mutagenesis, guided by these models, may be conducted to disturb




Final discussion and future
perspectives
The main aim of this work was to characterise the effects of H2O2 on the pre-
and post-transfer editing activity of AlaRS and ThrRS, and to identify specific
modifications arising due to H2O2. Secondary aims were to use a combination
of experimental and computational approaches to gain a better understanding of
MurM, its substrate specificty and its mechanism of action.
6.1 Characterising the effect of H2O2 on aminoacyl-tRNA
synthetases
Building on previous observations by Ling and Söll (2010), that oxidation by H2O2
resulted in an increase in production of seryl-tRNAThr by E. coli ThrRS, the effects of
H2O2 on S. pneumoniae AlaRS and ThrRS were characterised. This work utilised a
novel spectrophotometric editing assay which enabled the real-time monitoring of
pre- and post-transfer editing in vitro. This work supports previous findings, and
demonstrates that H2O2 specifically affects post-transfer editing, but not pre-transfer
editing of both AlaRS and ThrRS. It was also shown that oxidation of AlaRS and
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ThrRS is dependent upon the relative proportions of H2O2 and aaRS, as well as time.
Initial concentrations of H2O2 were varied from 0 mM to 75 mM demonstrating a
decrease in post-transfer editing activity. Incubation of a higher concentration of
enzyme, with a concentration of H2O2 previously identified to cause a reduction
in post-transfer editing activity, did not generate any loss in activity of AlaRS or
ThrRS. This result indicated that, as expected oxidation by H2O2 is a bi-molecular
reaction and so it was not the concentration of H2O2 per se which was important,
but rather the molar ratio of enzyme to H2O2. As such incubation experiments
were conducted with H2O2 at 10,000-fold and 200-fold H2O2 to AlaRS or ThrRS
respectively. Whilst from these ratios it is clear that ThrRS is much more sensitive
to H2O2 than AlaRS, these ratios seem reasonable given that previous experiments
by Ling and Söll (2010) on ThrRS were conducted at a 2666-fold excess of H2O2
(corresponding to 4 mM H2O2 in the assay with 1.5 µM ThrRS). Due to the high
concentrations of tRNA required in this novel editing assay it was not possible to
characterise differences in editing between individual tRNA isoacceptors. However,
individual tRNA isoacceptors are suitable for use in radiolabelled MurM assays and
can be used to investigate any difference in use as MurM substrates.
Demonstrating that exposure to H2O2 results in a loss of post-transfer editing in
AlaRS and ThrRS, prompted experiments to identify specific modifications which
corresponded to this loss in activity. Cys182 of E. coli ThrRS was identified as the
residue targeted by oxidation with H2O2 by experiments using Ellman’s reagent
(also known as 5,5’-dithiobis-(2-nitrobenzoic acid); DTNB) and subsequently DAz-2
(Wu et al., 2014). Whilst this does indicate that Cys182 is oxidised, it does not confirm
if any other (non-cysteine) residues such as methionine or tryptophan are oxidised.
Furthermore DAz-2 only identifies sulphenic acid and so if cysteine is oxidised
rapidly to sulphonic acid, the experiment would falsely indicate that there was no
oxidation occurring.
In order to keep these experiments consistent with the loss of post-transfer editing
function, the results from previous experiments were used to inform the incubation
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time and relative ratio of H2O2 required for aaRSs treatment. Intact protein mass
spectrometry suggested that there was a shift in mass between untreated and treated
samples, however the poor quality data, which was due to experimental limitations,
meant that further investigation was required. In an attempt to identify individual
oxidised residues and the oxidation state, peptide-based mass spectrometry was
used.
Initial proteomics data suggested that this protein was highly oxidised, AlaRS
and ThrRS showed oxidation at a total of 19 and 26 residues respectively. The
single Cys669 of AlaRS was oxidised to sulphonic acid in both treated and the
untreated control. This indicates that either the experimental procedure introduced
oxidation to the control sample, or that the modifications which result in the loss of
post-transfer editing activity are more complex than presence or absence of oxidation
and may instead pertain to the proportion of sample with oxidised residues. The
mass spectrometry techniques used here were unable to provide any quantitative
data and so it is possible that only a small proportion of control sample was oxidised,
compared to a larger proportion in the treated sample. Therefore, improved mass
spectrometry experiments, which minimise additional preparative oxidation and
allow quantitative analysis of oxidation must be used to determine residues which,
when oxidised by H2O2, result in a loss of post-transfer editing of both AlaRS and
ThrRS. Since cysteine residues have previously been demonstrated to be important
for post-transfer editing, a DTNB assay could be used to monitor oxidation of these
residues over time.
E. coli ProRS contains a Cys443; whilst a Gly443 mutant can still conduct
post-transfer editing, it is severely defective suggesting that Cys443 has an important
role in the editing mechanism (Beuning and Musier-Forsyth, 2000). The homologous
residue in S. pneumoniae ProRS is a Cys477 (the only cysteine in the open reading
frame), therefore it would be interesting to repeat these experiments to investigate
whether H2O2 effects the editing activity of ProRS in a similar way to that of AlaRS
and ThrRS. Interestingly, ProRS has a trans-editing factor YbaK, which does not
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contain Cys477. This suggests that YbaK has an additional mechanism for editing
which does not require a single cysteine. In S. pneumoniae, if oxidation of Cys477 by
H2O2 resulted in a reduction of post-transfer editing activity, the YbaK homologue
would likely provide protection by editing mis-charged tRNA using this alternative
mechanism, hence maintaining the fidelity of protein synthesis.
Now that the effects of H2O2 on aaRSs have been characterised in vitro, it would
be prudent to investigate the biological relevance in vivo. S. pneumoniae (159) has
been shown to preferentially incorporate alanine into the PG when grown in the
presence of catalase (mimicking anaerobic conditions), and MurM159 demonstrated a
preference towards alanyl-tRNAAla when compared to seryl-tRNASer in vitro (Lloyd
et al., 2008). However, Shepherd (2011) subsequently demonstrated that in vitro
MurM159 utilised mis-charged seryl-tRNAAla preferentially. Therefore, if MurM
directs mis-charged tRNA into the PG under aerobic growth conditions, in order to
maintain the fidelity of protein synthesis, it would be expected that the composition
of the PG would vary accordingly. S. pneumoniae (159) would therefore be a good
strain to use for in vivo experiments. Comparison of the PG from wild-type S.
pneumoniae (159) and S. pneumoniae (159)∆SpxB, grown in aerobic conditions, would
identify any changes in PG composition which can be attributed to the presence or
absence of H2O2. Since aerobic growth of S. pneumoniae is challenging, the same
result may be demonstrated by growth of S. pneumoniae in anaerobic conditions
with the addition of exogenous H2O2 into the growth media. Additionally, whilst
creating Cys669 mutants for AlaRS or Cys181 and Cys336 mutants for ThrRS, would
most likely be lethal, transformation of S. pneumoniae, grown anaerobically, with
donor DNA containing mutant aaRS may result in an increase in mis-charging
(mimicking oxidative stress) but maintain mis-charging below the lethal threshold.
The increase in mis-charged tRNA would be expected to alter the composition of
the PG accordingly. The composition of PG can be analysed by mass spectrometry,
and so any increase in serine incorporation due to aerobic growth, the presence of
exogenous H2O2 or the introduction of mutant AlaRS or ThrRS can be monitored
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(Severin and Tomasz, 1996; Garcia-Bustos and Tomasz, 1990; Lloyd et al., 2008).
6.2 Characterising the substrate specificity of MurM
The sequence of MurM159 and MurMPn16 was clarified, and due to their utility for
comparison between sensitive and highly penicillin resistant strains, full genome
sequencing of each was conducted. This provides the basis for other proteins of
interest, such as PBPs, MurN and GatD/MurT from these strains to be investigated
further.
The presence of iGln Lipid II(Lys) in the PG of S. pneumoniae and the recent
identification of the MurT/GatD complex responsible for amidation, led to the
question of the order that these modifications occur to the Lipid II(Lys) substrate. It
is possible that there is a strict order to amidation and branching of Lipid II(Lys),
or that there is no order, such that MurT/GatD can amidate both branched or
unbranched Lipid II(Lys) and MurM can branch both amidated or unamidated Lipid
II(Lys). Work by Morlot et al. (2018) investigating depletion of MurT/GatD showed
that, upon depletion of this complex, as expected, the proportion of amidated PG,
and cross-linked PG decreased. However, unexpectedly it was observed that there
was a concomitant increase in branched PG, and so was suggested that Lipid II(Lys)
may be a better substrate for MurM (Morlot et al., 2018). All previous work with
MurM has been conducted with Lipid II(Lys). This is because synthesis of iGln
Lipid II(Lys) results in very poor yields and this has been the limiting factor to
investigating iGln Lipid II(Lys) as a MurM substrate. In this work we improved
the yield of iGln Lipid II(Lys) and subsequently showed that both Lipid II(Lys)
and iGln Lipid II(Lys) are substrates for MurM159 in vitro. Future kinetic analysis
of Lipid II(Lys) and iGln Lipid II(Lys) would demonstrate whether MurM utilises
these substrates equally and therefore shed light onto any order to Lipid II(Lys)
modifications in vivo.
The absence of a G at position 51 or 63 of tRNA has been identified as a negative
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identity element for EF-Tu. It has been reported that in T. thermophilus, E. coli
and S. aureus tRNA without a G at this position bind EF-Tu weakly. It has been
proposed that tRNAs containing this negative identity element are retained for
non-proteogenic functions such as PG biosynthesis. As such it is important to
characterise the ability of MurM to utilise different tRNA isoacceptors as substrate.
The work in this thesis paves the way to conduct radioactive MurM experiments
for characterisation of different tRNA isoacceptors charged with cognate and
non-cognate amino acids. Crude S. pneumoniae (159) tRNA was prepared, cognate
charging by AlaRS, SerRS and ThrRS was demonstrated in a radiolabelled assay
and a good yield of charged tRNA was purified during a preparative charging
assay. In addition, tRNAAla, tRNASer1, tRNASer2, tRNASer3, tRNAThr1 and tRNAThr2
were synthesised by in vitro transcription. All tRNAAla and tRNASer isoacceptors
demonstrated cognate charging by AlaRS and SerRS (3 µM) in a radiolabelled
assay. No charging of tRNAThr isoacceptors was observed by ThrRS at the same
concentration; since ThrRS was found to be significantly less active than AlaRS
in both amino acid activation and editing assays, the low activity of the enzyme
may explain the lack of charging of the tRNAThr isoacceptors, and so this may be
overcome with a higher concentration of ThrRS in charging assays.
Some preliminary experiments generating radiolabelled mis-charged tRNA,
indicated that addition of high concentrations of H2O2 (aimed at abolishing
post-transfer editing) completely eliminated tRNA charging. This suggests that
at such high concentrations of H2O2 other components of the reaction such as the
tRNA is adversely effected. Therefore, the proposed best method to obtaining
mis-charged tRNA would be to treat the aaRS with H2O2, dialyse the H2O2 and
subsequently use the aaRS in the radiolabelled assay. Alternatively, for AlaRS and
ThrRS, editing site mutants can be used to generate large quantities of mis-charged
tRNA for radiolabelled experiments.
Once tRNAs charged with cognate and non-cognate amino acids have been
generated, any preference of MurM to use different tRNASer and tRNAThr
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isoacceptors can be investigated using radioactive MurM activity assays.
S. aureus contains several tRNAGly isoacceptors which do not posses the G at this
position and so are thought to be reserved for PG synthesis. Similarly, tRNASer1,
tRNASer2 and tRNAThr2 do not posses G at this position and are likely to be EF-Tu
unstable. Therefore it would be interesting to compare the use of tRNASer1, tRNASer2
and tRNASer3, and tRNAThr1 and tRNAThr2 as MurM substrates. tRNASer2 is a
known MurM substate since all previous published experiments were conducted
with this isoacceptor. In addition the 51:63 bp is located in the TψC loop, which is
required in the tRNAAla minihelix which is also a substrate for MurM. It is therefore
possible that the absence of a G at this position may also double as a positive
identity element for MurM recognition, and so introduction of a G at this position
in a non-proteogenic isoacceptor may enhance substrate recognition by MurM.
6.3 An improved understanding of the structure of MurM
A variety of computational techniques were used to model the structure of MurM
and predict its interactions with the Lipid II(Lys) substrate, the cytoplasmic face of
the membrane and other proteins. Despite using the same modelling software, some
significant differences were observed between the previous model of MurM (Fiser
et al., 2003) and the model generated in this work. The most likely explanation for
these differences is the homologue chosen as a template for the model; the previous
MurM model was generated using the crystal structure of S. aureus FemA, whilst
the new model detailed in this thesis used an unpublished structure of S. aureus
FemX (unpublished work from Roper lab). FemX, similarly to MurM, is responsible
for the addition of the first amino acid in the peptide bridge and so is a functional
homologue. In addition, the sequence identity between MurM and FemX is higher
than with FemA.
The new structure of MurM allowed identification of a MurM binding site which
contradicts the site previously proposed. In addition, the groove which was
217
previously proposed to be the Lipid II(Lys) binding site was not observed in the
new model, due to differences between the tertiary structure of the two models.
The prediction of the binding site in the previous MurM model was based on the
structure-function analogy between MurM and NMT proteins (Fiser et al., 2003).
However, whilst NMT binds lipid, MurM only binds the pentapeptide headgroup
of Lipid II, the prenyl tail of which is embedded in the membrane. The MurM
Lipid II(Lys) is more similar to the substrate of W. viridescens FemX, despite being a
soluble (and not Lipid-linked) PG precursor, than that of an NMT. When MurM was
compared with W. viridescens FemX, the binding sites overlaid well, moreover the
substrate of W. viridescens FemX appeared to fit into the proposed MurM binding site.
Since the MurM substrate is membrane embedded Lipid II(Lys), molecular docking
experiments were conducted with a truncated version which did not possess the
lipid tail. The same binding site was independently identified by molecular docking
studies, supporting this as the true MurM binding site, however the orientation
of the truncated Lipid II(Lys) in the binding site made little biological sense. MD
simulations were used to investigate the interactions of MurM with the membrane.
Unexpectedly perhaps, these simulations also identified an interaction between
Lipid II(Lys) and the newly proposed binding site of MurM, further supporting
this as the Lipid II(Lys) binding site of MurM. From the interaction of MurM with
Lipid II(Lys) embedded in the membrane, a number of conserved residues involved
in hydrogen bonding were identified. These studies were able to demonstrate
association of MurM to the membrane, and also the effect of MurM:membrane
interactions between phospholipids such as PhG and CL. Interplay between MurM
and the membrane phospholipids supports previous experimental evidence which
suggests that phospholipids in the membrane regulate MurM’s activity.
MurM was predicted to form homo- and hetero- dimers with a number of proteins
including MurN. This supports the possibility that MurM and MurN are targeted
to the membrane together, in order to streamline the sequential addition of amino
acids to form the dipeptide bridge. Furthermore, the orientation of MurM bound to
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Lipid II(Lys) at the membrane, exposes the surface of MurM proposed to interact
with MurN and so would permit heterodimerisation with MurN whilst bound to
Lipid II(Lys).
The orientation of MurM interacting with Lipid II(Lys) at the membrane shows that
the flexible coiled-coil domain is in close proximity to the membrane. Therefore,
given that this domain is proposed to be important for tRNA binding, it is unlikely
that MurM with tRNA bound could adopt this position at the membrane. It
is therefore proposed that the most likely mechanism of action of MurM is the
ping-pong mechanism, whereby MurM undergoes an acylation reaction in the
cytoplasm, and subsequently travels to the membrane with the amino acid for
transfer to Lipid II(Lys).
With the exception of residues important for the amino acid specificity (within
the coiled-coil domain) and the conserved Asp107 proposed to be important for
catalysis, these studies identify, for the first time, key residues in the MurM binding
site. Experiments conducted with both individual and combined site-directed
mutations at these residues, would likely reveal the importance of these residues on
binding and catalysis. In addition, further analysis of MurM:membrane interactions
may identify additional residues important for phospholipid interactions. Finally
predictions of MurM homo- and hetero-dimerisation indicates surfaces of MurM
which may be involved in protein:protein interactions and so could also be
investigated by in vivo mutagenesis experiments.
In conclusion, this work has generated data important in demonstrating that H2O2
causes a loss of post-transfer editing in multiple S. pneumoniae aaRSs in vitro.
Furthermore, significant progress has been made in preparation for investigating the
role of MurM in maintaining the fidelity of protein synthesis. Future experiments
proposed will provide in vivo evidence demonstrating a link between protein
synthesis and PG synthesis. Finally, computational studies have enhanced our
understanding of the structure and interactions of MurM, which together shed light
onto this protein’s possible mechanism of action. These studies will help guide in
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vitro and in vivo experiments which can further elucidate binding partners, substrate
specificity and mechanism of action for MurM. Overall, having an enhanced
structural and functional understanding of MurM, makes this protein a good
prospective target for the development of novel antimicrobial resistance inhibitors
which, by inhibition of MurM, could restore penicillin sensitivity in highly resistant




7.1 Gene fragments and primers for cloning
























Table 7.2: Primers used for cloning using the Gibson assembly R© method. The final
construct name and forward and reverse primers, for both plasmid and insert, are shown.
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7.2 Construct details
Figure 7.1: Construct maps for MurM. a) gMurM159 in pET22b(+) cloned using the Gibson
assembly R© method. The binding sites for plasmid and insert primers are indicated. b)
gMurMPn16 in pET22b(+) cloned using the Gibson assembly R© method. The binding sites
for plasmid and insert amplification primers are indicated. Figure made using GeneSnap R©.
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Figure 7.2: Construct map for ThrRS. ThrRS(N-term His-tag) in pET28a(+) cloned using
the Gibson assembly R© method. The binding sites for plasmid and insert amplification
primers are indicated. Figure made using GeneSnap R©.
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7.3 Protein sequences
Figure 7.3: MurM protein sequences. a) MurM159 and b) MurMPn16.
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Figure 7.4: AlaRS protein sequence. Theoretical pI and molecular weight (MW) were
calculated using ExPASy (Artimo et al., 2012)
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Figure 7.5: ThrRS protein sequence. Theoretical pI and molecular weight (MW) were
calculated using ExPASy (Artimo et al., 2012)
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7.4 Tandem mass spectra
Figure 7.6: Mass spectra of peptide containing Cys669 from AlaRS control sample. y16
ion corresponds to Cys+48 Da (indicating tri-oxidation). Data analysed using MaxQuant
and Scaffold (Version 4.8.1)
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Figure 7.7: Mass spectra of peptide containing Cys669 from AlaRS H2O2 treated sample.
y16 ion corresponds to Cys+48 Da (indicating tri-oxidation). Data analysed using MaxQuant
and Scaffold (Version 4.8.1)
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Figure 7.8: Mass spectra of peptide containing Cys181 from ThrRS control sample. y2
ion corresponds to Cys+48 Da (indicating tri-oxidation). Data analysed using MaxQuant
and Scaffold (Version 4.8.1)
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Figure 7.9: Mass spectra of peptide containing Cys181 from ThrRS H2O2 treated sample.
y2 ion corresponds to Cys+48 Da (indicating tri-oxidation). Data analysed using MaxQuant
and Scaffold (Version*)
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Figure 7.10: Mass spectra of peptide containing Cys336 from ThrRS control sample. y9
ion corresponds to Cys+48 Da (indicating tri-oxidation). Data analysed using MaxQuant
and Scaffold (Version 4.8.1)
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Figure 7.11: Mass spectra of peptide containing Cys336 from ThrRS H2O2 treated sample.
y9 ion corresponds to Cys+48 Da (indicating tri-oxidation). Data analysed using MaxQuant
and Scaffold (Version 4.8.1)
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7.5 Structures of synthesised substrates
Figure 7.12: Chemical structures of synthesised substrates. a) UDP-N-acetylmuramyl
pentapeptide (UDP-5P), b) iGln UDP-N-acetylmuramyl pentapeptide (UDP-5P), c) Lipid
II(lys) and d) Lipid II(lys). Figure created using ChemDraw Professional (Version 17.1.1.0).
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7.6 tRNA gene alignments in S. pneumoniae




tRNAAla 76 982.6 23,578
tRNASer1 91 1179.2 28,409
tRNASer2 91 1178.5 28,352
tRNASer3 93 1216.9 28,872
tRNAThr1 76 985 23,607
tRNAThr2 76 971.1 23,644
Table 7.3: Molecular features of tRNA isoacceptors. The isoacceptor, length, extinction
coefficient and molecular weight are shown.
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7.7 Structure of truncated Lipid II(lys)
Figure 7.13: Structure of MurM substrate and truncated version for molecular docking.
a) Lipid II(lys) - the true substrate of MurM, b) Truncated Lipid II(lys) - containing a
short hydrocarbon tail required for molecular docking predictions. Figure created using
ChemDraw Professional (Version 17.1.1.0).
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7.8 Discrete optimized protein energy (DOPE-HR) profile
Figure 7.14: Discrete Optimized Protein Energy Profile for MurM and FemX. Comparison
of DOPE-HR profiles for MurM model (red) and FemX template (green).
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7.9 Depletion-enrichment (D-E) index for simulated
membrane lipids
Figure 7.15: D-E index full data set. D-E index for phosphatidylethanolamine (POPE),
phosphotidylglycerol (POPG) and cardiolipin (CL) with MurM simulations beginning in
two alternate starting orientations for a) system 1, b) system 2 and c) system 3.
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7.10 Starting orientations for MurM in all-atom simulations
Figure 7.16: Starting orientations of MurM on the membrane. Alternate orientations of
MurM interactions with the membrane, as determined by coarse-grain simulations. Both
orientations used for all-atom simulations a) binding site facing towards the membrane and
b) binding site facing away from the membrane. Figure made using PyMOL (Version 2.2.0).
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7.11 Plasmid maps
Figure 7.17: Plasmid map for the bacterial expression vector pET-21b(+). The origin of
replication (ori), ampicillin resistance gene (AmpR), promotor and terminator from T7
phage (T7 promotor/terminator), C-terminal hexa-his tag (6xHis), multiple cloning site
(MCS), ribosome binding site (RBS), lactose operator, lactose repressor (lacI), replication
regulator protein encoding gene (rop) and restriction sites are indicated. Figure made using
GeneSnap R©.
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Figure 7.18: Plasmid map for the bacterial expression vector pET-22b(+). The origin of
replication (ori), ampicillin resistance gene (AmpR), promotor and terminator from T7 phage
(T7 promotor/terminator), C-terminal hexa-his tag (6xHis), multiple cloning site (MCS),
pelB signal sequence, ribosome binding site (RBS), lactose operator, lactose repressor (lacI),
replication regulator protein encoding gene (rop) and restriction sites are indicated. Figure
made using GeneSnap R©.
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Figure 7.19: Plasmid map for the bacterial expression vector pET-26b(+). The origin of
replication (ori), kanamycin resistance gene (KanR), promotor and terminator from T7
phage (T7 promotor/terminator), C-terminal hexa-his tag (6xHis), multiple cloning site
(MCS), ribosome binding site (RBS), lactose operator, lactose repressor (lacI), replication
regulator protein encoding gene (rop) and restriction sites are indicated. Figure made using
GeneSnap R©.
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Figure 7.20: Plasmid map for the bacterial expression vector pET-28a(+). The origin of
replication (ori), kanamycin resistance gene (KanR), promotor and terminator from T7 phage
(T7 promotor/terminator), thrombin cleavage site, N- and C-terminal hexa-his tag (6xHis),
multiple cloning site (MCS), ribosome binding site (RBS), lactose operator, lactose repressor
(lacI), replication regulator protein encoding gene (rop) and restriction sites are indicated.
Figure made using GeneSnap R©.
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Figure 7.21: Plasmid map for the bacterial expression vector pET-30a(+). The origin of
replication (ori), kanamycin resistance gene (KanR), promotor and terminator from T7 phage
(T7 promotor/terminator), thrombin cleavage site, N- and C-terminal hexa-his tag (6xHis),
multiple cloning site (MCS), ribosome binding site (RBS), lactose operator, lactose repressor
(lacI), replication regulator protein encoding gene (rop), and restriction sites are indicated.
Figure made using GeneSnap R©.
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Figure 7.22: Plasmid map for the bacterial expression vector pET-30a(+). The origin of
replication (ori), lactose repressor (lacI), lactose operator, N-terminal hexa-his tag (6xHis),
Tobacco Etch Virus (TEV) cleavage site, promotor and rrnB T1 and T2 terminator, ampicillin
resistance gene (AmpR), and restriction sites are indicated. Figure made using GeneSnap R©.
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and Dieter Söll. Aminoacylation of tRNA 2-or 3-hydroxyl by phosphoseryl-and
pyrrolysyl-tRNA synthetases. FEBS letters, 587(20):3360–3364, 2013.
Gilbert Eriani, Marc Delarue, Olivier Poch, Jean Gangloff, and Dino Moras. Partition
of tRNA synthetases into two classes based on mutually exclusive sets of sequence
motifs. Nature, 347(6289):203, 1990.
Narayanan Eswar, Ben Webb, Marc A Marti-Renom, MS Madhusudhan, David
Eramian, Min-yi Shen, Ursula Pieper, and Andrej Sali. Comparative protein
structure modeling using modeller. Current protocols in bioinformatics, 15(1):5–6,
2006.
EUCAST.
Joseph O Falkinham, Thomas E Wall, Justin R Tanner, Khaled Tawaha, Feras Q Alali,
Chen Li, and Nicholas H Oberlies. Proliferation of antibiotic-producing bacteria
253
and concomitant antibiotic production as the basis for the antibiotic activity of
jordan’s red soils. Appl. Environ. Microbiol., 75(9):2735–2741, 2009.
Thalia A Farazi, Gabriel Waksman, and Jeffrey I Gordon. Structures of
saccharomyces cerevisiae N-myristoyltransferase with bound myristoyl CoA and
peptide provide insights about substrate recognition and catalysis. Biochemistry,
40(21):6335–6343, 2001.
Daniel R. Feikin and Keith P. Klugman. Historical Changes in Pneumococcal
Serogroup Distribution: Implications for the Era of Pneumococcal Conjugate
Vaccines. Clinical Infectious Diseases, 35(5):547–555, 09 2002. ISSN 1058-4838. doi:
10.1086/341896. URL https://doi.org/10.1086/341896.
Sergio R. Filipe and Alexander Tomasz. Inhibition of the Expression of Penicillin
Resistance in Streptococcus Pneumoniae by Inactivation of Cell Wall Muropeptide
Branching Genes. Proceedings of the National Academy of Sciences of the United States
of America, 97(9):48914896, 2000.
Sergio R Filipe, Mariana G Pinho, and Alexander Tomasz. Characterization of the
murMN operon involved in the synthesis of branched peptidoglycan peptides in
Streptococcus pneumoniae. Journal of Biological Chemistry, 275(36):27768–27774,
2000a.
Sergio R Filipe, Elena Severina, and Alexander Tomasz. Distribution of the Mosaic
Structured murM Genes among Natural Populations of Streptococcus pneumoniae.
Journal of Bacteriology, 182(23):67986805, 2000b.
Sergio R Filipe, Elena Severina, and A Tomasz. The role of murMN operon
in penicillin resistance and antibiotic tolerance of Streptococcus pneumoniae.
Microbial drug resistance, 7(4):303–316, 2001a.
Sergio R. Filipe, Elena Severina, and Alexander Tomasz. Functional Analysis
of Streptococcus pneumoniae MurM Reveals the Region Responsible for Its
254
Specificity in the Synthesis of Branched Cell Wall Peptides. Journal of Biological
Chemistry, 276:39618–39628, 2001b.
Sergio R Filipe, Elena Severina, and Alexander Tomasz. The murMN operon:
a functional link between antibiotic resistance and antibiotic tolerance in
Streptococcus pneumoniae. Proceedings of the National Academy of Sciences, 99
(3):1550–1555, 2002.
Marcus Fischer, Brian K Shoichet, and James S Fraser. One crystal, two temperatures:
Cryocooling penalties alter ligand binding to transient protein sites. ChemBioChem,
16(11):1560–1564, 2015.
András Fiser, Richard Kinh Gian Do, et al. Modeling of loops in protein structures.
Protein science, 9(9):1753–1773, 2000.
Andrs Fiser, Sergio R. Filipe, and Alexander Tomasz. Cell wall branches, penicillin
resistance and the secrets of the MurM protein. Trends in Microbiology, 11(12):547 –
553, 2003.
Matthieu Fonvielle, Maryline Chemama, Maxime Lecerf, Régis Villet, Patricia Busca,
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Jiqiang Ling and Dieter Söll. Severe oxidative stress induces protein mistranslation
through impairment of an aminoacyl-tRNA synthetase editing site. Proceedings of
the National Academy of Sciences, 107(9):4028–4033, 2010.
262
Jiqiang Ling, Kaitlyn M Peterson, Ivana Simonović, Dieter Söll, and Miljan
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